{
      "Synthesis and preliminary pharmacological investigations of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine derivatives as potential atypical antipsychotic agents in mice .|In research towards the development of new atypical antipsychotic agents , one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system .|The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine ( 7 ) is described .|Compound 7e , 5 - { 2 - [ 4 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazinyl ] ethyl } - 2 , 3 - dihy dro - 1H - indol - 2 - one , from this series showed significant affinities at the 5 - HT1A and 5 - HT2A receptors and moderate affinity at the D2 receptor .|7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature .": "[[\"1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine derivatives\", \"investigated as\", \"potential atypical antipsychotic agents\"],\n[\"Dopaminergic system\", \"can be modulated through\", \"manipulation of the serotonergic system\"],\n[\"Synthesis and preliminary pharmacological evaluation\", \"of\", \"potential atypical antipsychotic agents\"],\n[\"Potential atypical antipsychotic agents\", \"based on the structure of\", \"1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine ( 7 )\"],\n[\"Compound 7e\", \"showed significant affinities at\", \"5 - HT1A and 5 - HT2A receptors\"],\n[\"Compound 7e\", \"showed moderate affinity at\", \"D2 receptor\"],\n[\"7e\", \"exhibits\", \"high reversal of catalepsy\"],\n[\"Catalepsy\", \"induced by\", \"haloperidol\"],\n[\"7e\", \"indicating\", \"its atypical antipsychotic nature\"]]",
      "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts .|Adenosine triphosphate ( ATP ) and sodium nitroprusside ( SNP ) are administered to patients to induce and control hypotension during anesthesia .|SNP is authorized for clinical use in USA and UK , and ATP is clinically used in other countries such as Japan .|We investigated how these two drugs act on the cardiovascular systems of 20 dogs whose hearts had been denervated by a procedure we had devised .|ATP ( 10 dogs ) or SNP ( 10 dogs ) was administered to reduce mean arterial pressure by 30 % to 70 % of control .|Before , during and after induced hypotension , we measured major cardiovascular parameters .|Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure ( p less than 0 . 001 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 001 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , total body oxygen consumption ( p less than 0 . 05 ) , and heart rate ( p less than 0 . 001 ) ; all these variables returned normal within 30 min after ATP was stopped .|Cardiac output did not change .|During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure ( p less than 0 . 01 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 01 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , and oxygen content difference between arterial and mixed venous blood ( p less than 0 . 05 ) , while heart rate ( p less than 0 . 001 ) and cardiac output ( p less than 0 . 05 ) were increased .|Recoveries of heart rate and left ventricular end - diastolic pressure were not shown within 60 min after SNP had been stopped .|Both ATP and SNP should act on the pacemaker tissue of the heart .": "[[\"Cardiovascular effects\", \"induced by\", \"hypotension\"],\n [\"Hypotension\", \"induced by\", \"adenosine triphosphate\"],\n [\"Hypotension\", \"induced by\", \"sodium nitroprusside\"],\n [\"Adenosine triphosphate\", \"administered to\", \"patients\"],\n [\"Sodium nitroprusside\", \"administered to\", \"patients\"],\n [\"Sodium nitroprusside\", \"authorized for clinical use in\", \"USA\"],\n [\"Sodium nitroprusside\", \"authorized for clinical use in\", \"UK\"],\n [\"Adenosine triphosphate\", \"clinically used in\", \"other countries\"],\n [\"Other countries\", \"such as\", \"Japan\"],\n [\"Investigation\", \"on\", \"cardiovascular systems of dogs\"],\n [\"Dogs\", \"had\", \"denervated hearts\"],\n [\"ATP\", \"administered to\", \"10 dogs\"],\n [\"SNP\", \"administered to\", \"10 dogs\"],\n [\"ATP\", \"reduces\", \"mean arterial pressure\"],\n [\"SNP\", \"reduces\", \"mean arterial pressure\"],\n [\"Measurement\", \"of\", \"major cardiovascular parameters\"],\n [\"Hypotension by ATP\", \"accompanied by\", \"significant decreases in cardiovascular parameters\"],\n [\"Cardiac output\", \"did not change\", \"during ATP induced hypotension\"],\n [\"Hypotension by SNP\", \"accompanied by\", \"similar decreases in cardiovascular parameters\"],\n [\"Heart rate\", \"increased during\", \"SNP induced hypotension\"],\n [\"Cardiac output\", \"increased during\", \"SNP induced hypotension\"],\n [\"Recovery of heart rate\", \"not shown within\", \"60 min after SNP stopped\"],\n [\"Recovery of left ventricular end-diastolic pressure\", \"not shown within\", \"60 min after SNP stopped\"],\n [\"ATP\", \"acts on\", \"pacemaker tissue of the heart\"],\n [\"SNP\", \"acts on\", \"pacemaker tissue of the heart\"]]",
      "Histamine antagonists and d - tubocurarine - induced hypotension in cardiac surgical patients .|Hemodynamic effects and histamine release by bolus injection of 0 . 35 mg / kg of d - tubocurarine were studied in 24 patients .|H1 - and H2 - histamine antagonists or placebo were given before dosing with d - tubocurarine in a randomized double - blind fashion to four groups : group 1 - - placebo ; group 2 - - cimetidine , 4 mg / kg , plus placebo ; group 3 - - chlorpheniramine , 0 . 1 mg / kg , plus placebo ; and group 4 - - cimetidine plus chlorpheniramine .|Histamine release occurred in most patients , the highest level 2 minutes after d - tubocurarine dosing .|Group 1 had a moderate negative correlation between plasma histamine change and systemic vascular resistance ( r = 0 . 58 ; P less than 0 . 05 ) not present in group 4 .|Prior dosing with antagonists partially prevented the fall in systemic vascular resistance .|These data demonstrate that the hemodynamic changes associated with d - tubocurarine dosing are only partially explained by histamine release .|Thus prior dosing with H1 - and H2 - antagonists provides only partial protection .": "[[\"Histamine antagonists\", \"used for\", \"cardiac surgical patients\"],\n [\"D-tubocurarine\", \"induces\", \"hypotension\"],\n [\"D-tubocurarine\", \"studied in\", \"24 patients\"],\n [\"D-tubocurarine\", \"dosage\", \"0.35 mg/kg\"],\n [\"H1- and H2-histamine antagonists\", \"administered with\", \"placebo\"],\n [\"Placebo\", \"given to\", \"group 1\"],\n [\"Cimetidine\", \"dosage for group 2\", \"4 mg/kg\"],\n [\"Cimetidine\", \"given with\", \"placebo\"],\n [\"Chlorpheniramine\", \"dosage for group 3\", \"0.1 mg/kg\"],\n [\"Chlorpheniramine\", \"given with\", \"placebo\"],\n [\"Cimetidine\", \"combined with\", \"chlorpheniramine for group 4\"],\n [\"Histamine\", \"release occurred after\", \"d-tubocurarine dosing\"],\n [\"Group 1\", \"showed\", \"moderate negative correlation between plasma histamine change and systemic vascular resistance\"],\n [\"Plasma histamine change\", \"correlates with\", \"systemic vascular resistance\"],\n [\"Systemic vascular resistance\", \"correlation value\", \"r = 0.58\"],\n [\"Correlation significance\", \"P value\", \"less than 0.05\"],\n [\"Group 4\", \"did not show\", \"correlation present in group 1\"],\n [\"Antagonists\", \"partially prevented\", \"fall in systemic vascular resistance\"],\n [\"Hemodynamic changes\", \"associated with\", \"d-tubocurarine dosing\"],\n [\"Hemodynamic changes\", \"partially explained by\", \"histamine release\"],\n [\"H1- and H2-antagonists\", \"provide\", \"partial protection\"]]",
      "Cholecystokinin - octapeptide restored morphine - induced hippocampal long - term potentiation impairment in rats .|Cholecystokinin - octapeptide ( CCK - 8 ) , which is a typical brain - gut peptide , exerts a wide range of biological activities on the central nervous system .|We have previously reported that CCK - 8 significantly alleviated morphine - induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine - treated animals .|Here , we investigated the effects of CCK - 8 on long - term potentiation ( LTP ) in the lateral perforant path ( LPP ) - granule cell synapse of rat dentate gyrus ( DG ) in acute saline or morphine - treated rats .|Population spikes ( PS ) , which were evoked by stimulation of the LPP , were recorded in the DG region .|Acute morphine ( 30mg / kg , s . c . ) treatment significantly attenuated hippocampal LTP and CCK - 8 ( 1ug , i . c . v . ) restored the amplitude of PS that was attenuated by morphine injection .|Furthermore , microinjection of CCK - 8 ( 0 . 1 and 1ug , i . c . v . ) also significantly augmented hippocampal LTP in saline - treated ( 1ml / kg , s . c . ) rats .|Pre - treatment of the CCK2 receptor antagonist L - 365 , 260 ( 10ug , i . c . v ) reversed the effects of CCK - 8 , but the CCK1 receptor antagonist L - 364 , 718 ( 10ug , i . c . v ) did not .|The present results demonstrate that CCK - 8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK - 8 on morphine - induced memory impairment .": "[[\"Cholecystokinin-octapeptide (CCK-8)\", \"restored\", \"morphine-induced hippocampal long-term potentiation impairment\"], [\"Cholecystokinin-octapeptide (CCK-8)\", \"is a type of\", \"brain-gut peptide\"], [\"Cholecystokinin-octapeptide (CCK-8)\", \"exerts\", \"biological activities on the central nervous system\"], [\"Cholecystokinin-octapeptide (CCK-8)\", \"alleviated\", \"morphine-induced amnesia\"], [\"Cholecystokinin-octapeptide (CCK-8)\", \"reversed\", \"spine density decreases in the CA1 region of the hippocampus\"], [\"CCK-8\", \"investigated for effects on\", \"long-term potentiation (LTP)\"], [\"Population spikes (PS)\", \"were evoked by\", \"stimulation of the LPP\"], [\"Population spikes (PS)\", \"recorded in\", \"DG region\"], [\"Acute morphine treatment\", \"attenuated\", \"hippocampal LTP\"], [\"CCK-8\", \"restored\", \"the amplitude of PS attenuated by morphine\"], [\"CCK-8\", \"augmented\", \"hippocampal LTP in saline-treated rats\"], [\"CCK2 receptor antagonist L-365,260\", \"reversed\", \"effects of CCK-8\"], [\"CCK1 receptor antagonist L-364,718\", \"did not reverse\", \"effects of CCK-8\"], [\"CCK-8\", \"attenuates\", \"effect of morphine on hippocampal LTP through CCK2 receptors\"], [\"CCK-8\", \"suggests ameliorative function on\", \"morphine-induced memory impairment\"]]",
      "Acute neurologic dysfunction after high - dose etoposide therapy for malignant glioma .|Etoposide ( VP - 16 - 213 ) has been used in the treatment of many solid tumors and hematologic malignancies .|When used in high doses and in conjunction with autologous bone marrow transplantation , this agent has activity against several treatment - resistant cancers including malignant glioma .|In six of eight patients ( 75 % ) who we treated for recurrent or resistant glioma , sudden severe neurologic deterioration occurred .|This developed a median of 9 days after initiation of high - dose etoposide therapy .|Significant clinical manifestations have included confusion , papilledema , somnolence , exacerbation of motor deficits , and sharp increase in seizure activity .|These abnormalities resolved rapidly after initiation of high - dose intravenous dexamethasone therapy .|In all patients , computerized tomographic ( CT ) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans .|This complication appears to represent a significant new toxicity of high - dose etoposide therapy for malignant glioma .": "[[\"Acute neurologic dysfunction\", \"occurs after\", \"high-dose etoposide therapy\"],\n [\"Etoposide\", \"used in\", \"treatment of solid tumors and hematologic malignancies\"],\n [\"Etoposide\", \"has activity against\", \"treatment-resistant cancers including malignant glioma\"],\n [\"Etoposide\", \"used in conjunction with\", \"autologous bone marrow transplantation\"],\n [\"Patients\", \"treated for\", \"recurrent or resistant glioma\"],\n [\"Patients\", \"experienced\", \"sudden severe neurologic deterioration\"],\n [\"Neurologic deterioration\", \"developed\", \"median of 9 days after initiation of high-dose etoposide therapy\"],\n [\"Clinical manifestations\", \"included\", \"confusion\"],\n [\"Clinical manifestations\", \"included\", \"papilledema\"],\n [\"Clinical manifestations\", \"included\", \"somnolence\"],\n [\"Clinical manifestations\", \"included\", \"exacerbation of motor deficits\"],\n [\"Clinical manifestations\", \"included\", \"sharp increase in seizure activity\"],\n [\"Abnormalities\", \"resolved after\", \"initiation of high-dose intravenous dexamethasone therapy\"],\n [\"CT brain scans\", \"demonstrated\", \"stability in tumor size and peritumor edema\"],\n [\"CT brain scans\", \"compared with\", \"pretransplant scans\"],\n [\"Complication\", \"represents\", \"new toxicity of high-dose etoposide therapy\"]]",
      "Increased anxiogenic effects of caffeine in panic disorders .|The effects of oral administration of caffeine ( 10 mg / kg ) on behavioral ratings , somatic symptoms , blood pressure and plasma levels of 3 - methoxy - 4 - hydroxyphenethyleneglycol ( MHPG ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM - III criteria for agoraphobia with panic attacks or panic disorder .|Caffeine produced significantly greater increases in subject - rated anxiety , nervousness , fear , nausea , palpitations , restlessness , and tremors in the patients compared with healthy subjects .|In the patients , but not the healthy subjects , these symptoms were significantly correlated with plasma caffeine levels .|Seventy - one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks .|Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients .|Caffeine increased plasma cortisol levels equally in the patient and healthy groups .|Because caffeine is an adenosine receptor antagonist , these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine .|Patients with anxiety disorders may benefit by avoiding caffeine - containing foods and beverages .": "[[\"caffeine\", \"has effects\", \"anxiogenic effects in panic disorders\"],\n [\"caffeine\", \"administered to\", \"healthy subjects\"],\n [\"caffeine\", \"administered to\", \"patients with agoraphobia with panic attacks or panic disorder\"],\n [\"caffeine\", \"produced\", \"increases in subject-rated anxiety\"],\n [\"caffeine\", \"produced\", \"increases in nervousness\"],\n [\"caffeine\", \"produced\", \"increases in fear\"],\n [\"caffeine\", \"produced\", \"increases in nausea\"],\n [\"caffeine\", \"produced\", \"increases in palpitations\"],\n [\"caffeine\", \"produced\", \"increases in restlessness\"],\n [\"caffeine\", \"produced\", \"increases in tremors\"],\n [\"patients\", \"compared with\", \"healthy subjects\"],\n [\"symptoms\", \"correlated with\", \"plasma caffeine levels in patients\"],\n [\"patients\", \"reported\", \"behavioral effects of caffeine similar to panic attacks\"],\n [\"caffeine\", \"did not alter\", \"plasma MHPG levels\"],\n [\"caffeine\", \"increased\", \"plasma cortisol levels\"],\n [\"patient and healthy groups\", \"experienced\", \"increase in plasma cortisol levels equally\"],\n [\"caffeine\", \"is an antagonist of\", \"adenosine receptor\"],\n [\"panic disorder patients\", \"may have\", \"abnormalities in neuronal systems involving adenosine\"],\n [\"patients with anxiety disorders\", \"may benefit by\", \"avoiding caffeine-containing foods and beverages\"]]",
      "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin - induced nephrotoxicity : protection by erdosteine .|The aims of this study were to examine vancomycin ( VCM ) - induced oxidative stress that promotes production of reactive oxygen species ( ROS ) and to investigate the role of erdosteine , an expectorant agent , which has also antioxidant properties , on kidney tissue against the possible VCM - induced renal impairment in rats .|Rats were divided into three groups : sham , VCM and VCM plus erdosteine .|VCM was administrated intraperitoneally ( i . p . ) with 200mgkg ( - 1 ) twice daily for 7 days .|Erdosteine was administered orally .|VCM administration to control rats significantly increased renal malondialdehyde ( MDA ) and urinary N - acetyl - beta - d - glucosaminidase ( NAG , a marker of renal tubular injury ) excretion but decreased superoxide dismutase ( SOD ) and catalase ( CAT ) activities .|Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion , and increased SOD activity , but not CAT activity in renal tissue when compared with VCM alone .|Erdosteine showed histopathological protection against VCM - induced nephrotoxicity .|There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , atrophy , desquamation , and necrosis in VCM - treated rats more than those of the control and the erdosteine groups .|Erdosteine caused a marked reduction in the extent of tubular damage .|It is concluded that oxidative tubular damage plays an important role in the VCM - induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM - induced kidney damage both at the biochemical and histological levels .": "[[\"oxidative stress\", \"suggested role in\", \"pathogenesis of vancomycin-induced nephrotoxicity\"],\n [\"erdosteine\", \"provides\", \"protection against vancomycin-induced nephrotoxicity\"],\n [\"study\", \"aims to examine\", \"vancomycin-induced oxidative stress\"],\n [\"study\", \"aims to investigate\", \"role of erdosteine\"],\n [\"erdosteine\", \"is an\", \"expectorant agent\"],\n [\"erdosteine\", \"has\", \"antioxidant properties\"],\n [\"rats\", \"divided into groups\", \"sham, VCM, VCM plus erdosteine\"],\n [\"VCM\", \"administered to\", \"rats\"],\n [\"VCM\", \"promotes production of\", \"ROS\"],\n [\"VCM administration\", \"increased\", \"renal MDA\"],\n [\"VCM administration\", \"increased\", \"urinary NAG excretion\"],\n [\"VCM administration\", \"decreased\", \"SOD activity\"],\n [\"VCM administration\", \"decreased\", \"CAT activity\"],\n [\"erdosteine administration\", \"decreased\", \"renal MDA\"],\n [\"erdosteine administration\", \"decreased\", \"urinary NAG excretion\"],\n [\"erdosteine administration\", \"increased\", \"SOD activity\"],\n [\"erdosteine\", \"did not increase\", \"CAT activity in renal tissue\"],\n [\"erdosteine\", \"showed\", \"histopathological protection against VCM-induced nephrotoxicity\"],\n [\"VCM-treated rats\", \"showed\", \"significant dilatation of tubular lumens\"],\n [\"VCM-treated rats\", \"showed\", \"extensive epithelial cell vacuolization\"],\n [\"VCM-treated rats\", \"showed\", \"atrophy\"],\n [\"VCM-treated rats\", \"showed\", \"desquamation\"],\n [\"VCM-treated rats\", \"showed\", \"necrosis\"],\n [\"erdosteine\", \"caused\", \"reduction in the extent of tubular damage\"],\n [\"oxidative tubular damage\", \"plays role in\", \"VCM-induced nephrotoxicity\"],\n [\"modulation of oxidative stress with erdosteine\", \"reduces\", \"VCM-induced kidney damage\"],\n [\"erdosteine\", \"reduces\", \"kidney damage at biochemical level\"],\n [\"erdosteine\", \"reduces\", \"kidney damage at histological level\"]]",
      "Comparison of laryngeal mask with endotracheal tube for anesthesia in endoscopic sinus surgery .|BACKGROUND : The purpose of this study was to compare surgical conditions , including the amount of intraoperative bleeding as well as intraoperative blood pressure , during functional endoscopic sinus surgery ( FESS ) using flexible reinforced laryngeal mask airway ( FRLMA ) versus endotracheal tube ( ETT ) in maintaining controlled hypotension anesthesia induced by propofol - remifentanil total i . v .|anesthesia ( TIVA ) .|METHODS : Sixty normotensive American Society of Anesthesiologists I - II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol - remifentanil - TIVA were randomly assigned into two groups : group I , FRLMA ; group II , ETT .|Hemorrhage was measured and the visibility of the operative field was evaluated according to a six - point scale .|RESULTS : Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil .|CONCLUSION : In summary , our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS .": "[[\"laryngeal mask\", \"compared with\", \"endotracheal tube\"],\n [\"laryngeal mask\", \"used for\", \"anesthesia in endoscopic sinus surgery\"],\n [\"endotracheal tube\", \"used for\", \"anesthesia in endoscopic sinus surgery\"],\n [\"study\", \"aimed to compare\", \"surgical conditions\"],\n [\"surgical conditions\", \"include\", \"amount of intraoperative bleeding\"],\n [\"surgical conditions\", \"include\", \"intraoperative blood pressure\"],\n [\"functional endoscopic sinus surgery (FESS)\", \"used\", \"flexible reinforced laryngeal mask airway (FRLMA)\"],\n [\"functional endoscopic sinus surgery (FESS)\", \"used\", \"endotracheal tube (ETT)\"],\n [\"anesthesia\", \"induced by\", \"propofol-remifentanil total i.v.\"],\n [\"patients\", \"underwent\", \"functional endoscopic sinus surgery (FESS)\"],\n [\"patients\", \"undergoing\", \"controlled hypotension anesthesia\"],\n [\"controlled hypotension anesthesia\", \"caused by\", \"propofol-remifentanil-TIVA\"],\n [\"group I\", \"assigned\", \"FRLMA\"],\n [\"group II\", \"assigned\", \"ETT\"],\n [\"Hemorrhage\", \"measured by\", \"visibility of operative field\"],\n [\"operative field\", \"evaluated by\", \"six-point scale\"],\n [\"controlled hypotension\", \"achieved using\", \"laryngeal mask\"],\n [\"laryngeal mask\", \"required lower rates of\", \"remifentanil infusion\"],\n [\"laryngeal mask\", \"required lower total dose of\", \"remifentanil\"],\n [\"FRLMA\", \"provided better\", \"surgical conditions\"],\n [\"surgical conditions\", \"measured by\", \"quality of operative field\"],\n [\"surgical conditions\", \"measured by\", \"blood loss\"],\n [\"FRLMA\", \"allowed for\", \"convenient induced hypotension\"],\n [\"induced hypotension\", \"with low doses of\", \"remifentanil\"],\n [\"TIVA\", \"used during\", \"FESS\"]]",
      "Paclitaxel 3 - hour infusion given alone and combined with carboplatin : preliminary results of dose - escalation trials .|Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) by 3 - hour infusion was combined with carboplatin in a phase I / II study directed to patients with non - small cell lung cancer .|Carboplatin was given at a fixed target area under the concentration - time curve of 6 . 0 by the Calvert formula , whereas paclitaxel was escalated in patient cohorts from 150 mg / m2 ( dose level I ) to 175 , 200 , 225 , and 250 mg / m2 .|The 225 mg / m2 level was expanded for the phase II study since the highest level achieved ( 250 mg / m2 ) required modification because of nonhematologic toxicities ( arthralgia and sensory neuropathy ) .|Therapeutic effects were noted at all dose levels , with objective responses in 17 ( two complete and 15 partial regressions ) of 41 previously untreated patients .|Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels .|Carboplatin did not appear to add to the hematologic toxicities observed , and the paclitaxel / carboplatin combination could be dosed every 3 weeks .": "[[\"Paclitaxel 3-hour infusion\", \"given alone and combined with\", \"carboplatin\"],\n [\"Paclitaxel\", \"used in\", \"phase I/II study\"],\n [\"Paclitaxel\", \"for patients with\", \"non-small cell lung cancer\"],\n [\"Carboplatin\", \"administered by\", \"fixed target area under the concentration-time curve\"],\n [\"Carboplatin\", \"fixed target area under the concentration-time curve value\", \"6.0\"],\n [\"Carboplatin administration\", \"based on\", \"Calvert formula\"],\n [\"Paclitaxel\", \"escalated in patient cohorts from\", \"150 mg/m2\"],\n [\"Paclitaxel\", \"escalated to\", \"175 mg/m2\"],\n [\"Paclitaxel\", \"escalated to\", \"200 mg/m2\"],\n [\"Paclitaxel\", \"escalated to\", \"225 mg/m2\"],\n [\"Paclitaxel\", \"escalated to\", \"250 mg/m2\"],\n [\"225 mg/m2 level\", \"expanded for\", \"phase II study\"],\n [\"250 mg/m2 level\", \"required modification due to\", \"nonhematologic toxicities\"],\n [\"Nonhematologic toxicities\", \"include\", \"arthralgia\"],\n [\"Nonhematologic toxicities\", \"include\", \"sensory neuropathy\"],\n [\"Therapeutic effects\", \"noted at\", \"all dose levels\"],\n [\"Objective responses\", \"observed in\", \"17 of 41 previously untreated patients\"],\n [\"Objective responses\", \"include\", \"two complete regressions\"],\n [\"Objective responses\", \"include\", \"15 partial regressions\"],\n [\"Toxicities\", \"compared with\", \"cohort of patients in phase I trial of paclitaxel alone\"],\n [\"Paclitaxel alone\", \"administered at\", \"identical dose levels\"],\n [\"Carboplatin\", \"did not add to\", \"hematologic toxicities\"],\n [\"Paclitaxel/carboplatin combination\", \"could be dosed every\", \"3 weeks\"]]",
      "Quinine - induced arrhythmia in a patient with severe malaria .|It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( premature ventricular contraction ) while getting quinine infusion was reported .|A man , 25 years old , was admitted to hospital with high fever , chill , vomiting , jaundice .|The patient was fully conscious , blood pressure 120 / 80 mmHg , pulse rate 100 x / minute , regular .|On admission , laboratory examination showed Plasmodium falciparum ( + + + + ) , total bilirubin 8 . 25 mg / dL , conjugated bilirubin 4 . 36 mg / dL , unconjugated bilirubin 3 . 89 mg / dL , potassium 3 . 52 meq / L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5 % 500 mg / 8 hour .|On the second day the patient had vomitus , diarrhea , tinnitus , loss of hearing .|After 30 hours of quinine infusion the patient felt palpitation and electrocardiography ( ECG ) recording showed premature ventricular contraction ( PVC ) > 5 x / minute , trigemini , constant type - - sinoatrial block , positive U wave .|He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5 % / 24 hour and potassium aspartate tablet .|Quinine infusion was discontinued and changed with sulfate quinine tablets .|Three hours later the patient felt better , the frequency of PVC reduced to 4 - 5 x / minute and on the third day ECG was normal , potassium level was 3 . 34 meq / L .|He was discharged on 7th day in good condition .|Quinine , like quinidine , is a chincona alkaloid that has anti - arrhythmic property , although it also pro - arrhythmic that can cause various arrhythmias , including severe arrhythmia such as multiple PVC .|Administration of parenteral quinine must be done carefully and with good observation because of its pro - arrhythmic effect , especially in older patients who have heart diseases or patients with electrolyte disorder ( hypokalemia ) which frequently occurs due to vomiting and or diarrhea in malaria cases .": "[[\"Quinine\", \"induced\", \"arrhythmia in a patient with severe malaria\"],\n[\"Severe malaria patient with jaundice\", \"presented with\", \"arrhythmia (premature ventricular contraction)\"],\n[\"Severe malaria patient with jaundice\", \"was getting\", \"quinine infusion\"],\n[\"A man, 25 years old\", \"was admitted to\", \"hospital\"],\n[\"The patient\", \"had\", \"high fever\"],\n[\"The patient\", \"had\", \"chill\"],\n[\"The patient\", \"had\", \"vomiting\"],\n[\"The patient\", \"had\", \"jaundice\"],\n[\"The patient\", \"was\", \"fully conscious\"],\n[\"The patient\", \"had blood pressure\", \"120/80 mmHg\"],\n[\"The patient\", \"had pulse rate\", \"100 x/minute\"],\n[\"Laboratory examination\", \"showed\", \"Plasmodium falciparum (++++)\"],\n[\"Laboratory examination\", \"showed\", \"total bilirubin 8.25 mg/dL\"],\n[\"Laboratory examination\", \"showed\", \"conjugated bilirubin 4.36 mg/dL\"],\n[\"Laboratory examination\", \"showed\", \"unconjugated bilirubin 3.89 mg/dL\"],\n[\"Laboratory examination\", \"showed\", \"potassium 3.52 meq/L\"],\n[\"Patient\", \"was diagnosed with\", \"severe malaria with jaundice\"],\n[\"Patient\", \"got\", \"quinine infusion in dextrose 5% 500 mg/8 hour\"],\n[\"The patient\", \"had\", \"vomitus\"],\n[\"The patient\", \"had\", \"diarrhea\"],\n[\"The patient\", \"had\", \"tinnitus\"],\n[\"The patient\", \"had\", \"loss of hearing\"],\n[\"After quinine infusion\", \"patient felt\", \"palpitation\"],\n[\"ECG recording\", \"showed\", \"premature ventricular contraction (PVC) > 5 x/minute\"],\n[\"ECG recording\", \"showed\", \"trigemini\"],\n[\"ECG recording\", \"showed\", \"sinoatrial block\"],\n[\"ECG recording\", \"showed\", \"positive U wave\"],\n[\"He\", \"was treated with\", \"lidocaine 50 mg intravenously\"],\n[\"He\", \"was treated with\", \"infusion 1500 mg in dextrose 5% / 24 hour\"],\n[\"He\", \"was treated with\", \"potassium aspartate tablet\"],\n[\"Quinine infusion\", \"was discontinued\"],\n[\"Patient\", \"changed to\", \"sulfate quinine tablets\"],\n[\"The patient\", \"felt better\", \"Three hours later\"],\n[\"Frequency of PVC\", \"reduced to\", \"4-5 x/minute\"],\n[\"On the third day\", \"ECG was\", \"normal\"],\n[\"Potassium level\", \"was\", \"3.34 meq/L\"],\n[\"He\", \"was discharged on\", \"7th day in good condition\"],\n[\"Quinine\", \"is a\", \"chincona alkaloid\"],\n[\"Quinine\", \"has\", \"anti-arrhythmic property\"],\n[\"Quinine\", \"can cause\", \"pro-arrhythmic effects\"],\n[\"Quinine\", \"can cause\", \"various arrhythmias\"],\n[\"Quinine\", \"can cause\", \"severe arrhythmia such as multiple PVC\"],\n[\"Administration of parenteral quinine\", \"must be done carefully due to\", \"pro-arrhythmic effect\"],\n[\"Administration of parenteral quinine\", \"requires\", \"good observation\"],\n[\"Pro-arrhythmic effect\", \"is especially risky for\", \"older patients with heart diseases\"],\n[\"Pro-arrhythmic effect\", \"is especially risky for\", \"patients with electrolyte disorder\"],\n[\"Electrolyte disorder\", \"occurs due to\",",
      "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU - induced cortical dysplasia .|Cortical dysplasia is a malformation characterized by defects in proliferation , migration and maturation .|This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine - [ 1 , 3 - bis ( 2 - chloroethyl ) - 1 - nitrosoure ] ( BCNU ) and to investigate the effects of exogenous melatonin upon cerebellar BCNU - induced cortical dysplasia , using histological and biochemical analyses .|Pregnant Wistar rats were assigned to five groups : intact - control , saline - control , melatonin - treated , BCNU - exposed and BCNU - exposed plus melatonin .|Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery .|Immuno / histochemistry and electron microscopy were carried out on the offspring cerebellum , and levels of malondialdehyde and superoxide dismutase were determined .|Histopathologically , typical findings were observed in the cerebella from the control groups , but the findings consistent with early embryonic development were noted in BCNU - exposed cortical dysplasia group .|There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU - exposed group , but a decreased immunoreactivity to glial fibrillary acidic protein , synaptophysin and transforming growth factor beta1 was observed , indicating a delayed maturation , and melatonin significantly reversed these changes .|Malondialdehyde level in BCNU - exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group ( P < 0 . 01 ) , while there were no significant differences in the superoxide dismutase levels between these groups .|These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU .": "[[\"Neuroprotective effects\", \"of\", \"melatonin\"], [\"melatonin\", \"upon\", \"offspring cerebellar cortex\"], [\"offspring cerebellar cortex\", \"in\", \"rat model of BCNU-induced cortical dysplasia\"], [\"Cortical dysplasia\", \"is a malformation characterized by\", \"defects in proliferation, migration, and maturation\"], [\"study\", \"designed to evaluate\", \"alterations in offspring rat cerebellum\"], [\"study\", \"investigate\", \"effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia\"], [\"maternal exposure\", \"to\", \"carmustine (BCNU)\"], [\"carmustine (BCNU)\", \"induces\", \"cortical dysplasia\"], [\"Pregnant Wistar rats\", \"assigned to\", \"five groups\"], [\"groups\", \"include\", \"intact-control\"], [\"groups\", \"include\", \"saline-control\"], [\"groups\", \"include\", \"melatonin-treated\"], [\"groups\", \"include\", \"BCNU-exposed\"], [\"groups\", \"include\", \"BCNU-exposed plus melatonin\"], [\"Rats\", \"exposed to\", \"BCNU on embryonic day 15\"], [\"melatonin\", \"given until\", \"delivery\"], [\"analyses\", \"carried out on\", \"offspring cerebellum\"], [\"levels determined\", \"of\", \"malondialdehyde\"], [\"levels determined\", \"of\", \"superoxide dismutase\"], [\"Histopathologically\", \"findings observed in\", \"cerebella from control groups\"], [\"findings\", \"consistent with\", \"early embryonic development\"], [\"findings\", \"noted in\", \"BCNU-exposed cortical dysplasia group\"], [\"increase in number\", \"of\", \"TUNEL positive cells\"], [\"increase in number\", \"of\", \"nestin positive cells\"], [\"BCNU-exposed group\", \"had decreased immunoreactivity to\", \"glial fibrillary acidic protein\"], [\"BCNU-exposed group\", \"had decreased immunoreactivity to\", \"synaptophysin\"], [\"BCNU-exposed group\", \"had decreased immunoreactivity to\", \"transforming growth factor beta1\"], [\"decreased immunoreactivity\", \"indicating\", \"delayed maturation\"], [\"melatonin\", \"significantly reversed\", \"these changes\"], [\"Malondialdehyde level\", \"higher in\", \"BCNU-exposed group\"], [\"melatonin\", \"decreased\", \"malondialdehyde levels in BCNU group\"], [\"no significant differences\", \"in\", \"superoxide dismutase levels between groups\"], [\"data\", \"suggest\", \"exposure to BCNU during pregnancy leads to delayed maturation of offspring cerebellum\"], [\"melatonin\", \"protects\", \"cerebellum against effects of BCNU\"]].",
      "Overexpression of copper / zinc - superoxide dismutase protects from kanamycin - induced hearing loss .|The participation of reactive oxygen species in aminoglycoside - induced ototoxicity has been deduced from observations that aminoglycoside - iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo .|We therefore hypothesized that overexpression of Cu / Zn - superoxide dismutase ( h - SOD1 ) should protect transgenic mice from ototoxicity .|Immunocytochemistry confirmed expression of h - SOD1 in inner ear tissues of transgenic C57BL / 6 - TgN [ SOD1 ] 3Cje mice .|Transgenic and nontransgenic littermates received kanamycin ( 400 mg / kg body weight / day ) for 10 days beginning on day 10 after birth .|Auditory thresholds were tested by evoked auditory brain stem responses at 1 month after birth .|In nontransgenic animals , the threshold in the kanamycin - treated group was 45 - 50 dB higher than in saline - injected controls .|In the transgenic group , kanamycin increased the threshold by only 15 dB over the respective controls .|The effects were similar at 12 and 24 kHz .|The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside - induced ototoxicity .|The results also suggest transgenic animals as suitable models to investigate the underlying mechanisms and possible strategies for prevention .": "[[\"Overexpression of copper/zinc-superoxide dismutase\", \"protects from\", \"kanamycin-induced hearing loss\"],\n[\"Reactive oxygen species\", \"participate in\", \"aminoglycoside-induced ototoxicity\"],\n[\"Aminoglycoside-iron complexes\", \"catalyze\", \"formation of superoxide radicals in vitro\"],\n[\"Antioxidants\", \"attenuate\", \"ototoxicity in vivo\"],\n[\"Overexpression of Cu/Zn-superoxide dismutase (h-SOD1)\", \"should protect\", \"transgenic mice from ototoxicity\"],\n[\"Immunocytochemistry\", \"confirmed expression of\", \"h-SOD1 in inner ear tissues\"],\n[\"Transgenic C57BL/6-TgN[SOD1]3Cje mice\", \"express\", \"h-SOD1\"],\n[\"Transgenic and nontransgenic littermates\", \"received\", \"kanamycin\"],\n[\"Auditory thresholds\", \"tested by\", \"evoked auditory brain stem responses\"],\n[\"Nontransgenic animals\", \"had higher threshold in\", \"kanamycin-treated group compared to saline-injected controls\"],\n[\"Transgenic group\", \"had increased threshold by\", \"15 dB over controls due to kanamycin\"],\n[\"Protection by overexpression of superoxide dismutase\", \"supports\", \"oxidant stress plays significant role in aminoglycoside-induced ototoxicity\"],\n[\"Transgenic animals\", \"suggest as\", \"suitable models to investigate prevention strategies\"]]",
      "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers : a placebo - controlled trial .|Lamivudine is a novel 2 ' , 3 ' - dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo .|We performed a single - blind , placebo - controlled study to assess its effectiveness and safety in Chinese hepatitis B surface antigen ( HBsAg ) carriers .|Forty - two Chinese HBsAg carriers were randomized to receive placebo ( 6 patients ) or lamivudine orally in dosages of 25 mg , 100 mg , or 300 mg daily ( 12 patients for each dosage ) .|The drug was given for 4 weeks .|The patients were closely monitored clinically , biochemically , and serologically up to 4 weeks after drug treatment .|All 36 patients receiving lamivudine had a decrease in hepatitis B virus ( HBV ) DNA values of > 90 % ( P < . 001 compared with placebo ) .|Although 25 mg of lamivudine was slightly less effective than 100 mg ( P = . 011 ) and 300 mg ( P = . 005 ) , it still induced 94 % suppression of HBV DNA after the fourth week of therapy .|HBV DNA values returned to pretreatment levels within 4 weeks of cessation of therapy .|There was no change in the hepatitis B e antigen status or in aminotransferase levels .|No serious adverse events were observed .|In conclusion , a 4 - week course of lamivudine was safe and effective in suppression of HBV DNA in Chinese HBsAg carriers .|The suppression was > 90 % but reversible .|Studies with long - term lamivudine administration should be performed to determine if prolonged suppression of HBV DNA can be achieved .": "[[\"Lamivudine\", \"is effective in suppressing\", \"hepatitis B virus DNA\"],\n [\"Lamivudine\", \"used in\", \"a placebo-controlled trial\"],\n [\"Lamivudine\", \"is a\", \"novel 2', 3' - dideoxy cytosine analogue\"],\n [\"Lamivudine\", \"has inhibitory effects on\", \"hepatitis B virus replication\"],\n [\"Study\", \"assessed\", \"effectiveness and safety of Lamivudine\"],\n [\"Study\", \"type\", \"single-blind, placebo-controlled\"],\n [\"Chinese HBsAg carriers\", \"were randomized to receive\", \"placebo\"],\n [\"Chinese HBsAg carriers\", \"were randomized to receive\", \"lamivudine\"],\n [\"Lamivudine\", \"administered orally in dosages of\", \"25 mg, 100 mg, or 300 mg daily\"],\n [\"Lamivudine\", \"given for\", \"4 weeks\"],\n [\"Patients\", \"monitored clinically, biochemically, and serologically\", \"up to 4 weeks after drug treatment\"],\n [\"Patients receiving lamivudine\", \"had a decrease in\", \"HBV DNA values of > 90%\"],\n [\"25 mg of lamivudine\", \"less effective than\", \"100 mg\"],\n [\"25 mg of lamivudine\", \"less effective than\", \"300 mg\"],\n [\"25 mg of lamivudine\", \"induced\", \"94% suppression of HBV DNA after the fourth week of therapy\"],\n [\"HBV DNA values\", \"returned to\", \"pretreatment levels within 4 weeks of cessation of therapy\"],\n [\"There was no change in\", \"hepatitis B e antigen status\", \"due to lamivudine\"],\n [\"There was no change in\", \"aminotransferase levels\", \"due to lamivudine\"],\n [\"No serious adverse events\", \"were observed\", \"during lamivudine treatment\"],\n [\"4-week course of lamivudine\", \"was\", \"safe and effective in suppression of HBV DNA\"],\n [\"Suppression of HBV DNA by lamivudine\", \"was\", \"> 90% but reversible\"],\n [\"Studies with long-term lamivudine administration\", \"should be performed to determine\", \"if prolonged suppression of HBV DNA can be achieved\"]]",
      "Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane .|A 69 - year - old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis .|Massive bleeding appeared during surgery which lasted for six hours .|Postoperative evolution under supportive therapy was favourable .|Complete recovery was confirmed by repeated controls performed over a period of one year after surgery .": "[[\"Hepatitis\", \"associated with\", \"anesthesia with methoxyflurane\"],\n[\"Renal tubular acidosis\", \"associated with\", \"anesthesia with methoxyflurane\"],\n[\"69-year-old man\", \"operated for\", \"acute cholecystitis\"],\n[\"69-year-old man\", \"developed after methoxyflurane anesthesia\", \"hepatic insufficiency syndrome\"],\n[\"69-year-old man\", \"developed after methoxyflurane anesthesia\", \"renal tubular acidosis\"],\n[\"Massive bleeding\", \"appeared during\", \"surgery\"],\n[\"Surgery\", \"lasted for\", \"six hours\"],\n[\"Postoperative evolution\", \"was\", \"favourable under supportive therapy\"],\n[\"Complete recovery\", \"confirmed by\", \"repeated controls\"],\n[\"Repeated controls\", \"performed over\", \"one year after surgery\"]]",
      "Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine - induced hypotension and bradycardia .|The effects of microinjection of clonidine ( 1 - 10 micrograms in 1 microliter ) into a region adjacent to the ventrolateral surface of the medulla oblongata on cardiovascular function were assessed in urethane - anesthetized rats .|Intramedullary administration of clonidine , but not saline vehicle , caused a dose - dependent decrease in both the mean arterial pressure and the heart rate .|The clonidine - induced hypotension was antagonized by prior spinal transection , but not bilateral vagotomy .|On the other hand , the clonidine - induced bradycardia was antagonized by prior bilateral vagotomy , but not spinal transection .|Furthermore , selective destruction of the spinal 5 - HT nerves , produced by bilateral spinal injection of 5 , 7 - dihydroxytryptamine , reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats .|The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine - induced hypotension and bradycardia .|The induced hypotension is brought about by a decrease in sympathetic efferent activity , whereas the induced bradycardia was due to an increase in vagal efferent activity .": "[[\"bulbospinal serotonergic pathway\", \"participates in\", \"clonidine-induced hypotension and bradycardia\"],\n [\"clonidine\", \"microinjected into\", \"region adjacent to ventrolateral surface of medulla oblongata\"],\n [\"clonidine\", \"affects\", \"cardiovascular function\"],\n [\"clonidine\", \"causes\", \"dose-dependent decrease in mean arterial pressure\"],\n [\"clonidine\", \"causes\", \"dose-dependent decrease in heart rate\"],\n [\"clonidine-induced hypotension\", \"antagonized by\", \"prior spinal transection\"],\n [\"clonidine-induced hypotension\", \"not antagonized by\", \"bilateral vagotomy\"],\n [\"clonidine-induced bradycardia\", \"antagonized by\", \"prior bilateral vagotomy\"],\n [\"clonidine-induced bradycardia\", \"not antagonized by\", \"spinal transection\"],\n [\"selective destruction of spinal 5-HT nerves\", \"produced by\", \"bilateral spinal injection of 5,7-dihydroxytryptamine\"],\n [\"selective destruction of spinal 5-HT nerves\", \"reduces magnitude of\", \"vasodepressor response to clonidine\"],\n [\"selective destruction of spinal 5-HT nerves\", \"reduces magnitude of\", \"bradycardiac response to clonidine\"],\n [\"bulbospinal serotonergic pathway\", \"involved in\", \"development of clonidine-induced hypotension\"],\n [\"bulbospinal serotonergic pathway\", \"involved in\", \"development of clonidine-induced bradycardia\"],\n [\"induced hypotension\", \"brought about by\", \"decrease in sympathetic efferent activity\"],\n [\"induced bradycardia\", \"due to\", \"increase in vagal efferent activity\"]]",
      "Treatment - related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter .|This report describes unique contrast enhancement of the white matter on T1 - weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy , which developed from acute lymphoblastic leukemia treated with high - dose methotrexate .|In both patients , the enhancement was more pronounced near the base of the brain than at the vertex .|Necropsy of the first case revealed loss of myelination and necrosis of the white matter .|Possible mechanisms causing such a leukoencephalopathy are discussed .": "[[\"Disseminated necrotizing leukoencephalopathy\", \"has characteristic\", \"contrast enhancement of the white matter\"],\n[\"Disseminated necrotizing leukoencephalopathy\", \"developed from\", \"acute lymphoblastic leukemia\"],\n[\"Disseminated necrotizing leukoencephalopathy\", \"treated with\", \"high-dose methotrexate\"],\n[\"Contrast enhancement\", \"observed on\", \"T1-weighted magnetic resonance images\"],\n[\"Patients\", \"had\", \"disseminated necrotizing leukoencephalopathy\"],\n[\"Enhancement\", \"was more pronounced near\", \"base of the brain\"],\n[\"Enhancement\", \"less pronounced at\", \"vertex\"],\n[\"First case\", \"revealed\", \"loss of myelination\"],\n[\"First case\", \"revealed\", \"necrosis of the white matter\"],\n[\"Report\", \"describes\", \"unique contrast enhancement\"],\n[\"Possible mechanisms\", \"causing\", \"leukoencephalopathy are discussed\"]]",
      "Oxidative damage precedes nitrative damage in adriamycin - induced cardiac mitochondrial injury .|The purpose of the present study was to determine if elevated reactive oxygen ( ROS ) / nitrogen species ( RNS ) reported to be present in adriamycin ( ADR ) - induced cardiotoxicity actually resulted in cardiomyocyte oxidative / nitrative damage , and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach .|B6C3 mice were treated with a single dose of 20 mg / kg ADR .|Ultrastructural damage and levels of 4 - hydroxy - 2 - nonenal ( 4HNE ) - protein adducts and 3 - nitrotyrosine ( 3NT ) were analyzed .|Quantitative ultrastructural damage using computerized image techniques showed cardiomyocyte injury as early as 3 hours , with mitochondria being the most extensively and progressively injured subcellular organelle .|Analysis of 4HNE protein adducts by immunogold electron microscopy showed appearance of 4HNE protein adducts in mitochondria as early as 3 hours , with a peak at 6 hours and subsequent decline at 24 hours .|3NT levels were significantly increased in all subcellular compartments at 6 hours and subsequently declined at 24 hours .|Our data showed ADR induced 4HNE - protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared .|These results document for the first time in vivo that mitochondrial oxidative damage precedes nitrative damage .|The progressive nature of mitochondrial injury suggests that mitochondria , not other subcellular organelles , are the major site of intracellular injury .": "[[\"Oxidative damage\", \"precedes\", \"nitrative damage in adriamycin-induced cardiac mitochondrial injury\"],\n[\"Study\", \"determine if\", \"elevated reactive oxygen (ROS)/nitrogen species (RNS) result in cardiomyocyte oxidative/nitrative damage\"],\n[\"Study\", \"determine\", \"time course and subcellular localization of damage products\"],\n[\"Study\", \"used\", \"in vivo approach\"],\n[\"B6C3 mice\", \"were treated with\", \"a single dose of 20 mg/kg ADR\"],\n[\"Ultrastructural damage\", \"analyzed by\", \"levels of 4-hydroxy-2-nonenal (4HNE) - protein adducts and 3-nitrotyrosine (3NT)\"],\n[\"Quantitative ultrastructural damage\", \"showed\", \"cardiomyocyte injury\"],\n[\"Cardiomyocyte injury\", \"occurred as early as\", \"3 hours\"],\n[\"Mitochondria\", \"most extensively and progressively injured\", \"subcellular organelle\"],\n[\"4HNE protein adducts\", \"appeared in\", \"mitochondria\"],\n[\"4HNE protein adducts\", \"peaked at\", \"6 hours\"],\n[\"4HNE protein adducts\", \"declined at\", \"24 hours\"],\n[\"3NT levels\", \"increased in\", \"all subcellular compartments at 6 hours\"],\n[\"3NT levels\", \"declined at\", \"24 hours\"],\n[\"ADR\", \"induced\", \"4HNE-protein adducts in mitochondria\"],\n[\"Mitochondrial injury\", \"initially appeared at\", \"same time point as 4HNE-protein adducts\"],\n[\"Results\", \"document\", \"mitochondrial oxidative damage precedes nitrative damage\"],\n[\"Mitochondrial injury\", \"suggests\", \"mitochondria are the major site of intracellular injury\"]]",
      "Ifosfamide related encephalopathy : the need for a timely EEG evaluation .|BACKGROUND : Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas , lymphoma , gynecologic and testicular cancers .|Encephalopathy has been reported in 10 - 40 % of patients receiving high - dose IV ifosfamide .|OBJECTIVE : To highlight the role of electroencephalogram ( EEG ) in the early detection and management of ifosfamide related encephalopathy .|METHODS : Retrospective chart review including clinical data and EEG recordings was done on five patients , admitted to MD Anderson Cancer Center between years 2009 and 2012 , who developed ifosfamide related acute encephalopathy .|RESULTS : All five patients experienced symptoms of encephalopathy soon after ( within 12 h - 2 days ) receiving ifosfamide .|Two patients developed generalized convulsions while one patient developed continuous non - convulsive status epilepticus ( NCSE ) that required ICU admission and intubation .|Initial EEG showed epileptiform discharges in three patients ; run of triphasic waves in one patient and moderate degree diffuse generalized slowing .|Mixed pattern with the presence of both sharps and triphasic waves were also noted .|Repeat EEGs within 24_h of symptom onset showed marked improvement that was correlated with clinical improvement .|CONCLUSIONS : Severity of ifosfamide related encephalopathy correlates with EEG changes .|We suggest a timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy .": "[[\"Ifosfamide related encephalopathy\", \"requires\", \"timely EEG evaluation\"],\n [\"Ifosfamide\", \"is an\", \"alkylating agent\"],\n [\"Ifosfamide\", \"is useful in the treatment of\", \"a wide range of cancers\"],\n [\"Ifosfamide\", \"includes treatment for\", \"sarcomas\"],\n [\"Ifosfamide\", \"includes treatment for\", \"lymphoma\"],\n [\"Ifosfamide\", \"includes treatment for\", \"gynecologic cancers\"],\n [\"Ifosfamide\", \"includes treatment for\", \"testicular cancers\"],\n [\"Encephalopathy\", \"has been reported in\", \"10 - 40% of patients receiving high-dose IV ifosfamide\"],\n [\"Objective\", \"is to highlight\", \"role of EEG\"],\n [\"EEG\", \"used in\", \"early detection and management of ifosfamide related encephalopathy\"],\n [\"Retrospective chart review\", \"included\", \"clinical data and EEG recordings\"],\n [\"Retrospective chart review\", \"done on\", \"five patients\"],\n [\"Patients\", \"admitted to\", \"MD Anderson Cancer Center\"],\n [\"Patients\", \"developed\", \"ifosfamide related acute encephalopathy\"],\n [\"Patients\", \"experienced symptoms of encephalopathy\", \"soon after receiving ifosfamide\"],\n [\"Patients\", \"received ifosfamide\", \"between years 2009 and 2012\"],\n [\"Two patients\", \"developed\", \"generalized convulsions\"],\n [\"One patient\", \"developed\", \"continuous non-convulsive status epilepticus\"],\n [\"One patient\", \"required\", \"ICU admission and intubation\"],\n [\"Initial EEG\", \"showed\", \"epileptiform discharges in three patients\"],\n [\"Initial EEG\", \"showed\", \"run of triphasic waves in one patient\"],\n [\"Initial EEG\", \"showed\", \"moderate degree diffuse generalized slowing\"],\n [\"EEG\", \"showed\", \"mixed pattern with presence of both sharps and triphasic waves\"],\n [\"Repeat EEGs\", \"showed\", \"marked improvement\"],\n [\"Repeat EEGs\", \"correlated with\", \"clinical improvement\"],\n [\"Severity of ifosfamide related encephalopathy\", \"correlates with\", \"EEG changes\"],\n [\"Authors\", \"suggest\", \"timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy\"]]",
      "Dose - dependent neurotoxicity of high - dose busulfan in children : a clinical and pharmacological study .|Busulfan is known to be neurotoxic in animals and humans , but its acute neurotoxicity remains poorly characterized in children .|We report here a retrospective study of 123 children ( median age , 6 . 5 years ) receiving high - dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors , brain tumors excluded .|Busulfan was given p . o . , every 6 hours for 16 doses over 4 days .|Two total doses were consecutively used : 16 mg / kg , then 600 mg / m2 .|The dose calculation on the basis of body surface area results in higher doses in young children than in older patients ( 16 to 28 mg / kg ) .|Ninety - six patients were not given anticonvulsive prophylaxis ; 7 ( 7 . 5 % ) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing .|When the total busulfan dose was taken into account , there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg / kg ( 1 of 57 , 1 . 7 % ) and patients under 600 mg / m2 ( 6 of 39 , 15 . 4 % ) ( P less than 0 . 02 ) .|Twenty - seven patients were given a 600 - mg / m2 busulfan total dose with continuous i . v .|infusion of clonazepam ; none had any neurological symptoms .|Busulfan levels were measured by a gas chromatographic - mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg / m2 busulfan with clonazepam : busulfan cerebrospinal fluid : plasma ratio was 1 . 39 .|This was significantly different ( P less than 0 . 02 ) from the cerebrospinal fluid : plasma ratio previously defined in children receiving a 16 - mg / kg total dose of busulfan .|This study shows that busulfan neurotoxicity is dose - dependent in children and efficiently prevented by clonazepam .|A busulfan dose calculated on the basis of body surface area , resulting in higher doses in young children , was followed by increased neurotoxicity , close to neurotoxicity incidence observed in adults .|Since plasma pharmacokinetic studies showed a faster busulfan clearance in children than in adults , this new dose may approximate more closely the adult systemic exposure obtained after the usual 16 - mg / kg total dose , with potential inferences in terms of anticancer or myeloablative effects .|The busulfan dose in children and infants undergoing bone marrow transplantation should be reconsidered on the basis of pharmacokinetic studies .": "[[\"Neurotoxicity\", \"is a characteristic of\", \"high-dose busulfan\"],\n [\"Neurotoxicity\", \"occurs in\", \"animals and humans\"],\n [\"Acute neurotoxicity\", \"is characterized as\", \"poorly in children\"],\n [\"Study\", \"reports on\", \"123 children\"],\n [\"Children\", \"receiving\", \"high-dose busulfan\"],\n [\"High-dose busulfan\", \"used for\", \"chemotherapy before bone marrow transplantation\"],\n [\"Chemotherapy\", \"excludes\", \"brain tumors\"],\n [\"Busulfan\", \"administered\", \"orally\"],\n [\"Busulfan\", \"administered every\", \"6 hours\"],\n [\"Busulfan\", \"administered for\", \"16 doses over 4 days\"],\n [\"Two total doses\", \"used consecutively\", \"16 mg/kg and 600 mg/m2\"],\n [\"Dose calculation\", \"based on\", \"body surface area\"],\n [\"Higher doses\", \"result in\", \"young children\"],\n [\"Patients\", \"not given\", \"anticonvulsive prophylaxis\"],\n [\"Patients\", \"developed\", \"seizures\"],\n [\"Neurotoxicity incidence\", \"significant difference between\", \"doses under 16 mg/kg and 600 mg/m2\"],\n [\"Patients\", \"given\", \"600-mg/m2 busulfan total dose with clonazepam\"],\n [\"Patients with clonazepam\", \"had no\", \"neurological symptoms\"],\n [\"Busulfan levels\", \"measured by\", \"gas chromatographic-mass spectrometry assay\"],\n [\"Busulfan levels\", \"measured in\", \"plasma and cerebrospinal fluid\"],\n [\"Busulfan cerebrospinal fluid:plasma ratio\", \"is\", \"1.39\"],\n [\"Cerebrospinal fluid:plasma ratio\", \"significantly different from\", \"children receiving 16-mg/kg total dose\"],\n [\"Study shows\", \"busulfan neurotoxicity\", \"is dose-dependent in children\"],\n [\"Busulfan neurotoxicity\", \"prevented by\", \"clonazepam\"],\n [\"Higher doses in young children\", \"followed by\", \"increased neurotoxicity\"],\n [\"Increased neurotoxicity\", \"close to\", \"neurotoxicity incidence in adults\"],\n [\"Busulfan clearance\", \"faster in\", \"children than in adults\"],\n [\"New dose\", \"may approximate\", \"adult systemic exposure\"],\n [\"Adult systemic exposure\", \"obtained after\", \"usual 16-mg/kg total dose\"],\n [\"Busulfan dose in children and infants\", \"should be reconsidered\", \"on the basis of pharmacokinetic studies\"],\n [\"Bone marrow transplantation\", \"in children and infants\", \"requires reconsideration of busulfan dose\"]]",
      "Impaired fear recognition in regular recreational cocaine users .|INTRODUCTION : The ability to read facial expressions is essential for normal human social interaction .|The aim of the present study was to conduct the first investigation of facial expression recognition performance in recreational cocaine users .|MATERIALS AND METHODS : Three groups , comprised of 21 cocaine naive participants ( CN ) , 30 occasional cocaine ( OC ) , and 48 regular recreational cocaine ( RC ) users , were compared .|An emotional facial expression ( EFE ) task consisting of a male and female face expressing six basic emotions ( happiness , surprise , sadness , anger , fear , and disgust ) was administered .|Mean percent accuracy and latencies for correct responses across eight presentations of each basic emotion were derived .|Participants were also assessed with the \" Eyes task \" to investigate their ability to recognize more complex emotional states and the Symptom CheckList - 90 - Revised to measure psychopathology .|RESULTS : There were no group differences in psychopathology or \" eyes task \" performance , but the RC group , who otherwise had similar illicit substance use histories to the OC group , exhibited impaired fear recognition accuracy compared to the OC and CN groups .|The RC group also correctly identified anger , fear , happiness , and surprise , more slowly than CN , but not OC participants .|The OC group was slower than CN when correctly identifying disgust .|The selective deficit in fear recognition accuracy manifested by the RC group can not be explained by the subacute effects of cocaine , or ecstasy , because recent and less recent users of these drugs within this group were similarly impaired .|Possible parallels between RC users and psychopaths with respect to impaired fear recognition , amygdala dysfunction , and etiology are discussed .": "[[\"Impaired fear recognition\", \"in\", \"regular recreational cocaine users\"],\n[\"Ability to read facial expressions\", \"is essential for\", \"normal human social interaction\"],\n[\"Present study\", \"aimed to investigate\", \"facial expression recognition performance in recreational cocaine users\"],\n[\"Three groups\", \"comprised of\", \"cocaine naive participants (CN), occasional cocaine (OC), and regular recreational cocaine (RC) users\"],\n[\"Emotional facial expression (EFE) task\", \"administered to\", \"three groups\"],\n[\"EFE task\", \"consists of\", \"male and female face expressing six basic emotions\"],\n[\"Six basic emotions\", \"include\", \"happiness, surprise, sadness, anger, fear, and disgust\"],\n[\"Participants\", \"assessed with\", \"\\\"Eyes task\\\"\"],\n[\"Participants\", \"assessed with\", \"Symptom CheckList-90-Revised\"],\n[\"RC group\", \"exhibited\", \"impaired fear recognition accuracy compared to OC and CN groups\"],\n[\"RC group\", \"identified emotions\", \"more slowly than CN\"],\n[\"OC group\", \"was slower than CN\", \"when correctly identifying disgust\"],\n[\"Selective deficit in fear recognition accuracy\", \"manifested by\", \"RC group\"],\n[\"Selective deficit in fear recognition accuracy\", \"cannot be explained by\", \"subacute effects of cocaine or ecstasy\"],\n[\"RC users\", \"discussed in relation to\", \"psychopaths\"],\n[\"RC users\", \"discussed in relation to\", \"amygdala dysfunction\"],\n[\"RC users\", \"discussed in relation to\", \"etiology\"]]",
      "Mania associated with fluoxetine treatment in adolescents .|Fluoxetine , a selective serotonin reuptake inhibitor , is gaining increased acceptance in the treatment of adolescent depression .|Generally safe and well tolerated by adults , fluoxetine has been reported to induce mania .|The cases of five depressed adolescents , 14 - 16 years of age , who developed mania during pharmacotherapy with fluoxetine , are reported here .|Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention - deficit hyperactivity disorder and affective instability ; major depression with psychotic features ; a family history of affective disorder , especially bipolar disorder ; and a diagnosis of bipolar disorder .|Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents .": "[[\"Mania\", \"associated with\", \"fluoxetine treatment in adolescents\"],\n[\"Fluoxetine\", \"is a type of\", \"selective serotonin reuptake inhibitor\"],\n[\"Fluoxetine\", \"used for\", \"treatment of adolescent depression\"],\n[\"Fluoxetine\", \"tolerated by\", \"adults\"],\n[\"Fluoxetine\", \"reported to induce\", \"mania\"],\n[\"Depressed adolescents\", \"developed\", \"mania during pharmacotherapy with fluoxetine\"],\n[\"Risk factors\", \"for development of\", \"mania or hypomania during fluoxetine pharmacotherapy\"],\n[\"Risk factors\", \"include\", \"combination of attention-deficit hyperactivity disorder and affective instability\"],\n[\"Risk factors\", \"include\", \"major depression with psychotic features\"],\n[\"Risk factors\", \"include\", \"family history of affective disorder, especially bipolar disorder\"],\n[\"Risk factors\", \"include\", \"diagnosis of bipolar disorder\"],\n[\"Study\", \"is needed to determine\", \"optimal dosage\"],\n[\"Study\", \"is needed to identify\", \"risk factors that increase vulnerability to fluoxetine induced mania in adolescents\"]]",
      "Use of argatroban and catheter - directed thrombolysis with alteplase in an oncology patient with heparin - induced thrombocytopenia with thrombosis .|PURPOSE : The case of an oncology patient who developed heparin - induced thrombocytopenia with thrombosis ( HITT ) and was treated with argatroban plus catheter - directed thrombolysis ( CDT ) with alteplase is presented .|SUMMARY : A 63 - year - old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper - extremity deep venous thrombosis ( DVT ) and pulmonary embolism secondary to heparin - induced thrombocytopenia .|A continuous i . v .|infusion of argatroban was initiated , and the patient was managed on the general medical floor .|After one week of therapy , he was transferred to the intensive care unit with cardiopulmonary compromise related to superior vena cava ( SVC ) syndrome .|A percutaneous mechanical thrombectomy and CDT with alteplase were attempted , but the procedure was aborted due to epistaxis .|The epistaxis resolved the next day , and the patient was restarted on argatroban .|A second percutaneous mechanical thrombectomy was performed six days later and resulted in partial revascularization of the SVC and central veins .|Postthrombectomy continuous CDT with alteplase was commenced while argatroban was withheld , and complete patency of the SVC and central veins was achieved after three days of therapy .|Alteplase was discontinued , and the patient was reinitiated on argatroban ; ultimately , he was transitioned to warfarin for long - term anticoagulation .|Although the patient recovered , he experienced permanent vision and hearing loss , as well as end - stage renal disease .|CONCLUSION : A 63 - year - old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase .": "[[\"Use of argatroban and catheter-directed thrombolysis with alteplase\", \"is for\", \"an oncology patient with heparin-induced thrombocytopenia with thrombosis\"],\n[\"Oncology patient\", \"developed\", \"heparin-induced thrombocytopenia with thrombosis (HITT)\"],\n[\"Oncology patient\", \"was treated with\", \"argatroban plus catheter-directed thrombolysis (CDT) with alteplase\"],\n[\"63-year-old Caucasian man\", \"has\", \"renal amyloidosis\"],\n[\"63-year-old Caucasian man\", \"undergoing\", \"peripheral blood stem cell collection\"],\n[\"63-year-old Caucasian man\", \"developed\", \"bilateral upper-extremity deep venous thrombosis (DVT)\"],\n[\"63-year-old Caucasian man\", \"developed\", \"pulmonary embolism\"],\n[\"Pulmonary embolism\", \"secondary to\", \"heparin-induced thrombocytopenia\"],\n[\"Argatroban\", \"administered as\", \"continuous i.v. infusion\"],\n[\"Patient\", \"was managed on\", \"general medical floor\"],\n[\"Patient\", \"transferred to\", \"intensive care unit\"],\n[\"Patient\", \"related cardiopulmonary compromise to\", \"superior vena cava (SVC) syndrome\"],\n[\"Percutaneous mechanical thrombectomy and CDT with alteplase\", \"attempted for\", \"patient\"],\n[\"Procedure\", \"aborted due to\", \"epistaxis\"],\n[\"Epistaxis\", \"resolved\", \"the next day\"],\n[\"Patient\", \"restarted on\", \"argatroban\"],\n[\"Second percutaneous mechanical thrombectomy\", \"performed\", \"six days later\"],\n[\"Second percutaneous mechanical thrombectomy\", \"resulted in\", \"partial revascularization of the SVC and central veins\"],\n[\"Continuous CDT with alteplase\", \"commenced postthrombectomy\", \"while argatroban was withheld\"],\n[\"SVC and central veins\", \"achieved complete patency after\", \"three days of therapy\"],\n[\"Alteplase\", \"discontinued\", \"\"],\n[\"Patient\", \"reinitiated on\", \"argatroban\"],\n[\"Patient\", \"transitioned to\", \"warfarin for long-term anticoagulation\"],\n[\"Patient\", \"recovered but experienced\", \"permanent vision and hearing loss\"],\n[\"Patient\", \"experienced\", \"end-stage renal disease\"],\n[\"63-year-old man with renal amyloidosis and SVC syndrome\", \"successfully treated with\", \"argatroban and CDT with alteplase\"]]",
      "Two cases of amisulpride overdose : a cause for prolonged QT syndrome .|Two cases of deliberate self - poisoning with 5 g and 3 . 6 g of amisulpride , respectively , are reported .|In both cases , QT prolongation and hypocalcaemia were noted .|The QT prolongation appeared to respond to administration of i . v .|calcium gluconate .": "[[\"amisulpride overdose\", \"is a cause for\", \"prolonged QT syndrome\"],\n[\"Two cases\", \"involve\", \"deliberate self-poisoning with amisulpride\"],\n[\"First case\", \"involved amount\", \"5 g of amisulpride\"],\n[\"Second case\", \"involved amount\", \"3.6 g of amisulpride\"],\n[\"In both cases\", \"were noted\", \"QT prolongation\"],\n[\"In both cases\", \"were noted\", \"hypocalcaemia\"],\n[\"QT prolongation\", \"appeared to respond to\", \"administration of i.v. calcium gluconate\"]]",
      "Amiodarone - related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease : Diagnostic pitfall and new findings .|Amiodarone is an anti - arrhythmic drug for life - threatening tachycardia , but various adverse effects have been reported .|Reported herein is an autopsy case of valvular heart disease , in a patient who developed a lung mass ( 1 . 5 cm in diameter ) and proteinuria ( 2 . 76 g / day ) after treatment with amiodarone for a long time .|The lung mass was highly suspected to be lung cancer on CT and positron emission tomography , but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra - alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies , indicating that it was an amiodarone - related lesion .|In addition , the lung tissue had unevenly distributed hemosiderin deposition , and abnormally tortuous capillaries were seen in the mass and in heavily hemosiderotic lung portions outside the mass .|In the kidneys , glomeruli had membrane spikes , prominent swelling of podocytes and subepithelial deposits , which were sometimes large and hump - like .|Autoimmune diseases , viral hepatitis , malignant neoplasms or other diseases with a known relationship to membranous glomerulonephritis were not found .|The present case highlights the possibility that differential diagnosis between an amiodarone - related pulmonary lesion and a neoplasm can be very difficult radiologically , and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment .": "[[\"Amiodarone\", \"is an\", \"anti-arrhythmic drug\"],\n[\"Amiodarone\", \"used for\", \"life-threatening tachycardia\"],\n[\"Amiodarone\", \"causes\", \"adverse effects\"],\n[\"Patient\", \"had\", \"valvular heart disease\"],\n[\"Patient\", \"developed\", \"lung mass\"],\n[\"Patient\", \"developed\", \"proteinuria\"],\n[\"Patient\", \"treated with\", \"amiodarone\"],\n[\"Lung mass\", \"suspected to be\", \"lung cancer\"],\n[\"Lung mass\", \"was actually\", \"amiodarone-related lesion\"],\n[\"Lung mass\", \"composed of\", \"lymphoplasmacytic infiltrates\"],\n[\"Lung mass\", \"showed\", \"intra-alveolar accumulation of foamy macrophages\"],\n[\"Foamy macrophages\", \"contained\", \"myelinoid bodies\"],\n[\"Lung tissue\", \"had\", \"hemosiderin deposition\"],\n[\"Lung tissue\", \"had\", \"abnormally tortuous capillaries\"],\n[\"Kidneys\", \"had\", \"glomeruli with membrane spikes\"],\n[\"Kidneys\", \"showed\", \"swelling of podocytes\"],\n[\"Kidneys\", \"had\", \"subepithelial deposits\"],\n[\"Autoimmune diseases\", \"not found in\", \"patient\"],\n[\"Viral hepatitis\", \"not found in\", \"patient\"],\n[\"Malignant neoplasms\", \"not found in\", \"patient\"],\n[\"Membranous glomerulonephritis\", \"not related to\", \"other known diseases\"],\n[\"Differential diagnosis\", \"difficult between\", \"amiodarone-related pulmonary lesion and neoplasm\"],\n[\"Membranous glomerulonephritis\", \"might be complication of\", \"amiodarone treatment\"]]",
      "Absence of PKC - alpha attenuates lithium - induced nephrogenic diabetes insipidus .|Lithium , an effective antipsychotic , induces nephrogenic diabetes insipidus ( NDI ) in 40 % of patients .|The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing urea transporter ( UT - A1 ) and water channel ( AQP2 ) expression in the inner medulla .|Targeting an alternative signaling pathway , such as PKC - mediated signaling , may be an effective method of treating lithium - induced polyuria .|PKC - alpha null mice ( PKCa KO ) and strain - matched wild type ( WT ) controls were treated with lithium for 0 , 3 or 5 days .|WT mice had increased urine output and lowered urine osmolality after 3 and 5 days of treatment whereas PKCa KO mice had no change in urine output or concentration .|Western blot analysis revealed that AQP2 expression in medullary tissues was lowered after 3 and 5 days in WT mice ; however , AQP2 was unchanged in PKCa KO .|Similar results were observed with UT - A1 expression .|Animals were also treated with lithium for 6 weeks .|Lithium - treated WT mice had 19 - fold increased urine output whereas treated PKCa KO animals had a 4 - fold increase in output .|AQP2 and UT - A1 expression was lowered in 6 week lithium - treated WT animals whereas in treated PKCa KO mice , AQP2 was only reduced by 2 - fold and UT - A1 expression was unaffected .|Urinary sodium , potassium and calcium were elevated in lithium - fed WT but not in lithium - fed PKCa KO mice .|Our data show that ablation of PKCa preserves AQP2 and UT - A1 protein expression and localization in lithium - induced NDI , and prevents the development of the severe polyuria associated with lithium therapy .": "[[\"Absence of PKC-alpha\", \"attenuates\", \"lithium-induced nephrogenic diabetes insipidus (NDI)\"],\n [\"Lithium\", \"is an\", \"effective antipsychotic\"],\n [\"Lithium\", \"induces\", \"nephrogenic diabetes insipidus (NDI)\"],\n [\"NDI\", \"occurs in\", \"40% of patients treated with lithium\"],\n [\"Lithium\", \"disrupts\", \"cAMP pathway\"],\n [\"Lithium\", \"reduces\", \"urea transporter (UT-A1) expression in the inner medulla\"],\n [\"Lithium\", \"reduces\", \"water channel (AQP2) expression in the inner medulla\"],\n [\"Targeting PKC-mediated signaling\", \"may be an effective method of treating\", \"lithium-induced polyuria\"],\n [\"PKC-alpha null mice (PKCa KO)\", \"treated with\", \"lithium\"],\n [\"Wild type (WT) mice\", \"treated with\", \"lithium\"],\n [\"WT mice\", \"had increased\", \"urine output\"],\n [\"WT mice\", \"had lowered\", \"urine osmolality\"],\n [\"PKCa KO mice\", \"had no change in\", \"urine output\"],\n [\"PKCa KO mice\", \"had no change in\", \"urine concentration\"],\n [\"AQP2 expression\", \"was lowered in\", \"medullary tissues of WT mice\"],\n [\"AQP2 expression\", \"was unchanged in\", \"PKCa KO\"],\n [\"UT-A1 expression\", \"had similar results to\", \"AQP2 expression\"],\n [\"Animals\", \"treated with\", \"lithium for 6 weeks\"],\n [\"Lithium-treated WT mice\", \"had increased\", \"urine output\"],\n [\"Lithium-treated PKCa KO mice\", \"had increased\", \"urine output\"],\n [\"AQP2 expression\", \"was lowered in\", \"6 week lithium-treated WT animals\"],\n [\"UT-A1 expression\", \"was lowered in\", \"6 week lithium-treated WT animals\"],\n [\"AQP2 expression\", \"was reduced by 2-fold in\", \"treated PKCa KO mice\"],\n [\"UT-A1 expression\", \"was unaffected in\", \"treated PKCa KO mice\"],\n [\"Urinary sodium\", \"was elevated in\", \"lithium-fed WT mice\"],\n [\"Urinary potassium\", \"was elevated in\", \"lithium-fed WT mice\"],\n [\"Urinary calcium\", \"was elevated in\", \"lithium-fed WT mice\"],\n [\"Urinary sodium\", \"was not elevated in\", \"lithium-fed PKCa KO mice\"],\n [\"Urinary potassium\", \"was not elevated in\", \"lithium-fed PKCa KO mice\"],\n [\"Urinary calcium\", \"was not elevated in\", \"lithium-fed PKCa KO mice\"],\n [\"Ablation of PKCa\", \"preserves\", \"AQP2 and UT-A1 protein expression\"],\n [\"Ablation of PKCa\", \"preserves\", \"localization in lithium-induced NDI\"],\n [\"Ablation of PKCa\", \"prevents\", \"development of severe polyuria associated with lithium therapy\"]]",
      "Indomethacin - induced hyperkalemia in three patients with gouty arthritis .|We describe three patients in whom severe , life - threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin .|This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism .|Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti - inflammatory agents , particularly in those patients with diabetes mellitus or preexisting renal disease , will help prevent this potentially serious complication .": "[[\"Indomethacin\", \"induced\", \"hyperkalemia\"], [\"hyperkalemia\", \"occurred in\", \"three patients\"], [\"three patients\", \"had\", \"gouty arthritis\"], [\"severe hyperkalemia\", \"developed after\", \"treatment with indomethacin\"], [\"treatment with indomethacin\", \"was for\", \"acute gouty arthritis\"], [\"hyperkalemia\", \"may result from\", \"inhibition of prostaglandin synthesis\"], [\"inhibition of prostaglandin synthesis\", \"causes\", \"hyporeninemic hypoaldosteronism\"], [\"Careful attention\", \"will help prevent\", \"potentially serious complication\"], [\"potentially serious complication\", \"is\", \"hyperkalemia\"], [\"renal function and potassium balance\", \"require\", \"Careful attention\"], [\"patients receiving indomethacin\", \"should be monitored for\", \"renal function and potassium balance\"], [\"patients with diabetes mellitus or preexisting renal disease\", \"are particularly in need of\", \"Careful attention\"]]",
      "Vinorelbine - related cardiac events : a meta - analysis of randomized clinical trials .|Several cases of cardiac adverse reactions related to vinorelbine ( VNR ) have been reported in the literature .|In order to quantify the incidence of these cardiac events , we performed a meta - analysis of clinical trials comparing VNR with other chemotherapeutic agents in the treatment of various malignancies .|Randomized clinical trials comparing VNR with other drugs in the treatment of cancer were searched in Medline , Embase , Evidence - based Medicine Reviews databases and the Cochrane library from 1987 to 2002 .|Outcomes of interest were severe cardiac events , toxic deaths and cardiac event - related deaths reported in each publication .|We found 19 trials , involving 2441 patients treated by VNR and 2050 control patients .|The incidence of cardiac events with VNR was 1 . 19 % [ 95 % confidence interval ( CI ) ( 0 . 75 ; 1 . 67 ) ] .|There was no difference in the risk of cardiac events between VNR and other drugs [ odds ratio : 0 . 92 , 95 % CI ( 0 . 54 ; 1 . 55 ) ] .|The risk of VNR cardiac events was similar to vindesine ( VDS ) and other cardiotoxic drugs [ fluorouracil , anthracyclines , gemcitabine ( GEM ) em leader ] .|Even if it did not reach statistical significance because of a few number of cases , the risk was lower in trials excluding patients with cardiac history , and seemed to be higher in trials including patients with pre - existing cardiac diseases .|Vinorelbine - related cardiac events concern about 1 % of treated patients in clinical trials .|However , the risk associated with VNR seems to be similar to that of other chemotherapeutic agents in the same indications .": "[[\"Vinorelbine-related cardiac events\", \"subject of\", \"meta-analysis\"],\n [\"Meta-analysis\", \"analyzes\", \"randomized clinical trials\"],\n [\"Vinorelbine\", \"associated with\", \"cardiac adverse reactions\"],\n [\"Meta-analysis\", \"performed to quantify\", \"incidence of cardiac events\"],\n [\"Clinical trials\", \"compared\", \"Vinorelbine with other chemotherapeutic agents\"],\n [\"Clinical trials\", \"searched in\", \"Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library\"],\n [\"Clinical trials\", \"time frame\", \"from 1987 to 2002\"],\n [\"Outcomes of interest\", \"were\", \"severe cardiac events, toxic deaths and cardiac event-related deaths\"],\n [\"Meta-analysis\", \"found\", \"19 trials\"],\n [\"19 trials\", \"involved\", \"2441 patients treated by Vinorelbine\"],\n [\"19 trials\", \"involved\", \"2050 control patients\"],\n [\"Incidence of cardiac events with Vinorelbine\", \"was\", \"1.19%\"],\n [\"Risk of cardiac events\", \"no difference between\", \"Vinorelbine and other drugs\"],\n [\"Risk of Vinorelbine cardiac events\", \"similar to\", \"vindesine (VDS) and other cardiotoxic drugs\"],\n [\"Cardiotoxic drugs\", \"include\", \"fluorouracil, anthracyclines, gemcitabine (GEM)\"],\n [\"Risk\", \"lower in trials excluding\", \"patients with cardiac history\"],\n [\"Risk\", \"seemed to be higher in\", \"trials including patients with pre-existing cardiac diseases\"],\n [\"Vinorelbine-related cardiac events\", \"concern\", \"about 1% of treated patients in clinical trials\"],\n [\"Risk associated with Vinorelbine\", \"seems to be similar to\", \"other chemotherapeutic agents in the same indications\"]]",
      "Caffeine challenge test in panic disorder and depression with panic attacks .|Our aim was to observe if patients with panic disorder ( PD ) and patients with major depression with panic attacks ( MDP ) ( Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition criteria ) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test .|We randomly selected 29 patients with PD , 27 with MDP , 25 with major depression without panic attacks ( MD ) , and 28 healthy volunteers .|The patients had no psychotropic drug for at least a 4 - week period .|In a randomized double - blind experiment performed in 2 occasions 7 days apart , 480 mg caffeine and a caffeine - free ( placebo ) solution were administered in a coffee form and anxiety scales were applied before and after each test .|A total of 58 . 6 % ( n = 17 ) of patients with PD , 44 . 4 % ( n = 12 ) of patients with MDP , 12 . 0 % ( n = 3 ) of patients with MD , and 7 . 1 % ( n = 2 ) of control subjects had a panic attack after the 480 - mg caffeine challenge test ( chi ( 2 ) ( 3 ) = 16 . 22 , P = . 001 ) .|The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers .|No panic attack was observed after the caffeine - free solution intake .|The patients with MD had a lower heart rate response to the test than all the other groups ( 2 - way analysis of variance , group by time interaction with Greenhouse - Geisser correction : F ( 3 , 762 ) = 2 . 85 , P = . 026 ) .|Our data suggest that there is an association between panic attacks , no matter if associated with PD or MDP , and hyperreactivity to an oral caffeine challenge test .": "[[\"Caffeine challenge test\", \"used in\", \"panic disorder\"],\n [\"Caffeine challenge test\", \"used in\", \"depression with panic attacks\"],\n [\"Aim\", \"was to observe\", \"response to caffeine challenge test in PD and MDP\"],\n [\"Patients with PD\", \"respond to\", \"oral caffeine challenge test\"],\n [\"Patients with MDP\", \"respond to\", \"oral caffeine challenge test\"],\n [\"Patients\", \"randomly selected\", \"29 with PD\"],\n [\"Patients\", \"randomly selected\", \"27 with MDP\"],\n [\"Patients\", \"randomly selected\", \"25 with MD\"],\n [\"Healthy volunteers\", \"randomly selected\", \"28 individuals\"],\n [\"Patients\", \"had no\", \"psychotropic drug for at least a 4-week period\"],\n [\"Experiment\", \"performed as\", \"randomized double-blind\"],\n [\"Experiment\", \"performed in\", \"2 occasions 7 days apart\"],\n [\"Caffeine\", \"administered in\", \"480 mg\"],\n [\"Placebo solution\", \"administered as\", \"caffeine-free\"],\n [\"Anxiety scales\", \"applied before and after\", \"each test\"],\n [\"Patients with PD\", \"had\", \"panic attack after 480 mg caffeine\"],\n [\"Patients with MDP\", \"had\", \"panic attack after 480 mg caffeine\"],\n [\"Patients with MD\", \"had\", \"panic attack after 480 mg caffeine\"],\n [\"Control subjects\", \"had\", \"panic attack after 480 mg caffeine\"],\n [\"Patients with PD and MDP\", \"more sensitive to\", \"caffeine than patients with MD and healthy volunteers\"],\n [\"No panic attack\", \"observed after\", \"caffeine-free solution intake\"],\n [\"Patients with MD\", \"had\", \"lower heart rate response to the test\"],\n [\"Data\", \"suggests association between\", \"panic attacks and hyperreactivity to oral caffeine challenge test\"]]",
      "Bilateral retinal artery and choriocapillaris occlusion following the injection of long - acting corticosteroid suspensions in combination with other drugs : I .|Clinical studies .|Two well - documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft - tissue injection with methylprednisolone acetate in combination with lidocaine , epinephrine , or penicillin are reported .|One case had only a unilateral injection .|The acute observations included hazy sensorium , superior gaze palsy , pupillary abnormalities , and conjunctival hemorrhages with edema .|Follow - up changes showed marked visual loss , constricted visual fields , optic nerve pallor , vascular attenuation , and chorioretinal atrophy .|The literature is reviewed , and possible causes are discussed .": "[[\"Bilateral retinal artery and choriocapillaris occlusion\", \"following\", \"injection of long-acting corticosteroid suspensions in combination with other drugs\"], \n[\"Bilateral retinal artery and choriocapillaris occlusions with blindness\", \"following\", \"head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin\"], \n[\"Cases\", \"reported\", \"bilateral retinal artery and choriocapillaris occlusions with blindness\"], \n[\"One case\", \"had\", \"only a unilateral injection\"], \n[\"Acute observations\", \"included\", \"hazy sensorium\"], \n[\"Acute observations\", \"included\", \"superior gaze palsy\"], \n[\"Acute observations\", \"included\", \"pupillary abnormalities\"], \n[\"Acute observations\", \"included\", \"conjunctival hemorrhages with edema\"], \n[\"Follow-up changes\", \"showed\", \"marked visual loss\"], \n[\"Follow-up changes\", \"showed\", \"constricted visual fields\"], \n[\"Follow-up changes\", \"showed\", \"optic nerve pallor\"], \n[\"Follow-up changes\", \"showed\", \"vascular attenuation\"], \n[\"Follow-up changes\", \"showed\", \"chorioretinal atrophy\"], \n[\"Literature\", \"is reviewed\", \"\"], \n[\"Possible causes\", \"are discussed\", \"\"]]",
      "Cocaine , ethanol , and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse .|OBJECTIVES : Simultaneous abuse of cocaine and ethanol affects 12 million Americans annually .|In combination , these substances are substantially more toxic than either drug alone .|Their combined cardiac toxicity may be due to independent effects of each drug ; however , they may also be due to cocaethylene ( CE ) , a cocaine metabolite formed only in the presence of ethanol .|The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse .|METHODS : Twenty - three dogs were randomized to receive either 1 ) three intravenous ( IV ) boluses of cocaine 7 . 5 mg / kg with ethanol ( 1 g / kg ) as an IV infusion ( C + E , n = 8 ) , 2 ) three cocaine boluses only ( C , n = 6 ) , 3 ) ethanol infusion only ( E , n = 5 ) , or 4 ) placebo boluses and infusion ( n = 4 ) .|Hemodynamic measurements , electrocardiograms , and serum drug concentrations were obtained at baseline , and then at fixed time intervals after each drug was administered .|RESULTS : Two of eight dogs in the C + E group experienced cardiovascular collapse .|The most dramatic hemodynamic changes occurred after each cocaine bolus in the C + E and C only groups ; however , persistent hemodynamic changes occurred in the C + E group .|Peak CE levels were associated with a 45 % ( SD + / - 22 % , 95 % CI = 22 % to 69 % ) decrease in cardiac output ( p < 0 . 05 ) , a 56 % ( SD + / - 23 % , 95 % CI = 32 % to 80 % ) decrease in dP / dt ( max ) ( p < . 006 ) , and a 23 % ( SD + / - 15 % , 95 % CI = 7 % to 49 % ) decrease in SVO ( 2 ) ( p < 0 . 025 ) .|Ventricular arrhythmias were primarily observed in the C + E group , in which four of eight dogs experienced ventricular tachycardia .|CONCLUSIONS : Cocaine and ethanol in combination were more toxic than either substance alone .|Co - administration resulted in prolonged cardiac toxicity and was dysrhythmogenic .|Peak serum cocaethylene concentrations were associated with prolonged myocardial depression .": "[[\"Cocaine and ethanol\", \"affects\", \"12 million Americans annually\"],\n[\"Cocaine and ethanol\", \"are more toxic in combination\", \"than either drug alone\"],\n[\"Cardiac toxicity\", \"may be due to\", \"independent effects of each drug\"],\n[\"Cardiac toxicity\", \"may be due to\", \"cocaethylene\"],\n[\"Cocaethylene\", \"is formed\", \"in the presence of ethanol\"],\n[\"Study\", \"delineate role of\", \"cocaethylene in combined cardiotoxicity of cocaine and ethanol\"],\n[\"Dogs\", \"were randomized to receive\", \"intravenous boluses of cocaine with ethanol\"],\n[\"Dogs\", \"were randomized to receive\", \"cocaine boluses only\"],\n[\"Dogs\", \"were randomized to receive\", \"ethanol infusion only\"],\n[\"Dogs\", \"were randomized to receive\", \"placebo\"],\n[\"Hemodynamic measurements, electrocardiograms, and serum drug concentrations\", \"were obtained\", \"after each drug was administered\"],\n[\"Dogs in C + E group\", \"experienced\", \"cardiovascular collapse\"],\n[\"Hemodynamic changes\", \"occurred after\", \"cocaine bolus in C + E and C only groups\"],\n[\"Persistent hemodynamic changes\", \"occurred in\", \"C + E group\"],\n[\"Peak CE levels\", \"associated with\", \"decrease in cardiac output\"],\n[\"Peak CE levels\", \"associated with\", \"decrease in dP/dt (max)\"],\n[\"Peak CE levels\", \"associated with\", \"decrease in SVO(2)\"],\n[\"Ventricular arrhythmias\", \"observed in\", \"C + E group\"],\n[\"Dogs in C + E group\", \"experienced\", \"ventricular tachycardia\"],\n[\"Cocaine and ethanol in combination\", \"resulted in\", \"prolonged cardiac toxicity\"],\n[\"Co-administration\", \"was\", \"dysrhythmogenic\"],\n[\"Peak serum cocaethylene concentrations\", \"were associated with\", \"prolonged myocardial depression\"]]",
      "Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson 's disease .|OBJECTIVES : Neuropsychiatric symptoms are increasingly recognised as a significant problem in patients with Parkinson 's disease ( PD ) .|These symptoms may be due to ' sensitisation ' following repeated levodopa treatment or a direct effect of dopamine on the disease state .|The levodopa - treated MPTP - lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients .|Here we compare the time course of levodopa - induced motor fluctuations and neuropsychiatric - like behaviors to determine the relationship between duration of treatment and onset of symptoms .|METHODS : Marmosets were administered 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( 2 . 0 mg / kg s . c . ) for five days , resulting in stable parkinsonism .|Levodopa ( 15 mg / kg and benserazide , 3 . 75 mg / kg ) p . o .|b . i . d , was administered for 30 days .|Animals were evaluated for parkinsonian disability , dyskinesia and on - time ( motor fluctuations ) and neuropsychiatric - like behaviors on Day 0 ( prior to levodopa ) and on Days 1 , 7 , 13 , 27 and 30 of treatment using post hoc DVD analysis by a trained rater , blind to the treatment day .|RESULTS : The neuropsychiatric - like behavior rating scale demonstrated high interrater reliability between three trained raters of differing professional backgrounds .|As anticipated , animals exhibited a progressive increase in levodopa - induced motor fluctuations , dyskinesia and wearing - off , that correlated with the duration of levodopa therapy .|In contrast , levodopa - induced neuropsychiatric - like behaviors were present on Day 1 of levodopa treatment and their severity did not correlate with duration of treatment .|CONCLUSIONS : The data suggest that neuropsychiatric disorders in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy .": "[[\"Neuropsychiatric behaviors\", \"are in\", \"MPTP marmoset model of Parkinson's disease\"],\n[\"Neuropsychiatric symptoms\", \"are a problem in\", \"patients with Parkinson's disease\"],\n[\"Symptoms\", \"may be due to\", \"sensitisation following repeated levodopa treatment\"],\n[\"Symptoms\", \"may be due to\", \"direct effect of dopamine on disease state\"],\n[\"Levodopa-treated MPTP-lesioned marmoset\", \"used as model of\", \"neuropsychiatric symptoms in PD patients\"],\n[\"Study\", \"compares\", \"time course of levodopa-induced motor fluctuations and neuropsychiatric-like behaviors\"],\n[\"Study\", \"determines\", \"relationship between duration of treatment and onset of symptoms\"],\n[\"Marmosets\", \"administered with\", \"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\"],\n[\"Marmosets\", \"resulting in\", \"stable parkinsonism\"],\n[\"Levodopa and benserazide\", \"administered to\", \"marmosets\"],\n[\"Animals\", \"evaluated for\", \"parkinsonian disability, dyskinesia and on-time\"],\n[\"Animals\", \"evaluated for\", \"neuropsychiatric-like behaviors\"],\n[\"Neuropsychiatric-like behavior rating scale\", \"demonstrated\", \"high interrater reliability\"],\n[\"Animals\", \"exhibited\", \"progressive increase in levodopa-induced motor fluctuations, dyskinesia and wearing-off\"],\n[\"Increase in symptoms\", \"correlated with\", \"duration of levodopa therapy\"],\n[\"Levodopa-induced neuropsychiatric-like behaviors\", \"present on\", \"Day 1 of levodopa treatment\"],\n[\"Severity of neuropsychiatric-like behaviors\", \"did not correlate with\", \"duration of treatment\"],\n[\"Data\", \"suggests\", \"neuropsychiatric disorders in PD likely interaction between levodopa and disease state\"],\n[\"Neuropsychiatric disorders in PD\", \"less likely due to\", \"sensitisation to repeated dopaminergic therapy\"]]",
      "Metronidazole - induced encephalopathy : an uncommon scenario .|Metronidazole can produce neurological complications although it is not a common scenario .|We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake .|Magnetic resonance imaging ( MRI ) brain showed abnormal signal intensity involving both dentate nuclei of cerebellum and splenium of corpus callosum .|The diagnosis of metronidazole toxicity was made by the MRI findings and supported clinically .": "[[\"Metronidazole-induced encephalopathy\", \"is an\", \"uncommon scenario\"],\n [\"Metronidazole\", \"can produce\", \"neurological complications\"],\n [\"Patient\", \"developed\", \"features of encephalopathy\"],\n [\"Patient\", \"had\", \"prolonged metronidazole intake\"],\n [\"MRI brain\", \"showed\", \"abnormal signal intensity\"],\n [\"Abnormal signal intensity\", \"involving\", \"both dentate nuclei of cerebellum\"],\n [\"Abnormal signal intensity\", \"involving\", \"splenium of corpus callosum\"],\n [\"Diagnosis\", \"was made by\", \"MRI findings\"],\n [\"Diagnosis\", \"supported clinically\", \"metronidazole toxicity\"]]",
      "Non - invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole infusion .|Electrocardiographic changes after dipyridamole infusion ( 0 . 568 mg / kg / 4 min ) were studied in 41 patients with coronary artery disease and compared with those after submaximal treadmill exercise by use of the body surface mapping technique .|Patients were divided into three groups ; 19 patients without myocardial infarction ( non - MI group ) , 14 with anterior infarction ( ANT - MI ) and eight with inferior infarction ( INF - MI ) .|Eighty - seven unipolar electrocardiograms ( ECGs ) distributed over the entire thoracic surface were simultaneously recorded .|After dipyridamole , ischemic ST - segment depression ( 0 . 05 mV or more ) was observed in 84 % of the non - MI group , 29 % of the ANT - MI group , 63 % of the INF - MI group and 61 % of the total population .|Exercise - induced ST depression was observed in 84 % of the non - MI group , 43 % of the ANT - MI group , 38 % of the INF - MI group and 61 % of the total .|For individual patients , there were no obvious differences between the body surface distribution of ST depression in both tests .|The increase in pressure rate product after dipyridamole was significantly less than that during the treadmill exercise .|The data suggest that the dipyridamole - induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow .|We conclude that the dipyridamole ECG test is as useful as the exercise ECG test for the assessment of coronary artery disease .": "[[\"Non-invasive detection\", \"used for\", \"coronary artery disease\"],\n [\"Electrocardiographic mapping\", \"performed after\", \"dipyridamole infusion\"],\n [\"Electrocardiographic changes\", \"studied in\", \"41 patients with coronary artery disease\"],\n [\"Electrocardiographic changes\", \"compared with\", \"changes after submaximal treadmill exercise\"],\n [\"Patients\", \"divided into\", \"three groups\"],\n [\"19 patients\", \"categorized as\", \"non-MI group\"],\n [\"14 patients\", \"categorized as\", \"ANT-MI group\"],\n [\"8 patients\", \"categorized as\", \"INF-MI group\"],\n [\"Unipolar electrocardiograms (ECGs)\", \"recorded on\", \"entire thoracic surface\"],\n [\"Ischemic ST-segment depression\", \"observed in\", \"84% of the non-MI group\"],\n [\"Ischemic ST-segment depression\", \"observed in\", \"29% of the ANT-MI group\"],\n [\"Ischemic ST-segment depression\", \"observed in\", \"63% of the INF-MI group\"],\n [\"Ischemic ST-segment depression\", \"observed in\", \"61% of the total population\"],\n [\"Exercise-induced ST depression\", \"observed in\", \"84% of the non-MI group\"],\n [\"Exercise-induced ST depression\", \"observed in\", \"43% of the ANT-MI group\"],\n [\"Exercise-induced ST depression\", \"observed in\", \"38% of the INF-MI group\"],\n [\"Exercise-induced ST depression\", \"observed in\", \"61% of the total\"],\n [\"Body surface distribution of ST depression\", \"similar in\", \"dipyridamole test and exercise test\"],\n [\"Pressure rate product increase\", \"less after\", \"dipyridamole than during treadmill exercise\"],\n [\"Dipyridamole-induced myocardial ischemia\", \"caused by\", \"inhomogenous distribution of myocardial blood flow\"],\n [\"Dipyridamole ECG test\", \"as useful as\", \"exercise ECG test for assessment of coronary artery disease\"]]",
      "Rifampicin - associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis .|Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis .|Changing epidemiology of infections such as infective endocarditis ( IE ) has led to an increase in the use of rifampicin for Staphylococcal infections .|We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin , and review the literature regarding this complication of rifampicin therapy .": "[[\"Rifampicin\", \"associated with\", \"segmental necrotizing glomerulonephritis in staphylococcal endocarditis\"],\n[\"Segmental necrotising glomerulonephritis\", \"reported as complication of\", \"rifampicin therapy\"],\n[\"Rifampicin therapy\", \"used for treatment\", \"tuberculosis\"],\n[\"Changing epidemiology\", \"led to increase in use of\", \"rifampicin for Staphylococcal infections\"],\n[\"Patient with Staphylococcal IE\", \"developed\", \"acute renal failure\"],\n[\"Acute renal failure\", \"secondary to\", \"segmental necrotising glomerulonephritis\"],\n[\"Patient\", \"being treated with\", \"rifampicin\"],\n[\"Literature\", \"regarding\", \"complication of rifampicin therapy\"]]",
      "A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients .|OBJECTIVE : Dexmedetomidine and propofol are commonly used sedatives in neurocritical care as they allow for frequent neurologic examinations .|However , both agents are associated with significant hemodynamic side effects .|The primary objective of this study is to compare the prevalence of severe hemodynamic effects in neurocritical care patients receiving dexmedetomidine and propofol .|DESIGN : Multicenter , retrospective , propensity - matched cohort study .|SETTING : Neurocritical care units at two academic medical centers with dedicated neurocritical care teams and board - certified neurointensivists .|PATIENTS : Neurocritical care patients admitted between July 2009 and September 2012 were evaluated and then matched 1 : 1 based on propensity scoring of baseline characteristics .|INTERVENTIONS : Continuous sedation with dexmedetomidine or propofol .|MEASUREMENTS AND MAIN RESULTS : A total of 342 patients ( 105 dexmedetomidine and 237 propofol ) were included in the analysis , with 190 matched ( 95 in each group ) by propensity score .|The primary outcome of this study was a composite of severe hypotension ( mean arterial pressure < 60 mm Hg ) and bradycardia ( heart rate < 50 beats / min ) during sedative infusion .|No difference in the primary composite outcome in both the unmatched ( 30 % vs 30 % , p = 0 . 94 ) or matched cohorts ( 28 % vs 34 % , p = 0 . 35 ) could be found .|When analyzed separately , no differences could be found in the prevalence of severe hypotension or bradycardia in either the unmatched or matched cohorts .|CONCLUSIONS : Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol .|Providers should similarly consider the likelihood of hypotension or bradycardia before starting either sedative .": "[[\"Dexmedetomidine\", \"compared with\", \"propofol\"],\n[\"Dexmedetomidine\", \"used for\", \"sedation in neurocritical care\"],\n[\"Propofol\", \"used for\", \"sedation in neurocritical care\"],\n[\"Dexmedetomidine\", \"associated with\", \"hemodynamic side effects\"],\n[\"Propofol\", \"associated with\", \"hemodynamic side effects\"],\n[\"Study\", \"aims to compare\", \"severe hemodynamic effects of dexmedetomidine and propofol\"],\n[\"Study\", \"is a type of\", \"Multicenter, retrospective, propensity-matched cohort study\"],\n[\"Study\", \"setting\", \"Neurocritical care units at two academic medical centers\"],\n[\"Patients\", \"admitted between\", \"July 2009 and September 2012\"],\n[\"Patients\", \"received\", \"dexmedetomidine or propofol\"],\n[\"Patients\", \"matched by\", \"propensity score\"],\n[\"Primary outcome\", \"is\", \"composite of severe hypotension and bradycardia during sedative infusion\"],\n[\"Unmatched cohorts\", \"showed no difference in\", \"primary composite outcome\"],\n[\"Matched cohorts\", \"showed no difference in\", \"primary composite outcome\"],\n[\"Severe hypotension\", \"occurrence compared\", \"in dexmedetomidine and propofol\"],\n[\"Bradycardia\", \"occurrence compared\", \"in dexmedetomidine and propofol\"],\n[\"Providers\", \"should consider\", \"likelihood of hypotension or bradycardia before starting sedative\"]]",
      "Nonalcoholic fatty liver disease during valproate therapy .|Valproic acid ( VPA ) is effective for the treatment of many types of epilepsy , but its use can be associated with an increase in body weight .|We report a case of nonalcoholic fatty liver disease ( NAFLD ) arising in a child who developed obesity during VPA treatment .|Laboratory data revealed hyperinsulinemia with insulin resistance .|After the withdrawal of VPA therapy , our patient showed a significant weight loss , a decrease of body mass index , and normalization of metabolic and endocrine parameters ; moreover , ultrasound measurements showed a complete normalization .|The present case suggests that obesity , hyperinsulinemia , insulin resistance , and long - term treatment with VPA may be all associated with the development of NAFLD ; this side effect is reversible after VPA withdrawal .": "[[\"Nonalcoholic fatty liver disease\", \"occurs during\", \"valproate therapy\"],\n [\"Valproic acid\", \"is effective for\", \"treatment of many types of epilepsy\"],\n [\"Valproic acid use\", \"can be associated with\", \"increase in body weight\"],\n [\"Case of nonalcoholic fatty liver disease\", \"arising in\", \"child\"],\n [\"Child\", \"developed\", \"obesity during VPA treatment\"],\n [\"Laboratory data\", \"revealed\", \"hyperinsulinemia with insulin resistance\"],\n [\"Withdrawal of VPA therapy\", \"resulted in\", \"significant weight loss\"],\n [\"Withdrawal of VPA therapy\", \"resulted in\", \"decrease of body mass index\"],\n [\"Withdrawal of VPA therapy\", \"resulted in\", \"normalization of metabolic and endocrine parameters\"],\n [\"Ultrasound measurements\", \"showed\", \"complete normalization after VPA withdrawal\"],\n [\"Obesity\", \"associated with\", \"development of NAFLD\"],\n [\"Hyperinsulinemia\", \"associated with\", \"development of NAFLD\"],\n [\"Insulin resistance\", \"associated with\", \"development of NAFLD\"],\n [\"Long-term treatment with VPA\", \"associated with\", \"development of NAFLD\"],\n [\"NAFLD\", \"is reversible after\", \"VPA withdrawal\"]]",
      "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine - induced seizures .|Garcinielliptone FC ( GFC ) isolated from hexanic fraction seed extract of species Platonia insignis Mart .|It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases .|However , there is no research on GFC effects in the central nervous system of rodents .|The present study aimed to evaluate the GFC effects at doses of 25 , 50 or 75 mg / kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ( r - aminobutyric acid ( GABA ) , glutamine , aspartate and glutathione ) levels as well as on acetylcholinesterase ( AChE ) activity in mice hippocampus after seizures .|GFC produced an increased latency to first seizure , at doses 25mg / kg ( 20 . 12 + 2 . 20 min ) , 50mg / kg ( 20 . 95 + 2 . 21 min ) or 75 mg / kg ( 23 . 43 + 1 . 99 min ) when compared with seized mice .|In addition , GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46 . 90 % when compared with seized mice .|In aspartate , glutamine and glutamate levels detected a decrease of 5 . 21 % , 13 . 55 % and 21 . 80 % , respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice .|Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity ( 63 . 30 % ) when compared with seized mice .|The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine - induced status epilepticus , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals .|In conclusion , our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus .|This compound may be useful to produce neuronal protection and it can be considered as an anticonvulsant agent .": "[[\"Garcinielliptone FC\", \"is isolated from\", \"hexanic fraction seed extract of species Platonia insignis Mart\"],\n[\"Garcinielliptone FC\", \"used in folk medicine to treat\", \"skin diseases\"],\n[\"Garcinielliptone FC\", \"used in folk medicine to treat\", \"diarrheas\"],\n[\"Garcinielliptone FC\", \"used in folk medicine to treat\", \"inflammatory diseases\"],\n[\"Garcinielliptone FC\", \"effects on\", \"central nervous system of rodents\"],\n[\"Garcinielliptone FC\", \"evaluated for\", \"anticonvulsant activity\"],\n[\"Garcinielliptone FC\", \"effects on\", \"amino acid levels in mice hippocampus after seizures\"],\n[\"Garcinielliptone FC\", \"effects on\", \"acetylcholinesterase activity in mice hippocampus after seizures\"],\n[\"Garcinielliptone FC\", \"produced\", \"increased latency to first seizure\"],\n[\"Garcinielliptone FC\", \"increased\", \"GABA content of mice hippocampus\"],\n[\"Garcinielliptone FC\", \"decreased\", \"aspartate levels in mice hippocampus\"],\n[\"Garcinielliptone FC\", \"decreased\", \"glutamine levels in mice hippocampus\"],\n[\"Garcinielliptone FC\", \"decreased\", \"glutamate levels in mice hippocampus\"],\n[\"Garcinielliptone FC\", \"increased\", \"AChE activity in mice hippocampus\"],\n[\"Garcinielliptone FC\", \"can exert\", \"anticonvulsant activity\"],\n[\"Garcinielliptone FC\", \"reduce\", \"frequency of installation of pilocarpine-induced status epilepticus\"],\n[\"Garcinielliptone FC\", \"decrease\", \"mortality rate of animals\"],\n[\"Garcinielliptone FC\", \"may influence\", \"epileptogenesis\"],\n[\"Garcinielliptone FC\", \"promote\", \"anticonvulsant actions in pilocarpine model\"],\n[\"Garcinielliptone FC\", \"modulating\", \"GABA and glutamate contents in seized mice hippocampus\"],\n[\"Garcinielliptone FC\", \"modulating\", \"AChE activity in seized mice hippocampus\"],\n[\"Garcinielliptone FC\", \"may be useful to produce\", \"neuronal protection\"],\n[\"Garcinielliptone FC\", \"considered as\", \"an anticonvulsant agent\"]]",
      "Zidovudine - induced hepatitis .|A case of acute hepatitis induced by zidovudine in a 38 - year - old patient with AIDS is presented .|The mechanism whereby the hepatitis was induced is not known .|However , the patient tolerated well an alternative reverse transcriptase inhibitor , 2 ' 3 ' dideoxyinosine .|Physicians caring for patients with AIDS should be aware of this hitherto rarely reported complication .": "[[\"Zidovudine\", \"induced\", \"hepatitis\"],\n[\"A case\", \"presents\", \"acute hepatitis induced by zidovudine\"],\n[\"A case\", \"involves\", \"a 38-year-old patient with AIDS\"],\n[\"The mechanism\", \"is not known\", \"whereby the hepatitis was induced\"],\n[\"The patient\", \"tolerated well\", \"an alternative reverse transcriptase inhibitor\"],\n[\"An alternative reverse transcriptase inhibitor\", \"is\", \"2' 3' dideoxyinosine\"],\n[\"Physicians\", \"should be aware of\", \"this hitherto rarely reported complication\"]]",
      "Centrally mediated cardiovascular effects of intracisternal application of carbachol in anesthetized rats .|The pressor response to the intracisternal ( i . c . ) injection of carbachol ( 1 mug ) in anesthetized rats was analyzed .|This response was significantly reduced by the intravenous ( i . v . ) injection of guanethidine ( 5 mg ) , hexamethonium ( 10 mg ) or phentolamine ( 5 mg ) , and conversely , potentiated by i . v .|desmethylimipramine ( 0 . 3 mg ) , while propranolol ( 0 . 5 mg ) i . v .|selectively inhibited the enlargement of pulse pressure and the tachycardia following i . c .|carbachol ( 1 mug ) .|On the other hand , the pressor response to i . c .|carbachol ( 1 mug ) was almost completely blocked by i . c .|atropine ( 3 mug ) or hexamethonium ( 500 mug ) , and significantly reduced by i . c .|chlorpromazine ( 50 mug ) but significantly potentiated by i . c .|desmethylimipramine ( 30 mug ) .|The pressor response to i . c .|carbachol ( 1 mug ) remained unchanged after sectioning of the bilateral cervical vagal nerves but disappeared after sectioning of the spinal cord ( C7 - C8 ) .|From the above result it is suggested that the pressor response to i . c .|carbachol ortral and peripheral adrenergic mechanisms , and that the sympathetic trunk is the main pathway .": "[[\"intracisternal application of carbachol\", \"has effect on\", \"cardiovascular effects in anesthetized rats\"],\n [\"intracisternal injection of carbachol\", \"causes\", \"pressor response\"],\n [\"pressor response\", \"reduced by\", \"intravenous injection of guanethidine\"],\n [\"pressor response\", \"reduced by\", \"intravenous injection of hexamethonium\"],\n [\"pressor response\", \"reduced by\", \"intravenous injection of phentolamine\"],\n [\"pressor response\", \"potentiated by\", \"intravenous desmethylimipramine\"],\n [\"propranolol intravenous\", \"inhibits\", \"enlargement of pulse pressure following intracisternal carbachol\"],\n [\"propranolol intravenous\", \"inhibits\", \"tachycardia following intracisternal carbachol\"],\n [\"pressor response to intracisternal carbachol\", \"blocked by\", \"intracisternal atropine\"],\n [\"pressor response to intracisternal carbachol\", \"blocked by\", \"intracisternal hexamethonium\"],\n [\"pressor response to intracisternal carbachol\", \"reduced by\", \"intracisternal chlorpromazine\"],\n [\"pressor response to intracisternal carbachol\", \"potentiated by\", \"intracisternal desmethylimipramine\"],\n [\"pressor response to intracisternal carbachol\", \"unchanged after\", \"sectioning of bilateral cervical vagal nerves\"],\n [\"pressor response to intracisternal carbachol\", \"disappeared after\", \"sectioning of the spinal cord\"],\n [\"pressor response to intracisternal carbachol\", \"involves\", \"central and peripheral adrenergic mechanisms\"],\n [\"sympathetic trunk\", \"is main pathway for\", \"pressor response to intracisternal carbachol\"]]",
      "Antiandrogenic therapy can cause coronary arterial disease .|AIM : To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer .|MATERIALS AND METHODS : We studied with a 2 . 5 years follow - up the changes in plasma cholesterols ( C ) , triglycerides ( TG ) , lipoproteins ( LP ) , and apolipoproteins ( Apo ) B - 100 , A - I , and A - II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer ( stage : T1cN0M0 , Gleason score : 2 - 5 ) during treatment with cyproterone acetate ( CPA ) without surgical management or radiation therapy .|RESULTS : Significant decreases of HDL - C , Apo A - I and Apo A - II and an increase of triglyceride levels in VLDL were induced by CPA .|After a period of 2 . 5 years on CPA treatment , four patients out of twenty - four were found to be affected by coronary heart disease .|CONCLUSIONS : Ischaemic coronary arteriosclerosis with an incidence rate of 16 . 6 % as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol , Apo A - I and Apo A - II pro fi les , other than the well - known hyperglyceridemic effect caused by estrogen .": "[[\"Antiandrogenic therapy\", \"can cause\", \"coronary arterial disease\"],\n[\"Aim\", \"is to study\", \"change of lipid metabolism by antiandrogen therapy in patients with prostate cancer\"],\n[\"Materials and Methods\", \"studied\", \"changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles\"],\n[\"Patients\", \"have\", \"low risk prostate cancer\"],\n[\"Patients\", \"mean age\", \"60 years\"],\n[\"Prostate cancer\", \"stage\", \"T1cN0M0\"],\n[\"Prostate cancer\", \"Gleason score\", \"2-5\"],\n[\"Treatment\", \"includes\", \"cyproterone acetate (CPA)\"],\n[\"Treatment\", \"excludes\", \"surgical management\"],\n[\"Treatment\", \"excludes\", \"radiation therapy\"],\n[\"CPA\", \"induced\", \"significant decreases of HDL-C\"],\n[\"CPA\", \"induced\", \"decreases of Apo A-I\"],\n[\"CPA\", \"induced\", \"decreases of Apo A-II\"],\n[\"CPA\", \"induced\", \"increase of triglyceride levels in VLDL\"],\n[\"After 2.5 years of CPA treatment\", \"patients affected by\", \"coronary heart disease\"],\n[\"Number of patients affected by coronary heart disease\", \"is\", \"four out of twenty-four\"],\n[\"Conclusions\", \"is\", \"Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% is caused by prolonged CPA therapy\"],\n[\"Ischaemic coronary arteriosclerosis\", \"is mediated through changes in\", \"HDL cholesterol\"],\n[\"Ischaemic coronary arteriosclerosis\", \"is mediated through changes in\", \"Apo A-I\"],\n[\"Ischaemic coronary arteriosclerosis\", \"is mediated through changes in\", \"Apo A-II profiles\"],\n[\"Ischaemic coronary arteriosclerosis\", \"is mediated through\", \"hyperglyceridemic effect caused by estrogen\"]]",
      "Paclitaxel , 5 - fluorouracil , and folinic acid in metastatic breast cancer : BRE - 26 , a phase II trial .|5 - Fluorouracil plus folinic acid and paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) are effective salvage therapies for metastatic breast cancer patients .|Paclitaxel and 5 - fluorouracil have additive cytotoxicity in MCF - 7 cell lines .|We performed a phase II trial of paclitaxel 175 mg / m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5 - fluorouracil 350 mg / m2 on days 1 to 3 every 28 days ( TFL ) in women with metastatic breast cancer .|Analysis is reported on 37 patients with a minimum of 6 months follow - up who received a total of 192 cycles of TFL : nine cycles ( 5 % ) were associated with grade 3 / 4 neutropenia requiring hospitalization ; seven ( 4 % ) cycles in two patients required granulocyte colony - stimulating factor due to neutropenia ; no patient required platelet transfusions .|Grade 3 / 4 nonhematologic toxicities were uncommon .|Among the 34 patients evaluable for response , there were three complete responses ( 9 % ) and 18 partial responses ( 53 % ) for an overall response rate of 62 % .|Of the 19 evaluable patients with prior doxorubicin exposure , 11 ( 58 % ) responded compared with nine of 15 ( 60 % ) without prior doxorubicin .|Plasma paclitaxel concentrations were measured at the completion of paclitaxel infusion and at 24 hours in 19 patients .|TFL is an active , well - tolerated regimen in metastatic breast cancer .": "[[\"Paclitaxel\", \"combined with\", \"5-fluorouracil\"],\n [\"Paclitaxel\", \"combined with\", \"folinic acid\"],\n [\"5-fluorouracil\", \"combined with\", \"folinic acid\"],\n [\"Paclitaxel\", \"used for\", \"metastatic breast cancer\"],\n [\"5-fluorouracil\", \"used for\", \"metastatic breast cancer\"],\n [\"Folinic acid\", \"used for\", \"metastatic breast cancer\"],\n [\"Paclitaxel\", \"has\", \"additive cytotoxicity with 5-fluorouracil\"],\n [\"5-fluorouracil\", \"has\", \"additive cytotoxicity with Paclitaxel\"],\n [\"Paclitaxel\", \"administered in\", \"phase II trial\"],\n [\"Folinic acid\", \"administered before\", \"5-fluorouracil\"],\n [\"Phase II trial\", \"for\", \"women with metastatic breast cancer\"],\n [\"TFL\", \"consists of\", \"Paclitaxel, folinic acid, 5-fluorouracil\"],\n [\"Patients\", \"received\", \"TFL\"],\n [\"Patients\", \"had\", \"neutropenia requiring hospitalization\"],\n [\"Patients\", \"required\", \"granulocyte colony-stimulating factor due to neutropenia\"],\n [\"Patients\", \"did not require\", \"platelet transfusions\"],\n [\"Nonhematologic toxicities\", \"were\", \"uncommon\"],\n [\"Patients\", \"evaluable for response\", \"34\"],\n [\"Complete responses\", \"were\", \"three\"],\n [\"Partial responses\", \"were\", \"eighteen\"],\n [\"Overall response rate\", \"was\", \"62%\"],\n [\"Patients with prior doxorubicin exposure\", \"responded\", \"58%\"],\n [\"Patients without prior doxorubicin exposure\", \"responded\", \"60%\"],\n [\"Plasma paclitaxel concentrations\", \"measured in\", \"patients\"],\n [\"TFL\", \"is\", \"active and well-tolerated regimen\"],\n [\"TFL\", \"used for\", \"metastatic breast cancer\"]]",
      "Curcumin prevents maleate - induced nephrotoxicity : relation to hemodynamic alterations , oxidative stress , mitochondrial oxygen consumption and activity of respiratory complex I .|The potential protective effect of the dietary antioxidant curcumin ( 120 mg / Kg / day for 6 days ) against the renal injury induced by maleate was evaluated .|Tubular proteinuria and oxidative stress were induced by a single injection of maleate ( 400 mg / kg ) in rats .|Maleate - induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein , glucose , sodium , neutrophil gelatinase - associated lipocalin ( NGAL ) and N - acetyl b - D - glucosaminidase ( NAG ) , upregulation of kidney injury molecule ( KIM ) - 1 , decrease in renal blood flow and claudin - 2 expression besides of necrosis and apoptosis of tubular cells on 24 h .|Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels .|Studies were also conducted in renal epithelial LLC - PK1 cells and in mitochondria isolated from kidneys of all the experimental groups .|Maleate induced cell damage and reactive oxygen species ( ROS ) production in LLC - PK1 cells in culture .|In addition , maleate treatment reduced oxygen consumption in ADP - stimulated mitochondria and diminished respiratory control index when using malate / glutamate as substrate .|The activities of both complex I and aconitase were also diminished .|All the above - described alterations were prevented by curcumin .|It is concluded that curcumin is able to attenuate in vivo maleate - induced nephropathy and in vitro cell damage .|The in vivo protection was associated to the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I , and the in vitro protection was associated to the prevention of ROS production .": "[[\"Curcumin\", \"prevents\", \"maleate-induced nephrotoxicity\"],\n [\"Curcumin\", \"related to\", \"hemodynamic alterations\"],\n [\"Curcumin\", \"related to\", \"oxidative stress\"],\n [\"Curcumin\", \"related to\", \"mitochondrial oxygen consumption\"],\n [\"Curcumin\", \"related to\", \"activity of respiratory complex I\"],\n [\"Curcumin\", \"evaluated for\", \"protective effect against renal injury\"],\n [\"Curcumin\", \"dosage\", \"120 mg/Kg/day for 6 days\"],\n [\"Maleate\", \"induces\", \"renal injury\"],\n [\"Maleate\", \"induces\", \"tubular proteinuria\"],\n [\"Maleate\", \"induces\", \"oxidative stress\"],\n [\"Maleate\", \"administered via\", \"single injection\"],\n [\"Maleate dosage\", \"is\", \"400 mg/kg in rats\"],\n [\"Maleate-induced renal injury\", \"includes\", \"increase in renal vascular resistance\"],\n [\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of total protein\"],\n [\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of glucose\"],\n [\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of sodium\"],\n [\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of NGAL\"],\n [\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of NAG\"],\n [\"Maleate-induced renal injury\", \"includes\", \"upregulation of KIM-1\"],\n [\"Maleate-induced renal injury\", \"includes\", \"decrease in renal blood flow\"],\n [\"Maleate-induced renal injury\", \"includes\", \"decrease in claudin-2 expression\"],\n [\"Maleate-induced renal injury\", \"includes\", \"necrosis of tubular cells\"],\n [\"Maleate-induced renal injury\", \"includes\", \"apoptosis of tubular cells\"],\n [\"Oxidative stress\", \"determined by\", \"measuring oxidation of lipids\"],\n [\"Oxidative stress\", \"determined by\", \"measuring oxidation of proteins\"],\n [\"Oxidative stress\", \"determined by\", \"diminution in renal Nrf2 levels\"],\n [\"Maleate\", \"induces\", \"cell damage in LLC-PK1 cells\"],\n [\"Maleate\", \"induces\", \"ROS production in LLC-PK1 cells\"],\n [\"Maleate treatment\", \"reduces\", \"oxygen consumption in ADP-stimulated mitochondria\"],\n [\"Maleate treatment\", \"diminishes\", \"respiratory control index\"],\n [\"Maleate treatment\", \"diminishes\", \"activity of complex I\"],\n [\"Maleate treatment\", \"diminishes\", \"activity of aconitase\"],\n [\"Curcumin\", \"prevents\", \"alterations described above\"],\n [\"Curcumin\", \"attenuates\", \"in vivo maleate-induced nephropathy\"],\n [\"Curcumin\", \"attenuates\", \"in vitro cell damage\"],\n [\"In vivo protection by curcumin\", \"associated with\", \"prevention of oxidative stress\"],\n [\"In vivo protection by curcumin\", \"associated with\", \"preservation of mitochondrial oxygen consumption\"],\n [\"In vivo protection by curcumin\", \"associated with\", \"preservation of activity of respiratory complex I\"],\n [\"In vitro protection by curcumin\", \"associated with\", \"prevention of ROS production\"]]",
      "Use of propranolol in the treatment of idiopathic orthostatic hypotension .|Five patients with idiopathic orthostatic hypotension who had physiologic and biochemical evidence of severe autonomic dysfunction were included in the study .|They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine .|Treatment with propanolol administered intravenously ( 1 - 5 mg ) produced increases in supine and upright blood pressure in 4 of the 5 individuals with rises ranging from 11 / 6 to 22 / 11 mmHg .|Chronic oral administration of propranolol ( 40 - 160 mg / day ) also elevated the blood pressures of these individuals with increases in the order of 20 - 35 / 15 - 25 mmg being observed .|In 1 patient , marked hypertension was induced by propranolol and the drug had to be withdrawn .|It otherwise was well tolerated and no important side effects were observed .|Treatment has been continued in 3 individuals for 6 - 13 months with persistence of the pressor effect , although there appears to have been some decrease in the degree of response with time .|Hemodynamic measurements in 1 of the patients demonstrated an increase in total peripheral resistance and essentially no change in cardiac output following propranolol therapy .|The studies suggest that propranolol is a useful drug in selected patients with severe idiopathic orthostatic hypotension .": "[[\"Use of propranolol\", \"is for\", \"treatment of idiopathic orthostatic hypotension\"],\n[\"Five patients\", \"had\", \"idiopathic orthostatic hypotension\"],\n[\"Five patients\", \"had\", \"physiologic and biochemical evidence of severe autonomic dysfunction\"],\n[\"Patients\", \"exhibited\", \"markedly reduced plasma catecholamines\"],\n[\"Patients\", \"exhibited\", \"markedly reduced plasma renin activity\"],\n[\"Patients\", \"had\", \"marked hypersensitivity to pressor effects of infused norepinephrine\"],\n[\"Treatment with propranolol\", \"produced\", \"increases in supine and upright blood pressure\"],\n[\"Propranolol\", \"administered intravenously\", \"1 - 5 mg\"],\n[\"Chronic oral administration of propranolol\", \"elevated\", \"blood pressures of individuals\"],\n[\"Propranolol\", \"administered\", \"40 - 160 mg/day\"],\n[\"1 patient\", \"induced by\", \"marked hypertension\"],\n[\"Propranolol\", \"had to be\", \"withdrawn\"],\n[\"Propranolol\", \"was\", \"well tolerated\"],\n[\"No important side effects\", \"were observed\", \"from propranolol\"],\n[\"Treatment with propranolol\", \"continued\", \"for 6 - 13 months\"],\n[\"Treatment with propranolol\", \"showed\", \"persistence of the pressor effect\"],\n[\"Hemodynamic measurements\", \"demonstrated\", \"increase in total peripheral resistance\"],\n[\"Hemodynamic measurements\", \"showed\", \"no change in cardiac output following propranolol therapy\"],\n[\"Studies\", \"suggest\", \"propranolol is useful for severe idiopathic orthostatic hypotension\"]]",
      "Drug - induced long QT syndrome in injection drug users receiving methadone : high frequency in hospitalized patients and risk factors .|BACKGROUND : Drug - induced long QT syndrome is a serious adverse drug reaction .|Methadone prolongs the QT interval in vitro in a dose - dependent manner .|In the inpatient setting , the frequency of QT interval prolongation with methadone treatment , its dose dependence , and the importance of cofactors such as drug - drug interactions remain unknown .|METHODS : We performed a systematic , retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5 - year period in a tertiary care hospital .|A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone .|In addition to methadone dose , 15 demographic , biological , and pharmacological variables were considered as potential risk factors for QT prolongation .|RESULTS : Among 167 methadone maintenance patients , the prevalence of QTc prolongation to 0 . 50 second ( ( 1 / 2 ) ) or longer was 16 . 2 % compared with 0 % in 80 control subjects .|Six patients ( 3 . 6 % ) in the methadone group presented torsades de pointes .|QTc length was weakly but significantly associated with methadone daily dose ( Spearman rank correlation coefficient , 0 . 20 ; P < . 01 ) .|Multivariate regression analysis allowed attribution of 31 . 8 % of QTc variability to methadone dose , cytochrome P - 450 3A4 drug - drug interactions , hypokalemia , and altered liver function .|CONCLUSIONS : QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding .|Methadone dose , presence of cytochrome P - 450 3A4 inhibitors , potassium level , and liver function contribute to QT prolongation .|Long QT syndrome can occur with low doses of methadone .": "[[\"Drug-induced long QT syndrome\", \"is a\", \"serious adverse drug reaction\"],\n[\"Methadone\", \"prolongs\", \"QT interval in vitro\"],\n[\"Methadone treatment\", \"associated with\", \"QT interval prolongation\"],\n[\"QT interval prolongation\", \"has unknown factors in\", \"inpatient setting\"],\n[\"QT interval prolongation\", \"has unknown factors like\", \"drug-drug interactions\"],\n[\"Study\", \"performed by\", \"researchers\"],\n[\"Study\", \"compared\", \"methadone recipients with non-recipients\"],\n[\"Patients receiving methadone\", \"fulfilled\", \"inclusion criteria\"],\n[\"Patients receiving methadone\", \"compared with\", \"control group\"],\n[\"Potential risk factors for QT prolongation\", \"include\", \"methadone dose\"],\n[\"Potential risk factors for QT prolongation\", \"include\", \"demographic variables\"],\n[\"Potential risk factors for QT prolongation\", \"include\", \"biological variables\"],\n[\"Potential risk factors for QT prolongation\", \"include\", \"pharmacological variables\"],\n[\"Prevalence of QTc prolongation\", \"was\", \"16.2% in methadone maintenance patients\"],\n[\"QTc prolongation\", \"was\", \"0% in control subjects\"],\n[\"Patients in methadone group\", \"presented\", \"torsades de pointes\"],\n[\"QTc length\", \"associated with\", \"methadone daily dose\"],\n[\"Methadone dose\", \"contributes to\", \"31.8% of QTc variability\"],\n[\"Cytochrome P-450 3A4 drug-drug interactions\", \"contributes to\", \"QTc variability\"],\n[\"Hypokalemia\", \"contributes to\", \"QTc variability\"],\n[\"Altered liver function\", \"contributes to\", \"QTc variability\"],\n[\"QT interval prolongation\", \"is a frequent finding in\", \"methadone maintenance patients hospitalized\"],\n[\"Methadone dose\", \"contributes to\", \"QT prolongation\"],\n[\"Cytochrome P-450 3A4 inhibitors\", \"contribute to\", \"QT prolongation\"],\n[\"Potassium level\", \"contributes to\", \"QT prolongation\"],\n[\"Liver function\", \"contributes to\", \"QT prolongation\"],\n[\"Long QT syndrome\", \"can occur with\", \"low doses of methadone\"]]",
      "Linezolid - induced optic neuropathy .|Many systemic antimicrobials have been implicated to cause ocular adverse effects .|This is especially relevant in multidrug therapy where more than one drug can cause a similar ocular adverse effect .|We describe a case of progressive loss of vision associated with linezolid therapy .|A 45 - year - old male patient who was on treatment with multiple second - line anti - tuberculous drugs including linezolid and ethambutol for extensively drug - resistant tuberculosis ( XDR - TB ) presented to us with painless progressive loss of vision in both eyes .|Color vision was defective and fundus examination revealed optic disc edema in both eyes .|Ethambutol - induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn .|Deterioration of vision occurred despite withdrawal of ethambutol .|Discontinuation of linezolid resulted in marked improvement of vision .|Our report emphasizes the need for monitoring of visual function in patients on long - term linezolid treatment .": "[[\"Linezolid-induced optic neuropathy\", \"is an example of\", \"ocular adverse effects\"],\n [\"Systemic antimicrobials\", \"implicated in causing\", \"ocular adverse effects\"],\n [\"Multidrug therapy\", \"can cause\", \"similar ocular adverse effect\"],\n [\"Case\", \"associated with\", \"linezolid therapy\"],\n [\"Male patient\", \"on treatment with\", \"multiple second-line anti-tuberculous drugs\"],\n [\"Male patient\", \"presented with\", \"painless progressive loss of vision\"],\n [\"Male patient\", \"had\", \"defective color vision\"],\n [\"Fundus examination\", \"revealed\", \"optic disc edema\"],\n [\"Ethambutol\", \"suspected in causing\", \"toxic optic neuropathy\"],\n [\"Ethambutol\", \"was withdrawn\", \"due to suspicion\"],\n [\"Vision deterioration\", \"occurred despite\", \"withdrawal of ethambutol\"],\n [\"Discontinuation of linezolid\", \"resulted in\", \"marked improvement of vision\"],\n [\"Report\", \"emphasizes the need for\", \"monitoring of visual function\"],\n [\"Patients on long-term linezolid treatment\", \"need\", \"monitoring of visual function\"]]",
      "Indomethacin induced hypotension in sodium and volume depleted rats .|After a single oral dose of 4 mg / kg indomethacin ( IDM ) to sodium and volume depleted rats plasma renin activity ( PRA ) and systolic blood pressure fell significantly within four hours .|In sodium repleted animals indomethacin did not change systolic blood pressure ( BP ) although plasma renin activity was decreased .|Thus , indomethacin by inhibition of prostaglandin synthesis may diminish the blood pressure maintaining effect of the stimulated renin - angiotensin system in sodium and volume depletion .": "[[\"Indomethacin\", \"induced\", \"hypotension in sodium and volume depleted rats\"],\n[\"A single oral dose of 4 mg / kg indomethacin\", \"administered to\", \"sodium and volume depleted rats\"],\n[\"Indomethacin\", \"caused\", \"plasma renin activity to fall\"],\n[\"Indomethacin\", \"caused\", \"systolic blood pressure to fall\"],\n[\"Indomethacin\", \"did not change\", \"systolic blood pressure in sodium repleted animals\"],\n[\"Indomethacin\", \"decreased\", \"plasma renin activity in sodium repleted animals\"],\n[\"Indomethacin\", \"may diminish\", \"blood pressure maintaining effect\"],\n[\"Inhibition of prostaglandin synthesis\", \"may diminish\", \"blood pressure maintaining effect\"],\n[\"Stimulated renin-angiotensin system\", \"has\", \"blood pressure maintaining effect\"],\n[\"Stimulated renin-angiotensin system\", \"in\", \"sodium and volume depletion\"]]",
      "Worsening of Parkinsonism after the use of veralipride for treatment of menopause : case report .|We describe a female patient with stable Parkinson 's disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride , as well as the improvement of her symptoms back to baseline after discontinuation of the drug .|We emphasize the anti - dopaminergic effect of veralipride .": "[[\"Worsening of Parkinsonism\", \"after\", \"use of veralipride for treatment of menopause\"], [\"Female patient with stable Parkinson's disease\", \"shown\", \"marked worsening of her motor functions following therapy with veralipride\"], [\"Female patient with stable Parkinson's disease\", \"had\", \"improvement of her symptoms back to baseline after discontinuation of veralipride\"], [\"Veralipride\", \"has\", \"anti-dopaminergic effect\"]]",
      "Mitochondrial impairment contributes to cocaine - induced cardiac dysfunction : Prevention by the targeted antioxidant MitoQ .|The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine - induced cardiac dysfunction .|We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction .|Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers , specifically through complex I and complex III .|ROS levels were increased , specifically in interfibrillar mitochondria .|In parallel there was a decrease in ATP synthesis , whereas no difference was observed in subsarcolemmal mitochondria .|This uncoupling effect on oxidative phosphorylation was not detectable after short - term exposure to cocaine , suggesting that these mitochondrial abnormalities were a late rather than a primary event in the pathological response to cocaine .|MitoQ , a mitochondrial - targeted antioxidant , was shown to completely prevent these mitochondrial abnormalities as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure - volume data .|Taken together , these results extend previous studies and demonstrate that cocaine - induced cardiac dysfunction may be due to a mitochondrial defect .": "[[\"Mitochondrial impairment\", \"contributes to\", \"cocaine-induced cardiac dysfunction\"],\n [\"Targeted antioxidant MitoQ\", \"prevents\", \"mitochondrial impairment\"],\n [\"Study\", \"was to assess\", \"mitochondrial function and ROS production\"],\n [\"Study\", \"was to assess\", \"cocaine-induced cardiac dysfunction\"],\n [\"Cocaine abuse\", \"may lead to\", \"altered mitochondrial function\"],\n [\"Altered mitochondrial function\", \"may cause\", \"left ventricular dysfunction\"],\n [\"Seven days of cocaine administration\", \"led to\", \"increased oxygen consumption in cardiac fibers\"],\n [\"Increased oxygen consumption\", \"detected through\", \"complex I and complex III\"],\n [\"ROS levels\", \"were increased in\", \"interfibrillar mitochondria\"],\n [\"There was a decrease in\", \"ATP synthesis\", \"\"],\n [\"No difference was observed in\", \"ATP synthesis\", \"subsarcolemmal mitochondria\"],\n [\"Mitochondrial abnormalities\", \"were a late event in\", \"pathological response to cocaine\"],\n [\"MitoQ\", \"prevented\", \"mitochondrial abnormalities\"],\n [\"MitoQ\", \"prevented\", \"cardiac dysfunction\"],\n [\"Cardiac dysfunction\", \"characterized by\", \"diastolic dysfunction\"],\n [\"Diastolic dysfunction\", \"studied with\", \"conductance catheter\"],\n [\"Conductance catheter\", \"obtain\", \"pressure-volume data\"],\n [\"Cocaine-induced cardiac dysfunction\", \"may be due to\", \"mitochondrial defect\"]]",
      "The enhancement of aminonucleoside nephrosis by the co - administration of protamine .|An experimental model of focal segmental glomerular sclerosis ( FSGS ) was developed in rats by the combined administration of puromycin - aminonucleoside ( AMNS ) and protamine sulfate ( PS ) .|Male Sprague - Dawley rats , uninephrectomized three weeks before , received daily injections of subcutaneous AMNS ( 1 mg / 100 g body wt ) and intravenous PS ( 2 separated doses of 2 . 5 mg / 100 g body wt ) for four days .|The series of injections were repeated another three times at 10 day intervals .|The animals were sacrificed on days 24 , 52 , and 80 .|They developed nephrotic syndrome and finally renal failure .|The time - course curve of creatinine clearance dropped and showed significant difference ( P less than 0 . 01 ) from that of each control group , such as , AMNS alone , PS alone or saline injected .|Their glomeruli showed changes of progressive FSGS .|The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ruthenium red on the lamina rara externa and marked changes in epithelial cell cytoplasm .|Therefore , it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end - stage renal disease .": "Based on the provided prompt, here are the relationships extracted:\n\n1. [[\"aminonucleoside nephrosis\", \"enhanced by\", \"co-administration of protamine\"]]\n2. [[\"experimental model of FSGS\", \"developed by\", \"combined administration of AMNS and PS\"]]\n3. [[\"Male Sprague-Dawley rats\", \"received\", \"daily injections of AMNS\"]]\n4. [[\"Male Sprague-Dawley rats\", \"received\", \"intravenous PS\"]]\n5. [[\"injections\", \"repeated\", \"three times at 10 day intervals\"]]\n6. [[\"animals\", \"sacrificed on\", \"days 24, 52, and 80\"]]\n7. [[\"animals\", \"developed\", \"nephrotic syndrome\"]]\n8. [[\"animals\", \"developed\", \"renal failure\"]]\n9. [[\"time-course curve of creatinine clearance\", \"showed\", \"significant difference from control groups\"]]\n10. [[\"control groups\", \"include\", \"AMNS alone\"]]\n11. [[\"control groups\", \"include\", \"PS alone\"]]\n12. [[\"control groups\", \"include\", \"saline injected\"]]\n13. [[\"glomeruli of animals\", \"showed\", \"changes of progressive FSGS\"]]\n14. [[\"ultrastructural studies\", \"revealed\", \"lack of particles of perfused ruthenium red on lamina rara externa\"]]\n15. [[\"ultrastructural studies\", \"revealed\", \"changes in epithelial cell cytoplasm\"]]\n16. [[\"administration of PS\", \"enhances\", \"toxicity of AMNS on glomerulus\"]]\n17. [[\"administration of PS and AMNS\", \"produces\", \"progressive FSGS in rats\"]]\n18. [[\"progressive FSGS in rats\", \"results in\", \"end-stage renal disease\"]]",
      "Pharmacological studies on a new dihydrothienopyridine calcium antagonist , S - 312 - d .|5th communication : anticonvulsant effects in mice .|S - 312 , S - 312 - d , but not S - 312 - l , L - type calcium channel antagonists , showed anticonvulsant effects on the audiogenic tonic convulsions in DBA / 2 mice ; and their ED50 values were 18 . 4 ( 12 . 8 - 27 . 1 ) mg / kg , p . o .|and 15 . 0 ( 10 . 2 - 23 . 7 ) mg / kg , p . o . , respectively , while that of flunarizine was 34 . 0 ( 26 . 0 - 44 . 8 ) mg / kg , p . o .|Although moderate anticonvulsant effects of S - 312 - d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole ( 85 mg / kg , s . c . ) or bemegride ( 40 mg / kg , s . c . ) , no effects were observed in convulsions induced by N - methyl - D - aspartate , picrotoxin , or electroshock in Slc : ddY mice .|S - 312 - d may be useful in the therapy of certain types of human epilepsy .": "[[\"S - 312 - d\", \"is a\", \"dihydrothienopyridine calcium antagonist\"],\n[\"S - 312 - d\", \"is a\", \"L-type calcium channel antagonist\"],\n[\"S - 312 - d\", \"showed\", \"anticonvulsant effects\"],\n[\"S - 312 - d\", \"used for\", \"audiogenic tonic convulsions in DBA / 2 mice\"],\n[\"S - 312 - d\", \"has ED50 value of\", \"18.4 (12.8 - 27.1) mg/kg, p.o.\"],\n[\"S - 312 - l\", \"showed no\", \"anticonvulsant effects\"],\n[\"Flunarizine\", \"has ED50 value of\", \"34.0 (26.0 - 44.8) mg/kg, p.o.\"],\n[\"S - 312 - d\", \"showed moderate anticonvulsant effects against\", \"clonic convulsions induced by pentylenetetrazole\"],\n[\"S - 312 - d\", \"showed moderate anticonvulsant effects against\", \"clonic convulsions induced by bemegride\"],\n[\"S - 312 - d\", \"showed no effects against\", \"convulsions induced by N - methyl - D - aspartate\"],\n[\"S - 312 - d\", \"showed no effects against\", \"convulsions induced by picrotoxin\"],\n[\"S - 312 - d\", \"showed no effects against\", \"convulsions induced by electroshock\"],\n[\"S - 312 - d\", \"may be useful in therapy of\", \"certain types of human epilepsy\"]]",
      "Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix .|BACKGROUND : The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma .|METHODS : The combination of carboplatin ( area under the concentration curve [ AUC ] , 5 ) and liposomal doxorubicin ( Doxil ; starting dose , 40 mg / m ( 2 ) ) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile .|RESULTS : Twenty - nine patients were assessable for response , and 35 patients were assessable for toxicity .|The overall response rate was 38 % , the median time to response was 10 weeks , the median duration of response was 26 weeks , and the median survival was 37 weeks .|The main toxic effect was myelosuppression , with Grade 3 and 4 neutropenia in 16 patients , anemia in 12 patients , thrombocytopenia in 11 patients , and neutropenic fever in 3 patients .|Four patients had five infusion - related reactions during the infusion of liposomal doxorubicin , leading to treatment discontinuation in three patients .|Grade > or = 2 nonhematologic toxicity included nausea in 17 patients , emesis in 14 patients , fatigue in 9 patients , mucositis and / or stomatitis in 8 patients , constipation in 6 patients , weight loss in 5 patients , hand - foot syndrome in 2 patients , and skin reactions in 3 patients .|CONCLUSIONS : The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma .": "[[\"Phase II study\", \"tested\", \"carboplatin and liposomal doxorubicin\"], [\"carboplatin and liposomal doxorubicin\", \"used in\", \"patients with recurrent cervical carcinoma\"], [\"carboplatin\", \"administered with\", \"liposomal doxorubicin\"], [\"carboplatin and liposomal doxorubicin\", \"administered to\", \"37 patients with recurrent squamous cell cervical carcinoma\"], [\"study\", \"to determine\", \"antitumor activity\"], [\"study\", \"to determine\", \"toxicity profile\"], [\"29 patients\", \"assessable for\", \"response\"], [\"35 patients\", \"assessable for\", \"toxicity\"], [\"overall response rate\", \"was\", \"38%\"], [\"median time to response\", \"was\", \"10 weeks\"], [\"median duration of response\", \"was\", \"26 weeks\"], [\"median survival\", \"was\", \"37 weeks\"], [\"main toxic effect\", \"was\", \"myelosuppression\"], [\"16 patients\", \"had\", \"Grade 3 and 4 neutropenia\"], [\"12 patients\", \"had\", \"anemia\"], [\"11 patients\", \"had\", \"thrombocytopenia\"], [\"3 patients\", \"had\", \"neutropenic fever\"], [\"Four patients\", \"had\", \"infusion-related reactions\"], [\"liposomal doxorubicin\", \"caused\", \"infusion-related reactions\"], [\"treatment discontinuation\", \"caused by\", \"infusion-related reactions\"], [\"treatment discontinuation\", \"in\", \"three patients\"], [\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"nausea\"], [\"17 patients\", \"experienced\", \"nausea\"], [\"14 patients\", \"experienced\", \"emesis\"], [\"9 patients\", \"experienced\", \"fatigue\"], [\"8 patients\", \"experienced\", \"mucositis and/or stomatitis\"], [\"6 patients\", \"experienced\", \"constipation\"], [\"5 patients\", \"experienced\", \"weight loss\"], [\"2 patients\", \"experienced\", \"hand-foot syndrome\"], [\"3 patients\", \"experienced\", \"skin reactions\"], [\"combination of carboplatin and liposomal doxorubicin\", \"has\", \"modest activity in patients with recurrent cervical carcinoma\"]]",
      "Electron microscopic investigations of the cyclophosphamide - induced lesions of the urinary bladder of the rat and their prevention by mesna .|Fully developed cyclophosphamide - induced cystitis is characterized by nearly complete detachment of the urothelium , severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses .|The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the luminal membrane .|This damages the cellular barrier against the hypertonic urine .|Subsequent breaks in the lateral cell membranes of the superficial cells and in all the plasma membranes of the intermediate and basal cells , intercellular and intracellular edema and disintegration of the desmosomes and hemidesmosomes lead to progressive degeneration and detachment of the epithelial cells with exposure and splitting of the basal membrane .|The morphological changes of the endothelial cells , which become more pronounced in the later stages of the experiment , the involvement of blood vessels regardless of their diameter and the location - dependent extent of the damage indicate a direct type of damage which is preceded by a mediator - induced increase in permeability , the morphological correlate of which is the formation of gaps in the interendothelial cell connections on the venules .|These changes can be effectively prevented by mesna .|The only sign of a possible involvement is the increase in the number of specific granules with a presumed lysosomal function in the superficial cells .": "[[\"cyclophosphamide-induced lesions\", \"investigated by\", \"Electron microscopic investigations\"],\n [\"cyclophosphamide-induced cystitis\", \"characterized by\", \"detachment of the urothelium\"],\n [\"cyclophosphamide-induced cystitis\", \"characterized by\", \"severe submucosal edema\"],\n [\"cyclophosphamide-induced cystitis\", \"characterized by\", \"focal muscle necroses\"],\n [\"primary attack by cyclophosphamide metabolites\", \"causes\", \"fragmentation of the luminal membrane\"],\n [\"fragmentation of the luminal membrane\", \"damages\", \"cellular barrier against hypertonic urine\"],\n [\"breaks in lateral cell membranes\", \"lead to\", \"progressive degeneration and detachment of epithelial cells\"],\n [\"breaks in plasma membranes\", \"lead to\", \"progressive degeneration and detachment of epithelial cells\"],\n [\"desmosomes and hemidesmosomes disintegration\", \"leads to\", \"progressive degeneration and detachment of epithelial cells\"],\n [\"epithelial cells detachment\", \"exposes and splits\", \"basal membrane\"],\n [\"morphological changes of endothelial cells\", \"become\", \"more pronounced in later stages\"],\n [\"damage\", \"indicates\", \"direct type of damage\"],\n [\"damage\", \"preceded by\", \"mediator-induced increase in permeability\"],\n [\"mediator-induced increase in permeability\", \"has morphological correlate\", \"formation of gaps in interendothelial cell connections\"],\n [\"mesna\", \"prevents\", \"cyclophosphamide-induced lesions\"],\n [\"specific granules increase\", \"sign of\", \"possible involvement\"],\n [\"specific granules\", \"presumed function\", \"lysosomal function in superficial cells\"]]",
      "Vasopressin as a possible contributor to hypertension .|The role of vasopressin as a pressor agent to the hypertensive process was examined .|Vasopressin plays a major role in the pathogenesis of DOCA - salt hypertension , since the elevation of blood pressure was not substantial in the rats with lithium - treated diabetes insipidus after DOCA - salt treatment .|Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP .|Furthermore , the pressor action of vasopressin appears to be important in the development of this model of hypertension , since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension .|Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension .|An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for sodium balance in the brain .|However , the role of vasopressin remains to be determined in human essential hypertension .": "[[\"Vasopressin\", \"possible contributor to\", \"hypertension\"],\n[\"Vasopressin\", \"role as\", \"pressor agent\"],\n[\"Vasopressin\", \"plays role in\", \"pathogenesis of DOCA-salt hypertension\"],\n[\"Blood pressure elevation\", \"not substantial in\", \"rats with lithium-treated diabetes insipidus after DOCA-salt treatment\"],\n[\"DDAVP\", \"has\", \"antidiuretic action\"],\n[\"DDAVP\", \"has minimal\", \"vasopressor effect\"],\n[\"DDAVP administration\", \"failed to increase\", \"blood pressure to levels observed after AVP administration\"],\n[\"Pressor action of vasopressin\", \"important in\", \"development of model of hypertension\"],\n[\"Pressor responsiveness to vasopressin\", \"enhanced in\", \"initial stage of hypertension\"],\n[\"Increased secretion of vasopressin from neurohypophysis\", \"promotes\", \"function as pathogenetic factor in hypertension\"],\n[\"Unproportional release of vasopressin\", \"may be induced by\", \"absence of adjusting control of angiotensin II\"],\n[\"Angiotensin II\", \"forming and receptor binding capacity for sodium balance\", \"in the brain\"],\n[\"Role of vasopressin\", \"remains to be determined in\", \"human essential hypertension\"]]",
      "Improvement by denopamine ( TA - 064 ) of pentobarbital - induced cardiac failure in the dog heart - lung preparation .|The efficacy of denopamine , an orally active beta 1 - adrenoceptor agonist , in improving cardiac failure was assessed in dog heart - lung preparations .|Cardiac functions depressed by pentobarbital ( 118 + / - 28 mg ; mean value + / - SD ) such that cardiac output and maximum rate of rise of left ventricular pressure ( LV dP / dt max ) had been reduced by about 35 % and 26 % of the respective controls were improved by denopamine ( 10 - 300 micrograms ) in a dose - dependent manner .|With 100 micrograms denopamine , almost complete restoration of cardiac performance was attained , associated with a slight increase in heart rate .|No arrhythmias were induced by these doses of denopamine .|The results warrant clinical trials of denopamine in the treatment of cardiac failure .": "[[\"denopamine (TA-064)\", \"improves\", \"pentobarbital-induced cardiac failure\"], [\"denopamine\", \"is an\", \"orally active beta 1-adrenoceptor agonist\"], [\"denopamine\", \"assessed in\", \"dog heart-lung preparations\"], [\"Cardiac functions\", \"depressed by\", \"pentobarbital\"], [\"pentobarbital\", \"reduces\", \"cardiac output\"], [\"pentobarbital\", \"reduces\", \"LV dP/dt max\"], [\"denopamine\", \"improves cardiac functions in a\", \"dose-dependent manner\"], [\"100 micrograms denopamine\", \"restores\", \"cardiac performance\"], [\"100 micrograms denopamine\", \"causes\", \"slight increase in heart rate\"], [\"denopamine\", \"does not induce\", \"arrhythmias\"], [\"results\", \"warrant\", \"clinical trials of denopamine\"], [\"clinical trials of denopamine\", \"for treatment of\", \"cardiac failure\"]]",
      "Milk - alkali syndrome induced by 1 , 25 ( OH ) 2D in a patient with hypoparathyroidism .|Milk - alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali .|Although with current ulcer therapy ( H - 2 blockers , omeprazole , and sucralfate ) , the frequency of milk - alkali syndrome has decreased significantly , the classic triad of hypercalcemia , alkalosis , and renal impairment remains the hallmark of the syndrome .|Milk - alkali syndrome can present serious and occasionally life - threatening illness unless diagnosed and treated appropriately .|This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .|The patient was successfully treated with intravenous pamidronate on his first admission and with hydrocortisone on the second .|This illustrates intravenous pamidronate as a valuable therapeutic tool when milk - alkali syndrome presents as hypercalcemic emergency .": "[[\"Milk-alkali syndrome\", \"induced by\", \"1, 25(OH)2D\"], [\"Milk-alkali syndrome\", \"occurs in\", \"patient with hypoparathyroidism\"], [\"Milk-alkali syndrome\", \"was first described\", \"70 years ago\"], [\"Milk-alkali syndrome\", \"associated with treatment of\", \"peptic ulcer disease\"], [\"Peptic ulcer disease\", \"treated with\", \"large amounts of calcium and alkali\"], [\"Milk-alkali syndrome\", \"frequency decreased by\", \"current ulcer therapy\"], [\"Current ulcer therapy\", \"includes\", \"H-2 blockers\"], [\"Current ulcer therapy\", \"includes\", \"omeprazole\"], [\"Current ulcer therapy\", \"includes\", \"sucralfate\"], [\"Milk-alkali syndrome\", \"characterized by\", \"hypercalcemia\"], [\"Milk-alkali syndrome\", \"characterized by\", \"alkalosis\"], [\"Milk-alkali syndrome\", \"characterized by\", \"renal impairment\"], [\"Milk-alkali syndrome\", \"can present\", \"serious illness\"], [\"Milk-alkali syndrome\", \"can present\", \"life-threatening illness\"], [\"Patient with hypoparathyroidism\", \"treated with\", \"calcium carbonate\"], [\"Patient with hypoparathyroidism\", \"treated with\", \"calcitriol\"], [\"Patient\", \"admitted to hospital for\", \"milk-alkali syndrome\"], [\"Patient\", \"treated with\", \"intravenous pamidronate\"], [\"Intravenous pamidronate\", \"used for\", \"milk-alkali syndrome\"], [\"Patient\", \"treated with\", \"hydrocortisone\"], [\"Intravenous pamidronate\", \"presents as\", \"therapeutic tool\"], [\"Milk-alkali syndrome\", \"presents as\", \"hypercalcemic emergency\"]]",
      "Etomidate : a foreshortened clinical trial .|A clinical evaluation of etomidate for outpatient cystoscopy was embarked upon .|Unpremedicated patients were given fentanyl 1 microgram / kg followed by etomidate 0 . 3 mg / kg .|Anaesthesia was maintained with intermittent etomidate in 2 - 4 mg doses .|Patients were interviewed personally later the same day , and by questionnaire three to four weeks later .|The trial was discontinued after 20 cases because of an unacceptable incidence of side effects .|Venous pain occurred in 68 % of patients and 50 % had redness , pain or swelling related to the injection site , in some cases lasting up to three weeks after anaesthesia .|Skeletal movements occurred in 50 % of patients ; 30 % experienced respiratory upset , one sufficiently severe to necessitate abandoning the technique .|Nausea and vomiting occurred in 40 % and 25 % had disturbing emergence psychoses .": "[[\"Etomidate\", \"used in\", \"clinical trial\"],\n[\"Clinical evaluation\", \"for\", \"outpatient cystoscopy\"],\n[\"Unpremedicated patients\", \"given\", \"fentanyl\"],\n[\"Unpremedicated patients\", \"followed by\", \"etomidate\"],\n[\"Anaesthesia\", \"maintained with\", \"intermittent etomidate\"],\n[\"Patients\", \"interviewed by\", \"personally\"],\n[\"Patients\", \"interviewed by\", \"questionnaire\"],\n[\"Trial\", \"discontinued after\", \"20 cases\"],\n[\"Venous pain\", \"occurred in\", \"68% of patients\"],\n[\"Redness, pain or swelling\", \"related to\", \"injection site\"],\n[\"Redness, pain or swelling\", \"lasted up to\", \"three weeks after anaesthesia\"],\n[\"Skeletal movements\", \"occurred in\", \"50% of patients\"],\n[\"Respiratory upset\", \"experienced by\", \"30% of patients\"],\n[\"Technique\", \"abandoned due to\", \"severe respiratory upset\"],\n[\"Nausea and vomiting\", \"occurred in\", \"40%\"],\n[\"Emergence psychoses\", \"experienced by\", \"25% of patients\"]]",
      "Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol .|BACKGROUND : Cisplatin is a widely used antineoplastic .|One of the major complications of cisplatin use is dose - limiting nephrotoxicity .|There are many strategies to prevent this toxicity , including the use of mannitol as a nephroprotectant in combination with hydration .|OBJECTIVE : We aimed to evaluate the rates of cisplatin - induced nephrotoxicity in cancer patients receiving single - agent cisplatin with and without mannitol .|METHODS : This single - center retrospective analysis was a quasi experiment created by the national mannitol shortage .|Data were collected on adult cancer patients receiving single - agent cisplatin as an outpatient from January 2011 to September 2012 .|The primary outcome was acute kidney injury ( AKI ) .|RESULTS : We evaluated 143 patients who received single - agent cisplatin ; 97 . 2 % of patients had head and neck cancer as their primary malignancy .|Patients who did not receive mannitol were more likely to develop nephrotoxicity : odds ratio [ OR ] = 2 . 646 ( 95 % CI = 1 . 008 , 6 . 944 ; P = 0 . 048 ) .|Patients who received the 100 mg / m ( 2 ) dosing and patients who had a history of hypertension also had a higher likelihood of developing nephrotoxicity : OR = 11 . 494 ( 95 % CI = 4 . 149 , 32 . 258 ; P < 0 . 0001 ) and OR = 3 . 219 ( 95 % CI = 1 . 228 , 8 . 439 ; P = 0 . 017 ) , respectively .|CONCLUSIONS : When limited quantities of mannitol are available , it should preferentially be given to patients at particularly high risk of nephrotoxicity .|Our analysis suggests that those patients receiving the dosing schedule of 100 mg / m ( 2 ) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol .": "[[\"Cisplatin\", \"is a\", \"antineoplastic\"],\n[\"Cisplatin\", \"causes\", \"nephrotoxicity\"],\n[\"Mannitol\", \"used as\", \"nephroprotectant\"],\n[\"Mannitol\", \"used in combination with\", \"hydration\"],\n[\"Study\", \"aims to evaluate\", \"rates of cisplatin-induced nephrotoxicity\"],\n[\"Study\", \"compares\", \"cisplatin with mannitol\"],\n[\"Study\", \"compares\", \"cisplatin without mannitol\"],\n[\"Analysis\", \"was\", \"single-center retrospective\"],\n[\"Analysis\", \"created by\", \"national mannitol shortage\"],\n[\"Data\", \"collected from\", \"adult cancer patients\"],\n[\"Patients\", \"received\", \"single-agent cisplatin\"],\n[\"Primary outcome\", \"was\", \"acute kidney injury\"],\n[\"Patients\", \"had\", \"head and neck cancer\"],\n[\"Patients without mannitol\", \"more likely to develop\", \"nephrotoxicity\"],\n[\"Patients with 100 mg/m(2) dosing\", \"higher likelihood of developing\", \"nephrotoxicity\"],\n[\"Patients with history of hypertension\", \"higher likelihood of developing\", \"nephrotoxicity\"],\n[\"Mannitol\", \"should be given to\", \"patients at high risk of nephrotoxicity\"],\n[\"Patients receiving 100 mg/m(2) cisplatin every 3 weeks\", \"at greatest risk of\", \"nephrotoxicity\"],\n[\"Patients with hypertension\", \"at greatest risk of\", \"nephrotoxicity\"],\n[\"Patients at greatest risk of nephrotoxicity\", \"would benefit from\", \"addition of mannitol\"]]",
      "Testosterone ameliorates streptozotocin - induced memory impairment in male rats .|AIM : To study the effects of testosterone on streptozotocin ( STZ ) - induced memory impairment in male rats .|METHODS : Adult male Wistar rats were intracerebroventricularly ( icv ) infused with STZ ( 750 ug ) on d 1 and d 3 , and a passive avoidance task was assessed 2 weeks after the first injection of STZ .|Castration surgery was performed in another group of rats , and the passive avoidance task was assessed 4 weeks after the operation .|Testosterone ( 1 mg . kg ( - 1 ) . d ( - 1 ) , sc ) , the androgen receptor antagonist flutamide ( 10 mg . kg ( - 1 ) . d ( - 1 ) , ip ) , the estrogen receptor antagonist tamoxifen ( 1 mg . kg ( - 1 ) . d ( - 1 ) , ip ) or the aromatase inhibitor letrozole ( 4 mg . kg ( - 1 ) . d ( - 1 ) , ip ) were administered for 6 d after the first injection of STZ .|RESULTS : STZ administration and castration markedly decreased both STL1 ( the short memory ) and STL2 ( the long memory ) in passive avoidance tests .|Testosterone replacement almost restored the STL1 and STL2 in castrated rats , and significantly prolonged the STL1 and STL2 in STZ - treated rats .|Administration of flutamide , letrozole or tamoxifen significantly impaired the memory in intact rats , and significantly attenuated the testosterone replacement in improving STZ - and castration - induced memory impairment .|CONCLUSION : Testosterone administration ameliorates STZ - and castration - induced memory impairment in male Wistar rats .": "[[\"Testosterone\", \"ameliorates\", \"streptozotocin-induced memory impairment in male rats\"],\n [\"Aim\", \"is to study\", \"effects of testosterone on memory impairment\"],\n [\"Memory impairment\", \"induced by\", \"streptozotocin (STZ)\"],\n [\"Adult male Wistar rats\", \"were infused with\", \"STZ\"],\n [\"STZ\", \"administered on\", \"d 1 and d 3\"],\n [\"Passive avoidance task\", \"assessed\", \"2 weeks after first injection of STZ\"],\n [\"Castration surgery\", \"performed in\", \"another group of rats\"],\n [\"Passive avoidance task\", \"assessed\", \"4 weeks after the operation\"],\n [\"Testosterone\", \"administered for\", \"6 days after first injection of STZ\"],\n [\"Flutamide\", \"administered for\", \"6 days after first injection of STZ\"],\n [\"Tamoxifen\", \"administered for\", \"6 days after first injection of STZ\"],\n [\"Letrozole\", \"administered for\", \"6 days after first injection of STZ\"],\n [\"STZ administration and castration\", \"decreased\", \"STL1 (short memory)\"],\n [\"STZ administration and castration\", \"decreased\", \"STL2 (long memory)\"],\n [\"Testosterone replacement\", \"almost restored\", \"STL1 in castrated rats\"],\n [\"Testosterone replacement\", \"almost restored\", \"STL2 in castrated rats\"],\n [\"Testosterone replacement\", \"prolonged\", \"STL1 in STZ-treated rats\"],\n [\"Testosterone replacement\", \"prolonged\", \"STL2 in STZ-treated rats\"],\n [\"Flutamide administration\", \"impaired\", \"memory in intact rats\"],\n [\"Letrozole administration\", \"impaired\", \"memory in intact rats\"],\n [\"Tamoxifen administration\", \"impaired\", \"memory in intact rats\"],\n [\"Flutamide administration\", \"attenuated\", \"testosterone replacement in improving memory impairment\"],\n [\"Letrozole administration\", \"attenuated\", \"testosterone replacement in improving memory impairment\"],\n [\"Tamoxifen administration\", \"attenuated\", \"testosterone replacement in improving memory impairment\"],\n [\"Testosterone administration\", \"ameliorates\", \"castration-induced memory impairment in male Wistar rats\"]]",
      "Nifedipine induced bradycardia in a patient with autonomic neuropathy .|An 80 year old diabetic male with evidence of peripheral and autonomic neuropathy was admitted with chest pain .|He was found to have atrial flutter at a ventricular rate of 70 / min which slowed down to 30 - 40 / min when nifedipine ( 60 mg ) in 3 divided doses , during which he was paced at a rate of 70 / min .|This is inconsistent with the well - established finding that nifedipine induces tachycardia in normally innervated hearts .|However , in hearts deprived of compensatory sympathetic drive , it may lead to bradycardia .": "[[\"Nifedipine\", \"induced\", \"bradycardia\"], [\"Patient\", \"has\", \"autonomic neuropathy\"], [\"Patient\", \"is\", \"80 year old diabetic male\"], [\"Patient\", \"has\", \"evidence of peripheral neuropathy\"], [\"Patient\", \"was admitted with\", \"chest pain\"], [\"Patient\", \"was found to have\", \"atrial flutter\"], [\"Atrial flutter\", \"had a ventricular rate of\", \"70/min\"], [\"Ventricular rate\", \"slowed down to\", \"30-40/min\"], [\"Nifedipine\", \"was administered in\", \"3 divided doses\"], [\"Patient\", \"was paced at a rate of\", \"70/min\"], [\"Nifedipine\", \"induces\", \"tachycardia in normally innervated hearts\"], [\"Hearts deprived of compensatory sympathetic drive\", \"may lead to\", \"bradycardia when treated with nifedipine\"]]",
      "Availability of human induced pluripotent stem cell - derived cardiomyocytes in assessment of drug potential for QT prolongation .|Field potential duration ( FPD ) in human - induced pluripotent stem cell - derived cardiomyocytes ( hiPS - CMs ) , which can express QT interval in an electrocardiogram , is reported to be a useful tool to predict K ( + ) channel and Ca ( 2 + ) channel blocker effects on QT interval .|However , there is no report showing that this technique can be used to predict multichannel blocker potential for QT prolongation .|The aim of this study is to show that FPD from MEA ( Multielectrode array ) of hiPS - CMs can detect QT prolongation induced by multichannel blockers .|hiPS - CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration .|IKr and IKs blockers concentration - dependently prolonged corrected FPD ( FPDc ) , whereas Ca ( 2 + ) channel blockers concentration - dependently shortened FPDc .|Also , the multichannel blockers Amiodarone , Paroxetine , Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner .|Finally , the IKr blockers , Terfenadine and Citalopram , which are reported to cause Torsade de Pointes ( TdP ) in clinical practice , produced early afterdepolarization ( EAD ) . hiPS - CMs using MEA system and FPDc can predict the effects of drug candidates on QT interval .|This study also shows that this assay can help detect EAD for drugs with TdP potential .": "[[\"human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs)\", \"used in\", \"assessment of drug potential for QT prolongation\"],\n[\"Field potential duration (FPD)\", \"expresses\", \"QT interval in an electrocardiogram\"],\n[\"FPD in hiPS-CMs\", \"predicts\", \"K(+) channel and Ca(2+) channel blocker effects on QT interval\"],\n[\"study\", \"aims to show\", \"FPD from MEA can detect QT prolongation by multichannel blockers\"],\n[\"hiPS-CMs\", \"were seeded onto\", \"MEA\"],\n[\"FPD\", \"was measured after\", \"drug exposure\"],\n[\"IKr and IKs blockers\", \"prolonged\", \"corrected FPD (FPDc)\"],\n[\"Ca(2+) channel blockers\", \"shortened\", \"FPDc\"],\n[\"Amiodarone, Paroxetine, Terfenadine, Citalopram\", \"prolonged\", \"FPDc in a concentration dependent manner\"],\n[\"IKr blockers\", \"produced\", \"early afterdepolarization (EAD)\"],\n[\"MEA system and FPDc\", \"can predict\", \"effects of drug candidates on QT interval\"],\n[\"assay\", \"can help detect\", \"EAD for drugs with TdP potential\"]]",
      "Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops .|A 69 - yr - old man , who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops , developed a bradycardia and became hypotensive during halothane anaesthesia .|Both timolol and pilocarpine were subsequently identified in a 24 - h collection of urine .|Timolol ( but not pilocarpine ) was detected in a sample of plasma removed during surgery ; the plasma concentration of timolol ( 2 . 6 ng ml - 1 ) was consistent with partial beta - adrenoceptor blockade .|It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension .|Pilocarpine may have had a contributory effect .": "[[\"Intraoperative bradycardia and hypotension\", \"associated with\", \"timolol\"], \n[\"Intraoperative bradycardia and hypotension\", \"associated with\", \"pilocarpine eye drops\"],\n[\"69-yr-old man\", \"treated with\", \"pilocarpine nitrate\"],\n[\"69-yr-old man\", \"treated with\", \"timolol maleate eye drops\"],\n[\"69-yr-old man\", \"developed\", \"bradycardia\"],\n[\"69-yr-old man\", \"became\", \"hypotensive\"],\n[\"69-yr-old man\", \"during\", \"halothane anaesthesia\"],\n[\"timolol\", \"identified in\", \"24-h collection of urine\"],\n[\"pilocarpine\", \"identified in\", \"24-h collection of urine\"],\n[\"timolol\", \"detected in\", \"sample of plasma\"],\n[\"plasma concentration of timolol\", \"consistent with\", \"partial beta-adrenoceptor blockade\"],\n[\"action\", \"may have been enhanced during\", \"halothane anaesthesia\"],\n[\"resultant bradycardia and hypotension\", \"postulated to be due to\", \"action\"],\n[\"Pilocarpine\", \"may have had\", \"contributory effect\"]]",
      "Conversion to sirolimus ameliorates cyclosporine - induced nephropathy in the rat : focus on serum , urine , gene , and protein renal expression biomarkers .|Protocols of conversion from cyclosporin A ( CsA ) to sirolimus ( SRL ) have been widely used in immunotherapy after transplantation to prevent CsA - induced nephropathy , but the molecular mechanisms underlying these protocols remain nuclear .|This study aimed to identify the molecular pathways and putative biomarkers of CsA - to - SRL conversion in a rat model .|Four animal groups ( n = 6 ) were tested during 9 weeks : control , CsA , SRL , and conversion ( CsA for 3 weeks followed by SRL for 6 weeks ) .|Classical and emergent serum , urinary , and kidney tissue ( gene and protein expression ) markers were assessed .|Renal lesions were analyzed in hematoxylin and eosin , periodic acid - Schiff , and Masson 's trichrome stains .|SRL - treated rats presented proteinuria and NGAL ( serum and urinary ) as the best markers of renal impairment .|Short CsA treatment presented slight or even absent kidney lesions and TGF - b , NF - kb , mTOR , PCNA , TP53 , KIM - 1 , and CTGF as relevant gene and protein changes .|Prolonged CsA exposure aggravated renal damage , without clear changes on the traditional markers , but with changes in serums TGF - b and IL - 7 , TBARs clearance , and kidney TGF - b and mTOR .|Conversion to SRL prevented CsA - induced renal damage evolution ( absent / mild grade lesions ) , while NGAL ( serum versus urine ) seems to be a feasible biomarker of CsA replacement to SRL .": "[[\"Conversion to sirolimus\", \"ameliorates\", \"cyclosporine-induced nephropathy in the rat\"],\n [\"Protocols of conversion\", \"used in\", \"immunotherapy after transplantation\"],\n [\"Protocols of conversion\", \"prevent\", \"CsA-induced nephropathy\"],\n [\"Molecular mechanisms\", \"remain\", \"nuclear\"],\n [\"Study\", \"aimed to identify\", \"molecular pathways and putative biomarkers of CsA-to-SRL conversion\"],\n [\"Study\", \"used\", \"rat model\"],\n [\"Animal groups\", \"tested during\", \"9 weeks\"],\n [\"Control\", \"is a\", \"animal group\"],\n [\"CsA\", \"is a\", \"animal group\"],\n [\"SRL\", \"is a\", \"animal group\"],\n [\"Conversion\", \"is a\", \"animal group\"],\n [\"Conversion\", \"consists of\", \"CsA for 3 weeks followed by SRL for 6 weeks\"],\n [\"Markers\", \"assessed in\", \"serum, urinary, and kidney tissue\"],\n [\"Renal lesions\", \"analyzed in\", \"hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome stains\"],\n [\"SRL-treated rats\", \"presented\", \"proteinuria\"],\n [\"SRL-treated rats\", \"presented\", \"NGAL as the best markers of renal impairment\"],\n [\"Short CsA treatment\", \"presented\", \"slight or even absent kidney lesions\"],\n [\"Short CsA treatment\", \"presented\", \"relevant gene and protein changes\"],\n [\"Prolonged CsA exposure\", \"aggravated\", \"renal damage\"],\n [\"Prolonged CsA exposure\", \"presented changes in\", \"serums TGF-b and IL-7, TBARs clearance, and kidney TGF-b and mTOR\"],\n [\"Conversion to SRL\", \"prevented\", \"CsA-induced renal damage evolution\"],\n [\"NGAL\", \"seems to be\", \"a feasible biomarker of CsA replacement to SRL\"]]",
      "Respiratory pattern in a rat model of epilepsy .|PURPOSE : Apnea is known to occur during seizures , but systematic studies of ictal respiratory changes in adults are few .|Data regarding respiratory pattern defects during interictal periods also are scarce .|Here we sought to generate information with regard to the interictal period in animals with pilocarpine - induced epilepsy .|METHODS : Twelve rats ( six chronically epileptic animals and six controls ) were anesthetized , given tracheotomies , and subjected to hyperventilation or hypoventilation conditions .|Breathing movements caused changes in thoracic volume and forced air to flow tidally through a pneumotachograph .|This flow was measured by using a differential pressure transducer , passed through a polygraph , and from this to a computer with custom software that derived ventilation ( VE ) , tidal volume ( VT ) , inspiratory time ( TI ) , expiratory time ( TE ) , breathing frequency ( f ) , and mean inspiratory flow ( VT / TI ) on a breath - by - breath basis .|RESULTS : The hyperventilation maneuver caused a decrease in spontaneous ventilation in pilocarpine - treated and control rats .|Although VE had a similar decrease in both groups , in the epileptic group , the decrease in VE was due to a significant ( p < 0 . 05 ) increase in TE peak in relation to that of the control animals .|The hypoventilation maneuver led to an increase in the arterial Paco2 , followed by an increase in VE .|In the epileptic group , the increase in VE was mediated by a significant ( p < 0 . 05 ) decrease in TE peak compared with the control group .|Systemic application of KCN , to evaluate the effects of peripheral chemoreception activation on ventilation , led to a similar increase in VE for both groups .|CONCLUSIONS : The data indicate that pilocarpine - treated animals have an altered ability to react to ( or compensate for ) blood gas changes with changes in ventilation and suggest that it is centrally determined .|We speculate on the possible relation of the current findings on treating different epilepsy - associated conditions .": "[[\"Respiratory pattern\", \"studied in\", \"rat model of epilepsy\"],\n [\"Apnea\", \"occurs during\", \"seizures\"],\n [\"Ictal respiratory changes\", \"systematically studied in\", \"adults are few\"],\n [\"Respiratory pattern defects\", \"during\", \"interictal periods\"],\n [\"Study\", \"sought to generate information\", \"interictal period in animals with pilocarpine-induced epilepsy\"],\n [\"Twelve rats\", \"subjected to\", \"hyperventilation or hypoventilation conditions\"],\n [\"Breathing movements\", \"caused changes in\", \"thoracic volume\"],\n [\"Air\", \"forced to flow tidally through\", \"a pneumotachograph\"],\n [\"Flow\", \"measured by\", \"differential pressure transducer\"],\n [\"Data\", \"passed through\", \"polygraph\"],\n [\"Data\", \"from polygraph to\", \"computer with custom software\"],\n [\"Software\", \"derived\", \"ventilation (VE)\"],\n [\"Software\", \"derived\", \"tidal volume (VT)\"],\n [\"Software\", \"derived\", \"inspiratory time (TI)\"],\n [\"Software\", \"derived\", \"expiratory time (TE)\"],\n [\"Software\", \"derived\", \"breathing frequency (f)\"],\n [\"Software\", \"derived\", \"mean inspiratory flow (VT/TI)\"],\n [\"Hyperventilation maneuver\", \"caused decrease in\", \"spontaneous ventilation in pilocarpine-treated and control rats\"],\n [\"VE\", \"had similar decrease in\", \"epileptic group and control group\"],\n [\"Decrease in VE\", \"due to\", \"increase in TE peak in epileptic group\"],\n [\"Hypoventilation maneuver\", \"led to increase in\", \"arterial Paco2\"],\n [\"Increase in arterial Paco2\", \"followed by\", \"increase in VE\"],\n [\"Increase in VE\", \"mediated by\", \"decrease in TE peak in epileptic group compared with control group\"],\n [\"Systemic application of KCN\", \"evaluate effects of\", \"peripheral chemoreception activation on ventilation\"],\n [\"KCN application\", \"led to similar increase in\", \"VE for both groups\"],\n [\"Data\", \"indicates\", \"pilocarpine-treated animals have altered ability to react to blood gas changes\"],\n [\"Altered ability to react to blood gas changes\", \"suggests\", \"centrally determined\"],\n [\"Current findings\", \"speculate on possible relation of\", \"treating different epilepsy-associated conditions\"]]",
      "Morphological evaluation of the effect of d - ribose on adriamycin - evoked cardiotoxicity in rats .|The influence of d - ribose on adriamycin - induced myocardiopathy in rats was studied .|Adriamycin in the cumulative dose of 25 mg / kg evoked fully developed cardiac toxicity .|D - ribose in the multiple doses of 200 mg / kg did not influence ADR cardiotoxicity .": "[[\"Morphological evaluation\", \"is of\", \"effect of d-ribose on adriamycin-evoked cardiotoxicity\"], [\"Effect\", \"is on\", \"adriamycin-evoked cardiotoxicity in rats\"], [\"Influence\", \"is of\", \"d-ribose on adriamycin-induced myocardiopathy\"], [\"Influence\", \"is on\", \"adriamycin-induced myocardiopathy in rats\"], [\"Adriamycin\", \"evoked\", \"cardiac toxicity\"], [\"Cardiac toxicity\", \"with dose of\", \"25 mg/kg\"], [\"D-ribose\", \"administered in doses of\", \"200 mg/kg\"], [\"D-ribose\", \"did not influence\", \"ADR cardiotoxicity\"]]",
      "Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson 's disease patients .|Levodopa is the most effective symptomatic therapy for Parkinson 's disease , but its chronic use could lead to chronic adverse outcomes , such as motor fluctuations , dyskinesia and visual hallucinations .|HOMER1 is a protein with pivotal function in glutamate transmission , which has been related to the pathogenesis of these complications .|This study investigates whether polymorphisms in the HOMER1 gene promoter region are associated with the occurrence of the chronic complications of levodopa therapy .|A total of 205 patients with idiopathic Parkinson 's disease were investigated .|Patients were genotyped for rs4704559 , rs10942891 and rs4704560 by allelic discrimination with Taqman assays .|The rs4704559 G allele was associated with a lower prevalence of dyskinesia ( prevalence ratio ( PR ) = 0 . 615 , 95 % confidence interval ( CI ) 0 . 426 - 0 . 887 , P = 0 . 009 ) and visual hallucinations ( PR = 0 . 515 , 95 % CI 0 . 295 - 0 . 899 , P = 0 . 020 ) .|Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects .": "[[\"HOMER1 gene\", \"associated with\", \"levodopa adverse effects in Parkinson's disease patients\"],\n[\"Levodopa\", \"is\", \"most effective symptomatic therapy for Parkinson's disease\"],\n[\"Levodopa\", \"use could lead to\", \"chronic adverse outcomes\"],\n[\"Chronic adverse outcomes\", \"include\", \"motor fluctuations\"],\n[\"Chronic adverse outcomes\", \"include\", \"dyskinesia\"],\n[\"Chronic adverse outcomes\", \"include\", \"visual hallucinations\"],\n[\"HOMER1\", \"is a protein with function in\", \"glutamate transmission\"],\n[\"Glutamate transmission\", \"related to\", \"pathogenesis of complications\"],\n[\"Study\", \"investigates\", \"association of HOMER1 gene polymorphisms with levodopa therapy complications\"],\n[\"Patients\", \"were genotyped for\", \"rs4704559\"],\n[\"Patients\", \"were genotyped for\", \"rs10942891\"],\n[\"Patients\", \"were genotyped for\", \"rs4704560\"],\n[\"rs4704559 G allele\", \"associated with\", \"lower prevalence of dyskinesia\"],\n[\"rs4704559 G allele\", \"associated with\", \"lower prevalence of visual hallucinations\"],\n[\"HOMER1 rs4704559 G allele\", \"has a protective role for\", \"development of levodopa adverse effects\"]]",
      "Recurrent myocardial infarction in a postpartum patient receiving bromocriptine .|Myocardial infarction in puerperium is infrequently reported .|Spasm , coronary dissection , or atheromatous etiology has been described .|Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium .|Our case ( including an inadvertent rechallenge ) suggests such a relationship .|Although generally regarded as \" safe , \" possible serious cardiac effects of bromocriptine should be acknowledged .": "[[\"Recurrent myocardial infarction\", \"in\", \"postpartum patient receiving bromocriptine\"],\n [\"Myocardial infarction in puerperium\", \"is\", \"infrequently reported\"],\n [\"Spasm\", \"has been described as\", \"etiology\"],\n [\"Coronary dissection\", \"has been described as\", \"etiology\"],\n [\"Atheromatous\", \"has been described as\", \"etiology\"],\n [\"Bromocriptine\", \"has been implicated in\", \"previous case reports of myocardial infarction in the puerperium\"],\n [\"Our case\", \"suggests\", \"relationship between bromocriptine and myocardial infarction\"],\n [\"Bromocriptine\", \"is generally regarded as\", \"\\\"safe\\\"\"],\n [\"Bromocriptine\", \"possible serious cardiac effects\", \"should be acknowledged\"]]",
      "Toleration of high doses of angiotensin - converting enzyme inhibitors in patients with chronic heart failure : results from the ATLAS trial .|The Assessment of Treatment with Lisinopril and Survival .|BACKGROUND : Treatment with angiotensin - converting enzyme ( ACE ) inhibitors reduces mortality and morbidity in patients with chronic heart failure ( CHF ) , but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials , primarily because of concerns about the safety and tolerability of these agents , especially at the recommended doses .|The present study examines the safety and tolerability of high - compared with low - dose lisinopril in CHF .|METHODS : The Assessment of Lisinopril and Survival study was a multicenter , randomized , double - blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium - dose lisinopril ( 12 . 5 or 15 . 0 mg once daily [ OD ] ) for 2 to 4 weeks and then randomized to high - ( 35 . 0 or 32 . 5 mg OD ) or low - dose ( 5 . 0 or 2 . 5 mg OD ) groups .|Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0 . 30 ( n = 3164 ) were randomized and followed up for a median of 46 months .|We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment , with a focus on hypotension and renal dysfunction .|RESULTS : Of 405 patients not previously receiving an ACE inhibitor , doses in only 4 . 2 % could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension ( 2 . 0 % ) or because of renal dysfunction or hyperkalemia ( 2 . 3 % ) .|Doses in more than 90 % of randomized patients in the high - and low - dose groups were titrated to their assigned target , and the mean doses of blinded medication in both groups remained similar throughout the study .|Withdrawals occurred in 27 . 1 % of the high - and 30 . 7 % of the low - dose groups .|Subgroups presumed to be at higher risk for ACE inhibitor intolerance ( blood pressure , < 120 mm Hg ; creatinine , > or = 132 . 6 micromol / L [ > or = 1 . 5 mg / dL ] ; age , > or = 70 years ; and patients with diabetes ) generally tolerated the high - dose strategy .|CONCLUSIONS : These findings demonstrate that ACE inhibitor therapy in most patients with CHF can be successfully titrated to and maintained at high doses , and that more aggressive use of these agents is warranted .": "[[\"ACE inhibitors\", \"reduce\", \"mortality and morbidity in patients with CHF\"],\n[\"Patients with CHF\", \"are not receiving\", \"ACE inhibitors\"],\n[\"Patients with CHF\", \"are being treated with\", \"doses lower than those found to be efficacious in trials\"],\n[\"Safety and tolerability\", \"concerns about\", \"ACE inhibitors\"],\n[\"Study\", \"examines\", \"safety and tolerability of high - compared with low - dose lisinopril in CHF\"],\n[\"Assessment of Lisinopril and Survival study\", \"was\", \"a multicenter, randomized, double-blind trial\"],\n[\"Patients\", \"were stabilized receiving\", \"medium-dose lisinopril\"],\n[\"Patients\", \"randomized to\", \"high-dose or low-dose groups\"],\n[\"Patients\", \"had\", \"New York Heart Association classes II to IV CHF\"],\n[\"Patients\", \"had\", \"left ventricular ejection fractions of no greater than 0.30\"],\n[\"Study\", \"examined\", \"occurrence of adverse events\"],\n[\"Study\", \"focused on\", \"hypotension and renal dysfunction\"],\n[\"Patients not previously receiving an ACE inhibitor\", \"could not be titrated to\", \"the medium doses required for randomization\"],\n[\"Randomized patients\", \"were titrated to\", \"their assigned target doses\"],\n[\"Withdrawals\", \"occurred in\", \"high-dose and low-dose groups\"],\n[\"Subgroups\", \"tolerated\", \"high-dose strategy\"],\n[\"Findings\", \"demonstrate\", \"ACE inhibitor therapy can be successfully titrated to high doses\"],\n[\"Findings\", \"suggest\", \"more aggressive use of ACE inhibitors is warranted\"]]",
      "Theophylline neurotoxicity in pregnant rats .|The purpose of this investigation was to determine whether the neurotoxicity of theophylline is altered in advanced pregnancy .|Sprague - Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively .|Theophylline concentrations at this endpoint in serum ( total ) and CSF were similar but serum ( free ) and brain concentrations were slightly different in pregnant rats .|Theophylline serum protein binding determined by equilibrium dialysis was lower in pregnant rats .|Fetal serum concentrations at onset of seizures in the mother were similar to maternal brain and CSF concentrations and correlated significantly with the former .|It is concluded that advanced pregnancy has a negligible effect on the neurotoxic response to theophylline in rats .": "[[\"Theophylline\", \"causes\", \"neurotoxicity in\", \"pregnant rats\"],\n[\"Investigation\", \"aimed to determine\", \"alteration of theophylline neurotoxicity in advanced pregnancy\"],\n[\"Sprague - Dawley rats\", \"were\", \"20 days pregnant\"],\n[\"Nonpregnant rats\", \"were of the same age and strain as\", \"Sprague - Dawley rats\"],\n[\"Rats\", \"received\", \"infusions of aminophylline\"],\n[\"Maximal seizures\", \"occurred after\", \"28 and 30 minutes\"],\n[\"Theophylline concentrations\", \"were similar in\", \"serum (total) and CSF\"],\n[\"Serum (free) and brain concentrations\", \"were slightly different\", \"in pregnant rats\"],\n[\"Theophylline serum protein binding\", \"was lower\", \"in pregnant rats\"],\n[\"Fetal serum concentrations\", \"were similar to\", \"maternal brain and CSF concentrations\"],\n[\"Fetal serum concentrations\", \"correlated significantly with\", \"maternal brain concentrations\"],\n[\"Advanced pregnancy\", \"has a negligible effect on\", \"neurotoxic response to theophylline in rats\"]]",
      "Antimicrobial - induced mania ( antibiomania ) : a review of spontaneous reports .|The authors reviewed reported cases of antibiotic - induced manic episodes by means of a MEDLINE and PsychLit search for reports of antibiotic - induced mania .|Unpublished reports were requested from the World Health Organization ( WHO ) and the Food and Drug Administration ( FDA ) .|Twenty - one reports of antimicrobial - induced mania were found in the literature .|There were 6 cases implicating clarithromycin , 13 implicating isoniazid , and 1 case each implicating erythromycin and amoxicillin .|The WHO reported 82 cases .|Of these , clarithromycin was implicated in 23 ( 27 . 6 % ) cases , ciprofloxacin in 12 ( 14 . 4 % ) cases , and ofloxacin in 10 ( 12 % ) cases .|Cotrimoxazole , metronidazole , and erythromycin were involved in 15 reported manic episodes .|Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania .|Statistical analysis of the data would not have demonstrated a significant statistical correlative risk and was therefore not undertaken .|Patients have an increased risk of developing mania while being treated with antimicrobials .|Although this is not a statistically significant risk , physicians must be aware of the effect and reversibility .|Further research clearly is required to determine the incidence of antimicrobial - induced mania , the relative risk factors of developing an antimicrobial - induced manic episode among various demographic populations , and the incidence of patients who continue to have persistent affective disorders once the initial episode , which occurs while the patient is taking antibiotics , subsides .|The authors elected to name this syndrome \" antibiomania . \"": "[[\"Antimicrobial-induced mania\", \"also known as\", \"antibiomania\"],\n[\"Antimicrobial-induced mania\", \"subject of\", \"review\"],\n[\"Authors\", \"reviewed\", \"antibiotic-induced manic episodes\"],\n[\"Authors\", \"used\", \"MEDLINE and PsychLit\"],\n[\"Authors\", \"requested unpublished reports from\", \"WHO\"],\n[\"Authors\", \"requested unpublished reports from\", \"FDA\"],\n[\"Literature\", \"found\", \"21 reports of antimicrobial-induced mania\"],\n[\"6 cases\", \"implicating\", \"clarithromycin\"],\n[\"13 cases\", \"implicating\", \"isoniazid\"],\n[\"1 case\", \"implicating\", \"erythromycin\"],\n[\"1 case\", \"implicating\", \"amoxicillin\"],\n[\"WHO\", \"reported\", \"82 cases\"],\n[\"23 cases\", \"implicating\", \"clarithromycin\"],\n[\"12 cases\", \"implicating\", \"ciprofloxacin\"],\n[\"10 cases\", \"implicating\", \"ofloxacin\"],\n[\"Cotrimoxazole\", \"involved in\", \"reported manic episodes\"],\n[\"Metronidazole\", \"involved in\", \"reported manic episodes\"],\n[\"Erythromycin\", \"involved in\", \"reported manic episodes\"],\n[\"FDA\", \"reported cases\", \"showing clarithromycin and ciprofloxacin most frequently associated with\", \"development of mania\"],\n[\"Statistical analysis\", \"would not have demonstrated\", \"significant statistical correlative risk\"],\n[\"Patients\", \"have increased risk of\", \"developing mania while being treated with antimicrobials\"],\n[\"Physicians\", \"must be aware of\", \"effect and reversibility of antimicrobial-induced mania\"],\n[\"Further research\", \"is required to determine\", \"incidence of antimicrobial-induced mania\"],\n[\"Further research\", \"is required to determine\", \"relative risk factors of developing an antimicrobial-induced manic episode\"],\n[\"Further research\", \"is required to determine\", \"incidence of patients with persistent affective disorders post initial episode\"],\n[\"Authors\", \"elected to name\", \"syndrome antibiomania\"]]",
      "Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence : a placebo - controlled , double - blind crossover study .|The aim of the study was to evaluate the potential role for a selective alpha1 - adrenoceptor agonist in the treatment of urinary stress incontinence .|A randomised , double - blind , placebo - controlled , crossover study design was employed .|Half log incremental doses of intravenous methoxamine or placebo ( saline ) were administered to a group of women with genuine stress incontinence while measuring maximum urethral pressure ( MUP ) , blood pressure , heart rate , and symptomatic side effects .|Methoxamine evoked non - significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage .|Systemic side effects including piloerection , headache , and cold extremities were experienced in all subjects .|The results indicate that the clinical usefulness of direct , peripherally acting sub - type - selective alpha1 - adrenoceptor agonists in the medical treatment of stress incontinence may be limited by associated piloerection and cardiovascular side effects .": "Based on the provided prompt, here are the relationships extracted:\n\n1. [[\"methoxamine\", \"used for\", \"maximum urethral pressure in women with genuine stress incontinence\"]]\n2. [[\"study\", \"aimed to evaluate\", \"role for selective alpha1-adrenoceptor agonist in treatment of urinary stress incontinence\"]]\n3. [[\"study\", \"employed\", \"randomised double-blind placebo-controlled crossover design\"]]\n4. [[\"methoxamine or placebo\", \"administered to\", \"group of women with genuine stress incontinence\"]]\n5. [[\"methoxamine or placebo\", \"administered while measuring\", \"maximum urethral pressure\"]]\n6. [[\"methoxamine or placebo\", \"administered while measuring\", \"blood pressure\"]]\n7. [[\"methoxamine or placebo\", \"administered while measuring\", \"heart rate\"]]\n8. [[\"methoxamine or placebo\", \"administered while measuring\", \"symptomatic side effects\"]]\n9. [[\"methoxamine\", \"caused\", \"non-significant increases in MUP\"]]\n10. [[\"methoxamine\", \"caused\", \"non-significant increases in diastolic blood pressure\"]]\n11. [[\"methoxamine\", \"caused\", \"significant rise in systolic blood pressure\"]]\n12. [[\"methoxamine\", \"caused\", \"significant fall in heart rate at maximum dosage\"]]\n13. [[\"methoxamine\", \"associated with\", \"systemic side effects\"]]\n14. [[\"systemic side effects\", \"include\", \"piloerection\"]]\n15. [[\"systemic side effects\", \"include\", \"headache\"]]\n16. [[\"systemic side effects\", \"include\", \"cold extremities\"]]\n17. [[\"results\", \"indicate\", \"clinical usefulness of direct peripherally acting sub-type-selective alpha1-adrenoceptor agonists may be limited\"]]\n18. [[\"clinical usefulness\", \"limited by\", \"associated piloerection\"]]\n19. [[\"clinical usefulness\", \"limited by\", \"cardiovascular side effects\"]]",
      "Effect of doxorubicin on [ omega - I - 131 ] heptadecanoic acid myocardial scintigraphy and echocardiography in dogs .|The effects of serial treatment with doxorubicin on dynamic myocardial scintigraphy with [ omega - I - 131 ] heptadecanoic acid ( I - 131 HA ) , and on global left - ventricular function determined echocardiographically , were studied in a group of nine mongrel dogs .|Total extractable myocardial lipid was compared postmortem between a group of control dogs and doxorubicin - treated dogs .|A significant and then progressive fall in global LV function was observed at a cumulative doxorubicin dose of 4 mg / kg .|A significant increase in the myocardial t1 / 2 of the I - 131 HA was observed only at a higher cumulative dose , 10 mg / kg .|No significant alteration in total extractable myocardial lipids was observed between control dogs and those treated with doxorubicin .|Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I - 131 HA are not the initiating factor in doxorubicin cardiotoxicity .": "[[\"Effect of doxorubicin\", \"on\", \"[omega - I - 131] heptadecanoic acid myocardial scintigraphy\"], \n[\"Effect of doxorubicin\", \"on\", \"echocardiography in dogs\"], \n[\"Doxorubicin\", \"used in treatment on\", \"dynamic myocardial scintigraphy with [omega - I - 131] heptadecanoic acid (I - 131 HA)\"], \n[\"Doxorubicin\", \"used in treatment on\", \"global left-ventricular function determined echocardiographically\"], \n[\"Doxorubicin\", \"studied in\", \"group of nine mongrel dogs\"], \n[\"Total extractable myocardial lipid\", \"compared postmortem between\", \"group of control dogs and doxorubicin-treated dogs\"], \n[\"Global LV function\", \"observed fall at cumulative doxorubicin dose of\", \"4 mg/kg\"], \n[\"Myocardial t1/2 of the I - 131 HA\", \"significant increase observed at cumulative dose of\", \"10 mg/kg\"], \n[\"Total extractable myocardial lipids\", \"no significant alteration observed between\", \"control dogs and doxorubicin-treated dogs\"], \n[\"Changes leading to alteration of myocardial dynamic imaging with I - 131 HA\", \"are not\", \"initiating factor in doxorubicin cardiotoxicity\"]]",
      "The flavonoid apigenin delays forgetting of passive avoidance conditioning in rats .|The present experiments were performed to study the effect of the flavonoid apigenin ( 20 mg / kg intraperitoneally ( i . p . ) , 1 h before acquisition ) , on 24 h retention performance and forgetting of a step - through passive avoidance task , in young male Wistar rats .|There were no differences between saline - and apigenin - treated groups in the 24 h retention trial .|Furthermore , apigenin did not prevent the amnesia induced by scopolamine ( 1mg / kg , i . p . , 30 min before the acquisition ) .|The saline - and apigenin - treated rats that did not step through into the dark compartment during the cut - off time ( 540 s ) were retested weekly for up to eight weeks .|In the saline treated group , the first significant decline in passive avoidance response was observed at four weeks , and complete memory loss was found five weeks after the acquisition of the passive avoidance task .|At the end of the experimental period , 60 % of the animals treated with apigenin still did not step through .|These data suggest that 1 ) apigenin delays the long - term forgetting but did not modulate the 24 h retention of fear memory and 2 ) the obtained beneficial effect of apigenin on the passive avoidance conditioning is mediated by mechanisms that do not implicate its action on the muscarinic cholinergic system .": "[[\"The flavonoid apigenin\", \"delays\", \"forgetting of passive avoidance conditioning in rats\"],\n[\"Experiments\", \"performed to study\", \"effect of the flavonoid apigenin\"],\n[\"Apigenin\", \"administered at\", \"20 mg/kg intraperitoneally\"],\n[\"Apigenin\", \"administered\", \"1 hour before acquisition\"],\n[\"Study\", \"focuses on\", \"24 h retention performance and forgetting of a step-through passive avoidance task\"],\n[\"Subjects of study\", \"are\", \"young male Wistar rats\"],\n[\"Saline-treated groups\", \"showed no differences in\", \"24 h retention trial compared to\"],\n[\"Apigenin-treated groups\", \"showed no differences in\", \"24 h retention trial compared to\"],\n[\"Apigenin\", \"did not prevent\", \"amnesia induced by scopolamine\"],\n[\"Saline- and apigenin-treated rats\", \"retested weekly for\", \"up to eight weeks\"],\n[\"Saline treated group\", \"observed first significant decline in passive avoidance response at\", \"four weeks\"],\n[\"Saline treated group\", \"found complete memory loss\", \"five weeks after acquisition of the passive avoidance task\"],\n[\"Animals treated with apigenin\", \"60% did not step through at\", \"end of the experimental period\"],\n[\"Apigenin\", \"delays\", \"long-term forgetting\"],\n[\"Apigenin\", \"did not modulate\", \"24 h retention of fear memory\"],\n[\"Beneficial effect of apigenin\", \"is mediated by mechanisms that do not implicate\", \"action on the muscarinic cholinergic system\"]]",
      "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5 - fluorouracil .|Cardiac symptoms , including hypotension , developed in three patients with advanced colorectal carcinoma while being treated with cisplatin ( CDDP ) and 5 - fluorouracil ( 5 - FU ) .|In two patients , hypotension was associated with severe left ventricular dysfunction .|All three patients required therapy discontinuation .|Cardiac enzymes remained normal despite transient electrocardiographic ( EKG ) changes .|The presentation and cardiac evaluation ( hemodynamic , echocardiographic , and scintigraphic ) of these patients suggest new manifestations of 5 - FU cardiotoxicity that may be influenced by CDDP .|The possible pathophysiologic mechanisms are discussed .": "[[\"Hypotension\", \"is a manifestation of\", \"cardiotoxicity\"],\n [\"Three patients\", \"receiving\", \"cisplatin and 5-fluorouracil\"],\n [\"Cardiac symptoms\", \"include\", \"hypotension\"],\n [\"Three patients\", \"developed cardiac symptoms while being treated with\", \"cisplatin (CDDP) and 5-fluorouracil (5-FU)\"],\n [\"Three patients\", \"had\", \"advanced colorectal carcinoma\"],\n [\"Two patients\", \"had hypotension associated with\", \"severe left ventricular dysfunction\"],\n [\"All three patients\", \"required\", \"therapy discontinuation\"],\n [\"Cardiac enzymes\", \"remained\", \"normal\"],\n [\"Transient electrocardiographic (EKG) changes\", \"occurred despite\", \"normal cardiac enzymes\"],\n [\"Patients\", \"suggest new manifestations of\", \"5-FU cardiotoxicity\"],\n [\"5-FU cardiotoxicity\", \"may be influenced by\", \"CDDP\"],\n [\"Possible pathophysiologic mechanisms\", \"are discussed\", \"\"]]",
      "Hypertensive response during dobutamine stress echocardiography .|Among 3 , 129 dobutamine stress echocardiographic studies , a hypertensive response , defined as systolic blood pressure ( BP ) > or = 220 mm Hg and / or diastolic BP > or = 110 mm Hg , occurred in 30 patients ( 1 % ) .|Patients with this response more often had a history of hypertension and had higher resting systolic and diastolic BP before dobutamine infusion .": "[[\"Hypertensive response\", \"occurs during\", \"dobutamine stress echocardiography\"],\n [\"Hypertensive response\", \"defined as\", \"systolic blood pressure > or = 220 mm Hg\"],\n [\"Hypertensive response\", \"defined as\", \"diastolic blood pressure > or = 110 mm Hg\"],\n [\"Hypertensive response\", \"occurred in\", \"30 patients\"],\n [\"Dobutamine stress echocardiographic studies\", \"number of\", \"3,129\"],\n [\"Patients with hypertensive response\", \"more often had\", \"history of hypertension\"],\n [\"Patients with hypertensive response\", \"had higher\", \"resting systolic and diastolic BP\"],\n [\"Resting systolic and diastolic BP\", \"measured before\", \"dobutamine infusion\"]]",
      "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1 - infected children treated with indinavir .|BACKGROUND : Prolonged administration of indinavir is associated with the occurrence of a variety of renal complications in adults .|These well - documented side effects have restricted the use of this potent protease inhibitor in children .|DESIGN : A prospective study to monitor indinavir - related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1 - infected children treated with indinavir .|METHODS : Urinary pH , albumin , creatinine , the presence of erythrocytes , leukocytes , bacteria and crystals , and culture were analyzed every 3 months for 96 weeks .|Serum creatinine levels were routinely determined at the same time points .|Steady - state pharmacokinetics of indinavir were done at week 4 after the initiation of indinavir .|RESULTS : The cumulative incidence of persistent sterile leukocyturia ( > or = 75 cells / micro L in at least 2 consecutive visits ) after 96 weeks was 53 % .|Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin / creatinine ratio and by microscopic hematuria .|The cumulative incidence of serum creatinine levels > 50 % above normal was 33 % after 96 weeks .|Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50 % above normal than those children without persistent sterile leukocyturia .|In children younger than 5 . 6 years , persistent sterile leukocyturia was significantly more frequent than in older children .|A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve > 19 mg / L x h or a peak serum level of indinavir > 12 mg / L .|In 4 children , indinavir was discontinued because of nephrotoxicity .|Subsequently , the serum creatinine levels decreased , the urine albumin / creatinine ratios returned to zero , and the leukocyturia disappeared within 3 months .|CONCLUSIONS : Children treated with indinavir have a high cumulative incidence of persistent sterile leukocyturia .|Children with persistent sterile leukocyturia more frequently had an increase in serum creatinine levels of > 50 % above normal .|Younger children have an additional risk for renal complications .|The impairment of the renal function in these children occurred in the absence of clinical symptoms of nephrolithiasis .|Indinavir - associated nephrotoxicity must be monitored closely , especially in children with risk factors such as persistent sterile leukocyturia , age < 5 . 6 years , an area under the curve of indinavir > 19 mg / L x h , and a C ( max ) > 12 mg / L .": "[[\"Persistent sterile leukocyturia\", \"is associated with\", \"impaired renal function in HIV type 1-infected children\"], [\"HIV type 1-infected children\", \"treated with\", \"indinavir\"], [\"Indinavir\", \"causes\", \"renal complications in adults\"], [\"Renal complications\", \"restrict use of\", \"indinavir in children\"], [\"Study\", \"to monitor\", \"indinavir-related nephrotoxicity\"], [\"Indinavir-related nephrotoxicity\", \"monitored in\", \"a cohort of 30 HIV type 1-infected children\"], [\"Urinary pH, albumin, creatinine, presence of erythrocytes, leukocytes, bacteria and crystals, and culture\", \"analyzed every 3 months for\", \"96 weeks\"], [\"Serum creatinine levels\", \"determined at\", \"the same time points\"], [\"Steady-state pharmacokinetics of indinavir\", \"done at\", \"week 4 after initiation of indinavir\"], [\"Cumulative incidence\", \"of persistent sterile leukocyturia after 96 weeks\", \"53%\"], [\"Persistent sterile leukocyturia\", \"associated with\", \"mild increase in urine albumin/creatinine ratio\"], [\"Persistent sterile leukocyturia\", \"associated with\", \"microscopic hematuria\"], [\"Cumulative incidence\", \"of serum creatinine levels > 50% above normal after 96 weeks\", \"33%\"], [\"Children with persistent sterile leukocyturia\", \"more frequently had\", \"serum creatinine levels of 50% above normal\"], [\"Persistent sterile leukocyturia\", \"more frequent in\", \"children younger than 5.6 years\"], [\"Higher cumulative incidence of persistent leukocyturia\", \"found in children with\", \"AUC > 19 mg/L x h\"], [\"Higher cumulative incidence of persistent leukocyturia\", \"found in children with\", \"peak serum level of indinavir > 12 mg/L\"], [\"Indinavir\", \"discontinued because of\", \"nephrotoxicity in 4 children\"], [\"Discontinuation of indinavir\", \"led to\", \"decrease in serum creatinine levels\"], [\"Discontinuation of indinavir\", \"led to\", \"urine albumin/creatinine ratios returned to zero\"], [\"Discontinuation of indinavir\", \"led to\", \"leukocyturia disappeared\"], [\"Children treated with indinavir\", \"have\", \"high cumulative incidence of persistent sterile leukocyturia\"], [\"Children with persistent sterile leukocyturia\", \"more frequently had\", \"increase in serum creatinine levels > 50% above normal\"], [\"Younger children\", \"have\", \"additional risk for renal complications\"], [\"Renal function impairment\", \"occurred in\", \"absence of clinical symptoms of nephrolithiasis\"], [\"Indinavir-associated nephrotoxicity\", \"must be monitored closely\", \"especially in children with risk factors\"], [\"Risk factors\", \"include\", \"persistent sterile leukocyturia\"], [\"Risk factors\", \"include\", \"age < 5.6 years\"], [\"Risk factors\", \"include\", \"AUC of indinavir > 19 mg/L x h\"], [\"Risk factors\", \"include\", \"C(max) > 12 mg/L\"]]",
      "Antirifampicin antibodies in acute rifampicin - associated renal failure .|5 patients with acute renal failure ( 3 with thrombopenia and hemolysis ) induced by the reintroduction of rifampicin are described .|No correlation was found between the severity of clinical manifestations and the total dose taken by the patients .|In all but 1 patient , antirifampicin antibodies were detected .|Antibodies suggested to be of the IgM class were detected in all 3 patients with hematological disorders .|The pattern of non - specific acute tubular necrosis found in the 2 biopsied patients , indistinguishable from that of ischemic origin , raised the possibility of a vascular - mediated damage .|In 3 patients , the possibility of a triggering immunoallergic mechanism is discussed .": "[[\"Antirifampicin antibodies\", \"associated with\", \"acute rifampicin-associated renal failure\"],\n[\"5 patients\", \"experienced\", \"acute renal failure\"],\n[\"acute renal failure\", \"induced by\", \"reintroduction of rifampicin\"],\n[\"3 patients\", \"had\", \"thrombopenia and hemolysis\"],\n[\"No correlation\", \"found between\", \"severity of clinical manifestations and total dose taken by the patients\"],\n[\"antirifampicin antibodies\", \"were detected\", \"in all but 1 patient\"],\n[\"Antibodies of the IgM class\", \"detected in\", \"all 3 patients with hematological disorders\"],\n[\"Pattern of non-specific acute tubular necrosis\", \"found in\", \"2 biopsied patients\"],\n[\"Pattern of non-specific acute tubular necrosis\", \"indistinguishable from\", \"ischemic origin\"],\n[\"Pattern of non-specific acute tubular necrosis\", \"raised the possibility of\", \"vascular-mediated damage\"],\n[\"In 3 patients\", \"possibility discussed of\", \"triggering immunoallergic mechanism\"]]",
      "Blood brain barrier in right - and left - pawed female rats assessed by a new staining method .|The asymmetrical breakdown of the blood - brain barrier ( BBB ) was studied in female rats .|Paw preference was assessed by a food reaching test .|Adrenaline - induced hypertension was used to destroy the BBB , which was evaluated using triphenyltetrazolium ( TTC ) staining of the brain slices just after giving adrenaline for 30 s .|In normal rats , the whole brain sections exhibited complete staining with TTC .|After adrenaline infusion for 30 s , there were large unstained areas in the left brain in right - pawed animals , and vice versa in left - pawed animals .|Similar results were obtained in seizure - induced breakdown of BBB .|These results were explained by an asymmetric cerebral blood flow depending upon the paw preference in rats .|It was suggested that this new method and the results are consistent with contralateral motor control that may be important in determining the dominant cerebral hemisphere in animals .": "[[\"Blood brain barrier\", \"assessed by\", \"new staining method\"],\n[\"Asymmetrical breakdown\", \"studied in\", \"female rats\"],\n[\"Paw preference\", \"assessed by\", \"food reaching test\"],\n[\"Adrenaline-induced hypertension\", \"used to destroy\", \"BBB\"],\n[\"BBB\", \"evaluated using\", \"triphenyltetrazolium (TTC) staining\"],\n[\"Brain slices\", \"stained with\", \"TTC after adrenaline for 30 s\"],\n[\"Normal rats\", \"exhibited\", \"complete staining with TTC\"],\n[\"Adrenaline infusion for 30 s\", \"caused\", \"large unstained areas in left brain in right-pawed animals\"],\n[\"Adrenaline infusion for 30 s\", \"caused\", \"large unstained areas in right brain in left-pawed animals\"],\n[\"Seizure-induced breakdown\", \"similar results obtained in\", \"BBB\"],\n[\"Results\", \"explained by\", \"asymmetric cerebral blood flow\"],\n[\"Asymmetric cerebral blood flow\", \"depends on\", \"paw preference in rats\"],\n[\"New method and results\", \"consistent with\", \"contralateral motor control\"],\n[\"Contralateral motor control\", \"may be important in determining\", \"dominant cerebral hemisphere in animals\"]]",
      "Quetiapine - induced neutropenia in a bipolar patient with hepatocellular carcinoma .|OBJECTIVE : Quetiapine is a dibenzothiazepine derivative , similar to clozapine , which has the highest risk of causing blood dyscrasias , especially neutropenia .|There are some case reports about this side effect of quetiapine , but possible risk factors are seldom discussed and identified .|A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here .|CASE REPORT : A 62 - year - old Taiwanese widow with bipolar disorder was diagnosed with hepatocellular carcinoma at age 60 .|She developed leucopenia after being treated with quetiapine .|After quetiapine was discontinued , her white blood cell count returned to normal .|CONCLUSIONS : Although neutropenia is not a common side effect of quetiapine , physicians should be cautious about its presentation and associated risk factors .|Hepatic dysfunction may be one of the possible risk factors , and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine .": "[[\"Quetiapine\", \"induced\", \"neutropenia\"],\n [\"Neutropenia\", \"in\", \"a bipolar patient\"],\n [\"Bipolar patient\", \"with\", \"hepatocellular carcinoma\"],\n [\"Quetiapine\", \"is a\", \"dibenzothiazepine derivative\"],\n [\"Quetiapine\", \"similar to\", \"clozapine\"],\n [\"Clozapine\", \"has the highest risk of causing\", \"blood dyscrasias\"],\n [\"Blood dyscrasias\", \"especially\", \"neutropenia\"],\n [\"Quetiapine\", \"has side effect of\", \"neutropenia\"],\n [\"Risk factors for neutropenia\", \"seldom discussed and identified\", \"in case reports\"],\n [\"Patient with hepatocellular carcinoma\", \"developed\", \"neutropenia after treatment with quetiapine\"],\n [\"62-year-old Taiwanese widow\", \"diagnosed with\", \"hepatocellular carcinoma\"],\n [\"62-year-old Taiwanese widow\", \"with\", \"bipolar disorder\"],\n [\"62-year-old Taiwanese widow\", \"developed\", \"leucopenia after being treated with quetiapine\"],\n [\"Quetiapine\", \"discontinued\", \"white blood cell count returned to normal\"],\n [\"Neutropenia\", \"not a common side effect of\", \"quetiapine\"],\n [\"Physicians\", \"should be cautious about\", \"neutropenia presentation and associated risk factors\"],\n [\"Hepatic dysfunction\", \"may be one of the possible risk factors\", \"for neutropenia\"],\n [\"Concomitant fever\", \"may be a diagnostic marker for\", \"adverse reaction to quetiapine\"]]",
      "Effects of cromakalim and pinacidil on large epicardial and small coronary arteries in conscious dogs .|The effects of i . v .|bolus administration of cromakalim ( 1 - 10 micrograms / kg ) and pinacidil ( 3 - 100 micrograms / kg ) on large ( circumflex artery ) and small coronary arteries and on systemic hemodynamics were investigated in chronically instrumented conscious dogs and compared to those of nitroglycerin ( 0 . 03 - 10 micrograms / kg ) .|Nitroglycerin , up to 0 . 3 micrograms / kg , selectively increased circumflex artery diameter ( CxAD ) without simultaneously affecting any other cardiac or systemic hemodynamic parameter .|In contrast , cromakalim and pinacidil at all doses and nitroglycerin at doses higher than 0 . 3 micrograms / kg simultaneously and dose - dependently increased CxAD , coronary blood flow and heart rate and decreased coronary vascular resistance and aortic pressure .|Cromakalim was approximately 8 - to 9 . 5 - fold more potent than pinacidil in increasing CxAD .|Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug - induced tachycardia was abolished .|When circumflex artery blood flow was maintained constant , the increases in CxAD induced by cromakalim ( 10 micrograms / kg ) , pinacidil ( 30 micrograms / kg ) and nitroglycerin ( 10 micrograms / kg ) were reduced by 68 + / - 7 , 54 + / - 9 and 1 + / - 1 % , respectively .|Thus , whereas nitroglycerin preferentially and flow - independently dilates large coronary arteries , cromakalim and pinacidil dilate both large and small coronary arteries and this effect is not dependent upon the simultaneous beta adrenoceptors - mediated rise in myocardial metabolic demand .|Finally , two mechanisms at least , direct vasodilation and flow dependency , are involved in the cromakalim - and pinacidil - induced increase in CxAD .": "[[\"cromakalim\", \"administered via\", \"i.v. bolus\"], \n [\"pinacidil\", \"administered via\", \"i.v. bolus\"], \n [\"cromakalim\", \"dosage\", \"1 - 10 micrograms/kg\"], \n [\"pinacidil\", \"dosage\", \"3 - 100 micrograms/kg\"], \n [\"nitroglycerin\", \"dosage\", \"0.03 - 10 micrograms/kg\"], \n [\"nitroglycerin\", \"increased\", \"circumflex artery diameter\"], \n [\"nitroglycerin\", \"affected without\", \"other cardiac or systemic hemodynamic parameter\"], \n [\"cromakalim\", \"increased\", \"circumflex artery diameter\"], \n [\"pinacidil\", \"increased\", \"circumflex artery diameter\"], \n [\"cromakalim\", \"increased\", \"coronary blood flow\"], \n [\"pinacidil\", \"increased\", \"coronary blood flow\"], \n [\"nitroglycerin\", \"increased\", \"coronary blood flow\"], \n [\"cromakalim\", \"increased\", \"heart rate\"], \n [\"pinacidil\", \"increased\", \"heart rate\"], \n [\"nitroglycerin\", \"increased\", \"heart rate\"], \n [\"cromakalim\", \"decreased\", \"coronary vascular resistance\"], \n [\"pinacidil\", \"decreased\", \"coronary vascular resistance\"], \n [\"nitroglycerin\", \"decreased\", \"coronary vascular resistance\"], \n [\"cromakalim\", \"decreased\", \"aortic pressure\"], \n [\"pinacidil\", \"decreased\", \"aortic pressure\"], \n [\"nitroglycerin\", \"decreased\", \"aortic pressure\"], \n [\"cromakalim\", \"more potent than\", \"pinacidil\"], \n [\"cromakalim\", \"induced\", \"vasodilation of large and small coronary vessels\"], \n [\"pinacidil\", \"induced\", \"vasodilation of large and small coronary vessels\"], \n [\"cromakalim\", \"induced\", \"hypotension\"], \n [\"pinacidil\", \"induced\", \"hypotension\"], \n [\"beta adrenergic and muscarinic receptors blockade\", \"not affect\", \"vasodilation by cromakalim and pinacidil\"], \n [\"beta adrenergic and muscarinic receptors blockade\", \"abolished\", \"drug-induced tachycardia\"], \n [\"cromakalim\", \"increase in CxAD reduced by\", \"68 +/- 7%\"], \n [\"pinacidil\", \"increase in CxAD reduced by\", \"54 +/- 9%\"], \n [\"nitroglycerin\", \"increase in CxAD reduced by\", \"1 +/- 1%\"], \n [\"nitroglycerin\", \"dilates preferentially and flow-independently\", \"large coronary arteries\"], \n [\"cromakalim\", \"dilates\", \"large and small coronary arteries\"], \n [\"pinacidil\", \"dilates\", \"large and small coronary arteries\"], \n [\"cromakalim\", \"effect not dependent on\", \"simultaneous beta adrenoceptors-mediated rise in myocardial metabolic demand\"], \n [\"pinacidil\", \"effect not dependent on\", \"simultaneous beta adrenoceptors-mediated rise in myocardial metabolic demand\"], \n [\"cromakalim\", \"involved in\", \"direct vasodilation and flow dependency\"], \n [\"pinacidil\", \"involved in\", \"direct vasodilation and flow dependency\"]]",
      "A prospective , open - label trial of galantamine in autistic disorder .|OBJECTIVE : Post - mortem studies have reported abnormalities of the cholinergic system in autism .|The purpose of this study was to assess the use of galantamine , an acetylcholinesterase inhibitor and nicotinic receptor modulator , in the treatment of interfering behaviors in children with autism .|METHODS : Thirteen medication - free children with autism ( mean age , 8 . 8 + / - 3 . 5 years ) participated in a 12 - week , open - label trial of galantamine .|Patients were rated monthly by parents on the Aberrant Behavior Checklist ( ABC ) and the Conners ' Parent Rating Scale - Revised , and by a physician using the Children 's Psychiatric Rating Scale and the Clinical Global Impressions scale .|RESULTS : Patients showed a significant reduction in parent - rated irritability and social withdrawal on the ABC as well as significant improvements in emotional lability and inattention on the Conners ' Parent Rating Scale - - Revised .|Similarly , clinician ratings showed reductions in the anger subscale of the Children 's Psychiatric Rating Scale .|Eight of 13 participants were rated as responders on the basis of their improvement scores on the Clinical Global Impressions scale .|Overall , galantamine was well - tolerated , with no significant adverse effects apart from headaches in one patient .|CONCLUSION : In this open trial , galantamine was well - tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism , particularly aggression , behavioral dyscontrol , and inattention .|Further controlled trials are warranted .": "[[\"galantamine\", \"is for\", \"autistic disorder\"],\n[\"studies\", \"have reported\", \"abnormalities of the cholinergic system in autism\"],\n[\"galantamine\", \"is an\", \"acetylcholinesterase inhibitor\"],\n[\"galantamine\", \"is a\", \"nicotinic receptor modulator\"],\n[\"galantamine\", \"used for\", \"treatment of interfering behaviors in children with autism\"],\n[\"Thirteen children with autism\", \"participated in\", \"12-week, open-label trial of galantamine\"],\n[\"Patients\", \"were rated by\", \"parents on the Aberrant Behavior Checklist\"],\n[\"Patients\", \"were rated by\", \"parents on the Conners' Parent Rating Scale - Revised\"],\n[\"Patients\", \"were rated by\", \"physician using the Children's Psychiatric Rating Scale\"],\n[\"Patients\", \"were rated by\", \"physician using the Clinical Global Impressions scale\"],\n[\"Patients\", \"showed reduction in\", \"irritability on the ABC\"],\n[\"Patients\", \"showed reduction in\", \"social withdrawal on the ABC\"],\n[\"Patients\", \"showed improvements in\", \"emotional lability on the Conners' Parent Rating Scale - Revised\"],\n[\"Patients\", \"showed improvements in\", \"inattention on the Conners' Parent Rating Scale - Revised\"],\n[\"clinician ratings\", \"showed reductions in\", \"anger on the Children's Psychiatric Rating Scale\"],\n[\"Eight of 13 participants\", \"were rated as\", \"responders on the Clinical Global Impressions scale\"],\n[\"galantamine\", \"was\", \"well-tolerated\"],\n[\"galantamine\", \"caused\", \"headaches in one patient\"],\n[\"galantamine\", \"appeared to be beneficial for\", \"treatment of interfering behaviors in children with autism\"],\n[\"galantamine\", \"appeared to be beneficial for\", \"aggression in children with autism\"],\n[\"galantamine\", \"appeared to be beneficial for\", \"behavioral dyscontrol in children with autism\"],\n[\"galantamine\", \"appeared to be beneficial for\", \"inattention in children with autism\"],\n[\"controlled trials\", \"are warranted for\", \"galantamine\"]]",
      "Cocaine - induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine - induced hyperactivity .|The influence of adenosine receptor agonists and antagonists on cocaine - and amphetamine - induced hyperactivity was examined in mice .|All adenosine receptor agonists significantly decreased the locomotor activity in mice , and the effects were dose - dependent .|It seems that adenosine A1 and A2 receptors might be involved in this reaction .|Moreover , all adenosine receptor agonists : 2 - p - ( 2 - carboxyethyl ) phenethylamino - 5 ' - N - ethylcarboxamidoadenosine ( CGS 21680 ) , A2A receptor agonist , N6 - cyclopentyladenosine ( CPA ) , A1 receptor agonist , and 5 ' - N - ethylcarboxamidoadenosine ( NECA ) , A2 / A1 receptor agonist significantly and dose - dependently decreased cocaine - induced locomotor activity .|CPA reduced cocaine action at the doses which , given alone , did not influence motility , while CGS 21680 and NECA decreased the action of cocaine at the doses which , given alone , decreased locomotor activity in animals .|These results suggest the involvement of both adenosine receptors in the action of cocaine although agonists of A1 receptors seem to have stronger influence on it .|The selective blockade of A2 adenosine receptor by DMPX ( 3 , 7 - dimethyl - 1 - propargylxanthine ) significantly enhanced cocaine - induced locomotor activity of animals .|Caffeine had similar action but the effect was not significant .|CPT ( 8 - cyclopentyltheophylline ) - - A1 receptor antagonist , did not show any influence in this test .|Similarly , all adenosine receptor agonists decreased amphetamine - induced hyperactivity , but at the higher doses than those which were active in cocaine - induced hyperactivity .|The selective blockade of A2 adenosine receptors ( DMPX ) and non - selective blockade of adenosine receptors ( caffeine ) significantly increased the action of amphetamine in the locomotor activity test .|Our results have shown that all adenosine receptor agonists ( A1 and A2 ) reduce cocaine - and amphetamine - induced locomotor activity and indicate that cocaine - induced hyperactivity is more influenced by adenosine receptor agonists ( particularly A1 receptors ) than amphetamine - induced hyperactivity .": "[[\"Cocaine-induced hyperactivity\", \"more influenced by\", \"adenosine receptor agonists\"], [\"Cocaine-induced hyperactivity\", \"less influenced by\", \"amphetamine-induced hyperactivity\"], [\"Adenosine receptor agonists\", \"examined on\", \"cocaine- and amphetamine-induced hyperactivity in mice\"], [\"Adenosine receptor agonists\", \"decreased\", \"locomotor activity in mice\"], [\"Effects\", \"were\", \"dose-dependent\"], [\"Adenosine A1 and A2 receptors\", \"might be involved in\", \"reaction\"], [\"CGS 21680\", \"is an\", \"A2A receptor agonist\"], [\"CPA\", \"is an\", \"A1 receptor agonist\"], [\"NECA\", \"is an\", \"A2/A1 receptor agonist\"], [\"Adenosine receptor agonists\", \"decreased\", \"cocaine-induced locomotor activity\"], [\"CPA\", \"reduced\", \"cocaine action\"], [\"CGS 21680 and NECA\", \"decreased\", \"action of cocaine\"], [\"Adenosine receptors\", \"involved in\", \"action of cocaine\"], [\"A1 receptors\", \"have stronger influence on\", \"cocaine action\"], [\"DMPX\", \"enhanced\", \"cocaine-induced locomotor activity\"], [\"Caffeine\", \"had similar action to\", \"DMPX\"], [\"CPT\", \"did not show any influence on\", \"locomotor activity test\"], [\"Adenosine receptor agonists\", \"decreased\", \"amphetamine-induced hyperactivity\"], [\"DMPX and caffeine\", \"increased\", \"action of amphetamine\"], [\"Adenosine receptor agonists\", \"reduce\", \"cocaine- and amphetamine-induced locomotor activity\"], [\"Cocaine-induced hyperactivity\", \"more influenced by\", \"A1 receptors than amphetamine-induced hyperactivity\"]]",
      "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin - induced cardiotoxicity in rats with breast cancer .|Oxidative stress is involved in several processes including cancer , aging and cardiovascular disease , and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin .|Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction .|Herein , we investigate whether doxorubicin - associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer .|Thirty - six rats bearing breast tumors induced chemically were divided into 4 groups : control , hydroxytyrosol ( 0 . 5mg / kg , 5days / week ) , doxorubicin ( 1mg / kg / week ) , and doxorubicin plus hydroxytyrosol .|Cardiac disturbances at the cellular and mitochondrial level , mitochondrial electron transport chain complexes I - IV and apoptosis - inducing factor , and oxidative stress markers have been analyzed .|Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage .|These results suggest that hydroxytyrosol improve the mitochondrial electron transport chain .|This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations .": "[[\"Hydroxytyrosol\", \"ameliorates\", \"oxidative stress in doxorubicin-induced cardiotoxicity\"],\n [\"Hydroxytyrosol\", \"ameliorates\", \"mitochondrial dysfunction in doxorubicin-induced cardiotoxicity\"],\n [\"Oxidative stress\", \"is involved in\", \"cancer\"],\n [\"Oxidative stress\", \"is involved in\", \"aging\"],\n [\"Oxidative stress\", \"is involved in\", \"cardiovascular disease\"],\n [\"Oxidative stress\", \"potentiates\", \"therapeutic effect of doxorubicin\"],\n [\"Doxorubicin\", \"causes\", \"cardiotoxicity\"],\n [\"Cardiotoxicity\", \"characterized by\", \"increases in oxidative stress\"],\n [\"Cardiotoxicity\", \"characterized by\", \"mitochondrial dysfunction\"],\n [\"Study\", \"investigates\", \"doxorubicin-associated chronic cardiac toxicity\"],\n [\"Hydroxytyrosol\", \"used for\", \"ameliorating chronic cardiac toxicity\"],\n [\"Rats with breast cancer\", \"treated with\", \"hydroxytyrosol\"],\n [\"Rats with breast cancer\", \"treated with\", \"doxorubicin\"],\n [\"Rats with breast cancer\", \"treated with\", \"doxorubicin plus hydroxytyrosol\"],\n [\"Study\", \"analyzed\", \"cardiac disturbances at cellular and mitochondrial level\"],\n [\"Study\", \"analyzed\", \"mitochondrial electron transport chain complexes I-IV\"],\n [\"Study\", \"analyzed\", \"apoptosis-inducing factor\"],\n [\"Study\", \"analyzed\", \"oxidative stress markers\"],\n [\"Hydroxytyrosol\", \"improved\", \"cardiac disturbances enhanced by doxorubicin\"],\n [\"Hydroxytyrosol\", \"reduced\", \"percentage of altered mitochondria\"],\n [\"Hydroxytyrosol\", \"reduced\", \"oxidative damage\"],\n [\"Results\", \"suggest\", \"hydroxytyrosol improves mitochondrial electron transport chain\"],\n [\"Study\", \"demonstrates\", \"hydroxytyrosol protect rat heart damage\"],\n [\"Hydroxytyrosol\", \"decreasing\", \"oxidative damage and mitochondrial alterations\"]]",
      "A metoprolol - terbinafine combination induced bradycardia .|To report a sinus bradycardia induced by metoprolol and terbinafine drug - drug interaction and its management .|A 63 year - old Caucasian man on metoprolol 200 mg / day for stable coronary artery disease was prescribed a 90 - day course of oral terbinafine 250 mg / day for onychomycosis .|On the 49th day of terbinafine therapy , he was brought to the emergency room for a decrease of his global health status , confusion and falls .|The electrocardiogram revealed a 37 beats / min sinus bradycardia .|A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient 's sinus bradycardia and the drug interaction between metoprolol and terbinafine .|The heart rate ameliorated first with a decrease in the dose of metoprolol .|It was subsequently changed to bisoprolol and the heart rate remained normal .|By inhibiting the cytochrome P450 2D6 , terbinafine had decreased metoprolol 's clearance , leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia .": "[[\"metoprolol - terbinafine combination\", \"induced\", \"bradycardia\"],\n[\"sinus bradycardia\", \"induced by\", \"metoprolol and terbinafine drug-drug interaction\"],\n[\"63 year-old Caucasian man\", \"on\", \"metoprolol 200 mg/day\"],\n[\"63 year-old Caucasian man\", \"prescribed\", \"oral terbinafine 250 mg/day\"],\n[\"63 year-old Caucasian man\", \"had\", \"stable coronary artery disease\"],\n[\"63 year-old Caucasian man\", \"had\", \"onychomycosis\"],\n[\"63 year-old Caucasian man\", \"brought to\", \"emergency room\"],\n[\"63 year-old Caucasian man\", \"experienced\", \"decrease of his global health status\"],\n[\"63 year-old Caucasian man\", \"experienced\", \"confusion\"],\n[\"63 year-old Caucasian man\", \"experienced\", \"falls\"],\n[\"electrocardiogram\", \"revealed\", \"37 beats/min sinus bradycardia\"],\n[\"Naranjo adverse drug reaction probability scale\", \"indicates\", \"probable relationship\"],\n[\"patient's sinus bradycardia\", \"related to\", \"drug interaction between metoprolol and terbinafine\"],\n[\"heart rate\", \"ameliorated first with\", \"decrease in the dose of metoprolol\"],\n[\"metoprolol dose\", \"changed to\", \"bisoprolol\"],\n[\"heart rate\", \"remained\", \"normal\"],\n[\"terbinafine\", \"inhibited\", \"cytochrome P450 2D6\"],\n[\"terbinafine\", \"decreased\", \"metoprolol's clearance\"],\n[\"decreased metoprolol's clearance\", \"led to\", \"metoprolol accumulation\"],\n[\"metoprolol accumulation\", \"resulted in\", \"clinically significant sinus bradycardia\"]]",
      "Progesterone potentiation of bupivacaine arrhythmogenicity in pentobarbital - anesthetized rats and beating rat heart cell cultures .|The effects of progesterone treatment on bupivacaine arrhythmogenicity in beating rat heart myocyte cultures and on anesthetized rats were determined .|After determining the bupivacaine AD50 ( the concentration of bupivacaine that caused 50 % of all beating rat heart myocyte cultures to become arrhythmic ) , we determined the effect of 1 - hour progesterone HCl exposure on myocyte contractile rhythm .|Each concentration of progesterone ( 6 . 25 , 12 . 5 , 25 , and 50 micrograms / ml ) caused a significant and concentration - dependent reduction in the AD50 for bupivacaine .|Estradiol treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures , but was only one fourth as potent as progesterone .|Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by epinephrine .|Chronic progesterone pretreatment ( 5 mg / kg / day for 21 days ) caused a significant increase in bupivacaine arrhythmogenicity in intact pentobarbital - anesthetized rats .|There was a significant decrease in the time to onset of arrhythmia as compared with control nonprogesterone - treated rats ( 6 . 2 + / - 1 . 3 vs . 30 . 8 + / - 2 . 5 min , mean + / - SE ) .|The results of this study indicate that progesterone can potentiate bupivacaine arrhythmogenicity both in vivo and in vitro .|Potentiation of bupivacaine arrhythmia in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level .": "[[\"Progesterone\", \"potentiates\", \"bupivacaine arrhythmogenicity\"], [\"Progesterone\", \"used in\", \"pentobarbital-anesthetized rats\"], [\"Progesterone\", \"used in\", \"beating rat heart cell cultures\"], [\"Effects\", \"of\", \"progesterone treatment\"], [\"Progesterone treatment\", \"on\", \"bupivacaine arrhythmogenicity\"], [\"Bupivacaine AD50\", \"is\", \"concentration causing 50% arrhythmia in cultures\"], [\"Progesterone HCl exposure\", \"affects\", \"myocyte contractile rhythm\"], [\"Progesterone concentration\", \"causes\", \"reduction in AD50 for bupivacaine\"], [\"Estradiol treatment\", \"increases\", \"arrhythmogenicity of bupivacaine\"], [\"Estradiol\", \"less potent than\", \"progesterone\"], [\"Progesterone effects\", \"not potentiated by\", \"epinephrine\"], [\"Estradiol effects\", \"not potentiated by\", \"epinephrine\"], [\"Chronic progesterone pretreatment\", \"causes\", \"increase in bupivacaine arrhythmogenicity\"], [\"Chronic progesterone pretreatment\", \"compared with\", \"control nonprogesterone-treated rats\"], [\"Time to onset of arrhythmia\", \"decreased by\", \"progesterone pretreatment\"], [\"Study results\", \"indicate\", \"progesterone potentiates bupivacaine arrhythmogenicity\"], [\"Potentiation of bupivacaine arrhythmia\", \"mediated at\", \"myocyte level\"]]",
      "Effect of vincristine sulfate on Pseudomonas infections in monkeys .|In rhesus monkeys , intravenous challenge with 0 . 6 x 10 ( 10 ) to 2 . 2 x 10 ( 10 ) Pseudomonas aeruginosa organisms caused acute illness of 4 to 5 days ' duration with spontaneous recovery in 13 of 15 monkeys ; blood cultures became negative 3 to 17 days after challenge .|Leukocytosis was observed in all monkeys .|Intravenous or intratracheal inoculation of 2 . 0 to 2 . 5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days .|Intravenous inoculation of 4 . 2 x 10 ( 10 ) to 7 . 8 x 10 ( 10 ) pyocin type 6 Pseudomonas organisms in monkeys given vincristine sulfate 4 days previously resulted in fatal infection in 11 of 14 monkeys , whereas none of four receiving Pseudomonas alone died .|These studies suggest that an antimetabolite - induced leukopenia predisposes to severe Pseudomonas sepsis and that such monkeys may serve as a biological model for study of comparative efficacy of antimicrobial agents .": "[[\"vincristine sulfate\", \"has effect on\", \"Pseudomonas infections in monkeys\"],\n[\"intravenous challenge with Pseudomonas aeruginosa\", \"caused\", \"acute illness of 4 to 5 days' duration\"],\n[\"intravenous challenge with Pseudomonas aeruginosa\", \"resulted in\", \"spontaneous recovery in 13 of 15 monkeys\"],\n[\"blood cultures\", \"became negative\", \"3 to 17 days after challenge\"],\n[\"all monkeys\", \"observed with\", \"Leukocytosis\"],\n[\"vincristine sulfate\", \"followed by\", \"leukopenia in 4 to 5 days\"],\n[\"intravenous inoculation of pyocin type 6 Pseudomonas organisms\", \"resulted in\", \"fatal infection in 11 of 14 monkeys\"],\n[\"monkeys given vincristine sulfate\", \"developed\", \"leukopenia\"],\n[\"monkeys given vincristine sulfate\", \"predisposes to\", \"severe Pseudomonas sepsis\"],\n[\"monkeys\", \"may serve as\", \"biological model for study of comparative efficacy of antimicrobial agents\"],\n[\"none of four receiving Pseudomonas alone\", \"died\", \"\"],\n[\"vincristine sulfate\", \"administered 4 days before\", \"Pseudomonas organisms\"]]",
      "Comparison of valsartan / hydrochlorothiazide combination therapy at doses up to 320 / 25 mg versus monotherapy : a double - blind , placebo - controlled study followed by long - term combination therapy in hypertensive adults .|BACKGROUND : One third of patients treated for hypertension attain adequate blood pressure ( BP ) control , and multidrug regimens are often required .|Given the lifelong nature of hypertension , there is a need to evaluate the long - term efficacy and tolerability of higher doses of combination anti - hypertensive therapies .|OBJECTIVE : This study investigated the efficacy and tolerability of valsartan ( VAL ) or hydrochlorothiazide ( HCTZ ) - monotherapy and higher - dose combinations in patients with essential hypertension .|METHODS : The first part of this study was an 8 - week , multicenter , randomized , double - blind , placebo controlled , parallel - group trial .|Patients with essential hypertension ( mean sitting diastolic BP [ MSDBP ] , > or = 95 mm Hg and < 110 mm Hg ) were randomized to 1 of 8 treatment groups : VAL 160 or 320 mg ; HCTZ 12 . 5 or 25 mg ; VAL / HCTZ 160 / 12 . 5 , 320 / 12 . 5 , or 320 / 25 mg ; or placebo .|Mean changes in MSDBP and mean sitting systolic BP ( MSSBP ) were analyzed at the 8 - week core study end point .|VAL / HCTZ 320 / 12 . 5 and 320 / 25 mg were further investigated in a 54 - week , open - label extension .|Response was defined as MSDBP < 90 mm Hg or a > or = 10 mm Hg decrease compared to baseline .|Control was defined as MSDBP < 90 mm Hg compared with baseline .|Tolerability was assessed by monitoring adverse events at randomization and all subsequent study visits and regular evaluation of hematology and blood chemistry .|RESULTS : A total of 1346 patients were randomized into the 8 - week core study ( 734 men , 612 women ; 924 white , 291 black , 23 Asian , 108 other ; mean age , 52 . 7 years ; mean weight , 92 . 6 kg ) .|All active treatments were associated with significantly reduced MSSBP and MSDBP during the core 8 - week study , with each monotherapy significantly contributing to the overall effect of combination therapy ( VAL and HCTZ , P < 0 . 001 ) .|Each combination was associated with significantly greater reductions in MSSBP and MSDBP compared with the monotherapies and placebo ( all , P < 0 . 001 ) .|The mean reduction in MSSBP / MSDBP with VAL / HCTZ 320 / 25 mg was 24 . 7 / 16 . 6 mm Hg , compared with 5 . 9 / 7 . 0 mm Hg with placebo .|The reduction in MSSBP was significantly greater with VAL / HCTZ 320 / 25 mg compared with VAL / HCTZ 160 / 12 . 5 mg ( P < 0 . 002 ) .|Rates of response and BP control were significantly higher in the groups that received combination treatment compared with those that received monotherapy .|The incidence of hypokalemia was lower with VAL / HCTZ combinations ( 1 . 8 % - 6 . 1 % ) than with HCTZ monotherapies ( 7 . 1 % - 13 . 3 % ) .|The majority of adverse events in the core study were of mild to moderate severity .|The efficacy and tolerability of VAL / HCTZ combinations were maintained during the extension ( 797 patients ) .|CONCLUSIONS : In this study population , combination therapies with VAL / HCTZ were associated with significantly greater BP reductions compared with either monotherapy , were well tolerated , and were associated with less hypokalemia than HCTZ alone .": "[[\"valsartan/hydrochlorothiazide combination therapy\", \"compared to\", \"monotherapy\"],\n[\"valsartan/hydrochlorothiazide combination therapy\", \"used for\", \"hypertensive adults\"],\n[\"valsartan/hydrochlorothiazide combination therapy\", \"doses up to\", \"320/25 mg\"],\n[\"study\", \"type of\", \"double-blind, placebo-controlled study\"],\n[\"study\", \"followed by\", \"long-term combination therapy\"],\n[\"hypertension\", \"requires\", \"multidrug regimens\"],\n[\"hypertension\", \"has\", \"lifelong nature\"],\n[\"study\", \"investigated\", \"efficacy and tolerability of valsartan/hydrochlorothiazide\"],\n[\"valsartan\", \"combined with\", \"hydrochlorothiazide\"],\n[\"study\", \"duration\", \"8-week\"],\n[\"study\", \"type of\", \"multicenter, randomized, double-blind, placebo-controlled, parallel-group trial\"],\n[\"patients\", \"had\", \"essential hypertension\"],\n[\"patients\", \"randomized to\", \"treatment groups\"],\n[\"valsartan\", \"dosages\", \"160 or 320 mg\"],\n[\"hydrochlorothiazide\", \"dosages\", \"12.5 or 25 mg\"],\n[\"treatment groups\", \"included\", \"valsartan/hydrochlorothiazide 160/12.5, 320/12.5, or 320/25 mg\"],\n[\"treatment groups\", \"included\", \"placebo\"],\n[\"study\", \"analyzed\", \"mean changes in MSDBP and MSSBP\"],\n[\"valsartan/hydrochlorothiazide 320/12.5 and 320/25 mg\", \"investigated in\", \"54-week, open-label extension\"],\n[\"response\", \"defined as\", \"MSDBP < 90 mm Hg or a >= 10 mm Hg decrease\"],\n[\"control\", \"defined as\", \"MSDBP < 90 mm Hg\"],\n[\"tolerability\", \"assessed by\", \"monitoring adverse events\"],\n[\"tolerability\", \"assessed by\", \"evaluation of hematology and blood chemistry\"],\n[\"patients\", \"number of\", \"1346\"],\n[\"active treatments\", \"associated with\", \"reduced MSSBP and MSDBP\"],\n[\"monotherapy\", \"contributed to\", \"overall effect of combination therapy\"],\n[\"combination therapy\", \"associated with\", \"greater reductions in MSSBP and MSDBP compared with monotherapies and placebo\"],\n[\"valsartan/hydrochlorothiazide 320/25 mg\", \"mean reduction in MSSBP/MSDBP\", \"24.7/16.6 mm Hg\"],\n[\"placebo\", \"mean reduction in MSSBP/MSDBP\", \"5.9/7.0 mm Hg\"],\n[\"valsartan/hydrochlorothiazide 320/25 mg\", \"greater reduction in MSSBP compared with\", \"valsartan/hydrochlorothiazide 160/12.5 mg\"],\n[\"combination treatment\", \"rates of response and BP control\", \"higher compared with monotherapy\"],\n[\"hypokalemia incidence\", \"lower with\", \"valsartan/hydrochlorothiazide combinations\"],\n[\"hypokalemia incidence\", \"higher with\", \"hydrochlorothiazide monotherapies\"],\n[\"adverse events\", \"severity\", \"mild to moderate\"],\n[\"valsartan/hydrochlorothiazide combinations\", \"efficacy and tolerability\", \"maintained during extension\"],\n[\"combination therapies with valsartan/hydrochlorothiazide\", \"associated with\", \"greater BP reductions compared with either monotherapy\"],\n[\"combination therapies with valsartan/hydrochlorothiazide\", \"tolerated\", \"well\"],\n[\"combination therapies with valsartan/hydrochlorothiazide\", \"associated with",
      "Nontraumatic dissecting aneurysm of the basilar artery .|A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension , smoke , and oral contraceptives is reported in a young female patient with a locked - in syndrome .": "[[\"Nontraumatic dissecting aneurysm of the basilar artery\", \"is associated with\", \"hypertension\"], [\"Nontraumatic dissecting aneurysm of the basilar artery\", \"is associated with\", \"smoke\"], [\"Nontraumatic dissecting aneurysm of the basilar artery\", \"is associated with\", \"oral contraceptives\"], [\"Nontraumatic dissecting aneurysm of the basilar artery\", \"occurred in\", \"a young female patient\"], [\"A young female patient\", \"developed\", \"locked-in syndrome\"]]",
      "Cancer incidence and metolachlor use in the Agricultural Health Study : An update .|UNASSIGNED : Metolachlor , a widely used herbicide , is classified as a Group C carcinogen by the U . S .|Environmental Protection Agency based on increased liver neoplasms in female rats .|Epidemiologic studies of the health effects of metolachlor have been limited .|The Agricultural Health Study ( AHS ) is a prospective cohort study including licensed private and commercial pesticide applicators in Iowa and North Carolina enrolled 1993 - 1997 .|We evaluated cancer incidence through 2010 / 2011 ( NC / IA ) for 49 , 616 applicators , 53 % of whom reported ever using metolachlor .|We used Poisson regression to evaluate relations between two metrics of metolachlor use ( lifetime days , intensity - weighted lifetime days ) and cancer incidence .|We saw no association between metolachlor use and incidence of all cancers combined ( n = 5 , 701 with a 5 - year lag ) or most site - specific cancers .|For liver cancer , in analyses restricted to exposed workers , elevations observed at higher categories of use were not statistically significant .|However , trends for both lifetime and intensity - weighted lifetime days of metolachor use were positive and statistically significant with an unexposed reference group .|A similar pattern was observed for follicular cell lymphoma , but no other lymphoma subtypes .|An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update .|This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies .|However , our findings for both liver cancer and follicular cell lymphoma warrant follow - up to better differentiate effects of metolachlor use from other factors .": "[[\"Metolachlor\", \"is classified as\", \"Group C carcinogen\"], [\"Metolachlor\", \"associated with\", \"increased liver neoplasms in female rats\"], [\"Metolachlor\", \"used by\", \"licensed private and commercial pesticide applicators\"], [\"Agricultural Health Study (AHS)\", \"is a\", \"prospective cohort study\"], [\"AHS\", \"includes\", \"licensed private and commercial pesticide applicators\"], [\"AHS\", \"enrolled applicators during\", \"1993 - 1997\"], [\"AHS\", \"evaluated cancer incidence through\", \"2010 / 2011 (NC / IA)\"], [\"AHS\", \"had\", \"49,616 applicators\"], [\"53% of applicators\", \"reported\", \"ever using metolachlor\"], [\"Study\", \"used\", \"Poisson regression\"], [\"Study\", \"evaluated relationship between\", \"metolachlor use and cancer incidence\"], [\"Metolachlor use\", \"showed no association with\", \"incidence of all cancers combined\"], [\"Metolachlor use\", \"showed no association with\", \"most site-specific cancers\"], [\"Liver cancer\", \"showed elevations at higher categories of use among\", \"exposed workers\"], [\"Liver cancer\", \"had positive trends with\", \"lifetime and intensity-weighted lifetime days of metolachlor use\"], [\"Follicular cell lymphoma\", \"showed a similar pattern to liver cancer with\", \"metolachlor use\"], [\"Lung cancer risk\", \"was not confirmed with\", \"high levels of metolachlor use in this update\"], [\"Association\", \"between metolachlor and\", \"liver cancer\"], [\"Findings\", \"warrant follow-up for\", \"liver cancer and follicular cell lymphoma\"], [\"Metolachlor use\", \"needs differentiation from\", \"other factors\"]]",
      "Neuroleptic malignant syndrome complicated by massive intestinal bleeding in a patient with chronic renal failure .|A patient with chronic renal failure ( CRF ) developed neuroleptic malignant syndrome ( NMS ) after administration of risperidone and levomepromazine .|In addition to the typical symptoms of NMS , massive intestinal bleeding was observed during the episode .|This report suggests that NMS in a patient with CRF may be complicated by intestinal bleeding and needs special caution for this complication .": "[[\"Neuroleptic malignant syndrome\", \"complicated by\", \"massive intestinal bleeding\"], [\"patient\", \"with\", \"chronic renal failure\"], [\"patient\", \"developed\", \"Neuroleptic malignant syndrome\"], [\"Neuroleptic malignant syndrome\", \"after administration of\", \"risperidone\"], [\"Neuroleptic malignant syndrome\", \"after administration of\", \"levomepromazine\"], [\"massive intestinal bleeding\", \"observed during\", \"Neuroleptic malignant syndrome episode\"], [\"report\", \"suggests\", \"Neuroleptic malignant syndrome in patient with chronic renal failure may be complicated by intestinal bleeding\"], [\"report\", \"indicates need for special caution for\", \"intestinal bleeding complication\"]]",
      "Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine - induced status epilepticus in the adult rat .|Following status epilepticus in the rat , dentate granule cell neurogenesis increases greatly , and many of the new neurons appear to develop ectopically , in the hilar region of the hippocampal formation .|It has been suggested that the ectopic hilar granule cells could contribute to the spontaneous seizures that ultimately develop after status epilepticus .|However , the population has never been quantified , so it is unclear whether it is substantial enough to have a strong influence on epileptogenesis .|To quantify this population , the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine - induced status epilepticus .|The number of hilar neurons immunoreactive for Prox - 1 , a granule - cell - specific marker , was estimated using the optical fractionator method .|The results indicate that the size of the hilar ectopic granule cell population after status epilepticus is substantial , and stable over time .|Interestingly , the size of the population appears to be correlated with the frequency of behavioral seizures , because animals with more ectopic granule cells in the hilus have more frequent behavioral seizures .|The hilar ectopic granule cell population does not appear to vary systematically across the septotemporal axis , although it is associated with an increase in volume of the hilus .|The results provide new insight into the potential role of ectopic hilar granule cells in the pilocarpine model of temporal lobe epilepsy .": "[[\"Stereological methods\", \"reveal\", \"size and stability of ectopic hilar granule cells\"],\n [\"Ectopic hilar granule cells\", \"result from\", \"pilocarpine-induced status epilepticus\"],\n [\"Ectopic hilar granule cells\", \"located in\", \"adult rat\"],\n [\"Status epilepticus\", \"increases\", \"dentate granule cell neurogenesis\"],\n [\"New neurons\", \"develop ectopically in\", \"hilar region of the hippocampal formation\"],\n [\"Ectopic hilar granule cells\", \"could contribute to\", \"spontaneous seizures\"],\n [\"Population of ectopic hilar granule cells\", \"has never been\", \"quantified\"],\n [\"Unbiased stereology\", \"used to estimate\", \"total number of ectopic hilar granule cells\"],\n [\"Pilocarpine-induced status epilepticus\", \"followed by\", \"quantification of ectopic hilar granule cells\"],\n [\"Hilar neurons\", \"immunoreactive for\", \"Prox-1\"],\n [\"Optical fractionator method\", \"used to estimate\", \"number of Prox-1 immunoreactive neurons\"],\n [\"Hilar ectopic granule cell population\", \"is\", \"substantial and stable over time\"],\n [\"Size of hilar ectopic granule cell population\", \"correlated with\", \"frequency of behavioral seizures\"],\n [\"Animals with more ectopic granule cells\", \"have\", \"more frequent behavioral seizures\"],\n [\"Hilar ectopic granule cell population\", \"does not vary systematically across\", \"septotemporal axis\"],\n [\"Hilar ectopic granule cell population\", \"associated with\", \"increase in volume of the hilus\"],\n [\"Results\", \"provide insight into\", \"role of ectopic hilar granule cells in temporal lobe epilepsy\"]]",
      "Topotecan in combination with radiotherapy in unresectable glioblastoma : a phase 2 study .|Improving glioblastoma multiforme ( GBM ) treatment with radio - chemotherapy remains a challenge .|Topotecan is an attractive option as it exhibits growth inhibition of human glioma as well as brain penetration .|The present study assessed the combination of radiotherapy ( 60 Gy / 30 fractions / 40 days ) and topotecan ( 0 . 9 mg / m ( 2 ) / day on days 1 - 5 on weeks 1 , 3 and 5 ) in 50 adults with histologically proven and untreated GBM .|The incidence of non - hematological toxicities was low and grade 3 - 4 hematological toxicities were reported in 20 patients ( mainly lymphopenia and neutropenia ) .|Partial response and stabilization rates were 2 % and 32 % , respectively , with an overall time to progression of 12 weeks .|One - year overall survival ( OS ) rate was 42 % , with a median OS of 40 weeks .|Topotecan in combination with radiotherapy was well tolerated .|However , while response and stabilization concerned one - third of the patients , the study did not show increased benefits in terms of survival in patients with unresectable GBM .": "[[\"Topotecan\", \"used in combination with\", \"radiotherapy\"],\n [\"Topotecan\", \"for treatment of\", \"unresectable glioblastoma\"],\n [\"Topotecan\", \"exhibits\", \"growth inhibition of human glioma\"],\n [\"Topotecan\", \"has\", \"brain penetration\"],\n [\"The present study\", \"assessed\", \"combination of radiotherapy and topotecan\"],\n [\"Radiotherapy\", \"dose\", \"60 Gy / 30 fractions / 40 days\"],\n [\"Topotecan\", \"dose\", \"0.9 mg/m^2/day on days 1-5 on weeks 1, 3 and 5\"],\n [\"The present study\", \"involved\", \"50 adults with histologically proven and untreated GBM\"],\n [\"Non-hematological toxicities\", \"incidence was\", \"low\"],\n [\"Grade 3-4 hematological toxicities\", \"reported in\", \"20 patients\"],\n [\"Toxicities observed\", \"included\", \"lymphopenia and neutropenia\"],\n [\"Partial response rate\", \"was\", \"2%\"],\n [\"Stabilization rate\", \"was\", \"32%\"],\n [\"Overall time to progression\", \"was\", \"12 weeks\"],\n [\"One-year overall survival rate\", \"was\", \"42%\"],\n [\"Median overall survival\", \"was\", \"40 weeks\"],\n [\"Topotecan and radiotherapy\", \"was\", \"well tolerated\"],\n [\"The study\", \"did not show\", \"increased benefits in terms of survival\"]]",
      "Long term hormone therapy for perimenopausal and postmenopausal women .|BACKGROUND : Hormone therapy ( HT ) is widely used for controlling menopausal symptoms .|It has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational .|OBJECTIVES : To assess the effect of long - term HT on mortality , heart disease , venous thromboembolism , stroke , transient ischaemic attacks , breast cancer , colorectal cancer , ovarian cancer , endometrial cancer , gallbladder disease , cognitive function , dementia , fractures and quality of life .|SEARCH STRATEGY : We searched the following databases up to November 2004 : the Cochrane Menstrual Disorders and Subfertility Group Trials Register , Cochrane Central Register of Controlled Trials ( CENTRAL ) , MEDLINE , EMBASE , Biological Abstracts .|Relevant non - indexed journals and conference abstracts were also searched .|SELECTION CRITERIA : Randomised double - blind trials of HT ( oestrogens with or without progestogens ) versus placebo , taken for at least one year by perimenopausal or postmenopausal women .|DATA COLLECTION AND ANALYSIS : Fifteen RCTs were included .|Trials were assessed for quality and two review authors extracted data independently .|They calculated risk ratios for dichotomous outcomes and weighted mean differences for continuous outcomes .|Clinical heterogeneity precluded meta - analysis for most outcomes .|MAIN RESULTS : All the statistically significant results were derived from the two biggest trials .|In relatively healthy women , combined continuous HT significantly increased the risk of venous thromboembolism or coronary event ( after one year 's use ) , stroke ( after 3 years ) , breast cancer ( after 5 years ) and gallbladder disease .|Long - term oestrogen - only HT also significantly increased the risk of stroke and gallbladder disease .|Overall , the only statistically significant benefits of HT were a decreased incidence of fractures and colon cancer with long - term use .|Among relatively healthy women over 65 years taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .|Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thromboembolism .|No trials focussed specifically on younger women .|However , one trial analysed subgroups of 2839 relatively healthy 50 to 59 year - old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .|The only significantly increased risk reported was for venous thromboembolism in women taking combined continuous HT ; their absolute risk remained very low .|AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .|We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .": "[[\"Hormone therapy (HT)\", \"is used for\", \"controlling menopausal symptoms\"],\n [\"Hormone therapy (HT)\", \"used for\", \"management and prevention of cardiovascular disease\"],\n [\"Hormone therapy (HT)\", \"used for\", \"prevention of osteoporosis\"],\n [\"Hormone therapy (HT)\", \"used for\", \"prevention of dementia\"],\n [\"Hormone therapy (HT)\", \"evidence supporting use is\", \"largely observational\"],\n [\"Long-term HT\", \"assessed for effect on\", \"mortality\"],\n [\"Long-term HT\", \"assessed for effect on\", \"heart disease\"],\n [\"Long-term HT\", \"assessed for effect on\", \"venous thromboembolism\"],\n [\"Long-term HT\", \"assessed for effect on\", \"stroke\"],\n [\"Long-term HT\", \"assessed for effect on\", \"transient ischaemic attacks\"],\n [\"Long-term HT\", \"assessed for effect on\", \"breast cancer\"],\n [\"Long-term HT\", \"assessed for effect on\", \"colorectal cancer\"],\n [\"Long-term HT\", \"assessed for effect on\", \"ovarian cancer\"],\n [\"Long-term HT\", \"assessed for effect on\", \"endometrial cancer\"],\n [\"Long-term HT\", \"assessed for effect on\", \"gallbladder disease\"],\n [\"Long-term HT\", \"assessed for effect on\", \"cognitive function\"],\n [\"Long-term HT\", \"assessed for effect on\", \"dementia\"],\n [\"Long-term HT\", \"assessed for effect on\", \"fractures\"],\n [\"Long-term HT\", \"assessed for effect on\", \"quality of life\"],\n [\"Search strategy\", \"included\", \"Cochrane Menstrual Disorders and Subfertility Group Trials Register\"],\n [\"Search strategy\", \"included\", \"Cochrane Central Register of Controlled Trials (CENTRAL)\"],\n [\"Search strategy\", \"included\", \"MEDLINE\"],\n [\"Search strategy\", \"included\", \"EMBASE\"],\n [\"Search strategy\", \"included\", \"Biological Abstracts\"],\n [\"Selection criteria\", \"specified\", \"Randomised double-blind trials\"],\n [\"Selection criteria\", \"specified\", \"HT versus placebo\"],\n [\"Selection criteria\", \"specified\", \"at least one year duration\"],\n [\"Selection criteria\", \"specified\", \"perimenopausal or postmenopausal women\"],\n [\"Data collection and analysis\", \"included\", \"Fifteen RCTs\"],\n [\"Review authors\", \"extracted data\", \"independently\"],\n [\"Combined continuous HT\", \"increased risk of\", \"venous thromboembolism\"],\n [\"Combined continuous HT\", \"increased risk of\", \"coronary event\"],\n [\"Combined continuous HT\", \"increased risk of\", \"stroke\"],\n [\"Combined continuous HT\", \"increased risk of\", \"breast cancer\"],\n [\"Combined continuous HT\", \"increased risk of\", \"gallbladder disease\"],\n [\"Oestrogen-only HT\", \"increased risk of\", \"stroke\"],\n [\"Oestrogen-only HT\", \"increased risk of\", \"gallbladder disease\"],\n [\"HT\", \"decreased incidence of\", \"fractures\"],\n [\"HT\", \"decreased incidence of\", \"colon cancer\"],\n [\"Continuous combined HT\", \"increased incidence of\", \"dementia in women over 65\"],\n [\"Combined continuous HT\", \"increased risk of\", \"venous thromboembolism in women with cardiovascular disease\"],\n [\"Trials\", \"did not focus on\", \"younger women\"],\n [\"Combined continuous HT\", \"increased risk of\", \"venous thromboembolism in healthy 50 to 59 year-old women\"],\n [\"Authors' conclusions\", \"indicate\", \"HT is not indicated for routine management of chronic disease\"],\n [\"HT\", \"need more evidence on safety for\", \"menopausal symptom control\"],\n [\"Short-term HT use\",",
      "Deliberate hypotension induced by labetalol with halothane , enflurane or isoflurane for middle - ear surgery .|The feasibility of using labetalol , an alpha - and beta - adrenergic blocking agent , as a hypotensive agent in combination with inhalation anaesthetics ( halothane , enflurane or isoflurane ) was studied in 23 adult patients undergoing middle - ear surgery .|The mean arterial pressure was decreased from 86 + / - 5 ( s . e .|mean ) mmHg to 52 + / - 1 mmHg ( 11 . 5 + / - 0 . 7 to 6 . 9 + / - 0 . 1 kPa ) for 98 + / - 10 min in the halothane ( H ) group , from 79 + / - 5 to 53 + / - 1 mmHg ( 10 . 5 + / - 0 . 7 to 7 . 1 + / - 0 . 1 kPa ) for 129 + / - 11 min in the enflurane ( E ) group , and from 80 + / - 4 to 49 + / - 1 mmHg ( 10 . 7 + / - 0 . 5 to 6 . 5 + / - 0 . 1 kPa ) for 135 + / - 15 min in the isoflurane ( I ) group .|The mean H concentration during hypotension in the inspiratory gas was 0 . 7 + / - 0 . 1 vol % , the mean E concentration 1 . 6 + / - 0 . 2 vol % , and the mean I concentration 1 . 0 + / - 0 . 1 vol % .|In addition , the patients received fentanyl and d - tubocurarine .|The initial dose of labetalol for lowering blood pressure was similar , 0 . 52 - 0 . 59 mg / kg , in all the groups .|During hypotension , the heart rate was stable without tachy - or bradycardia .|The operating conditions regarding bleeding were estimated in a double - blind manner , and did not differ significantly between the groups .|During hypotension , the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups , except the isoflurane group .|After hypotension there was no rebound phenomenon in either blood pressure or heart rate .|These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension .": "[[\"Deliberate hypotension\", \"induced by\", \"labetalol with halothane, enflurane, isoflurane\"], [\"labetalol\", \"used for\", \"middle-ear surgery\"], [\"labetalol\", \"is an\", \"alpha- and beta-adrenergic blocking agent\"], [\"labetalol\", \"used in combination with\", \"inhalation anaesthetics\"], [\"inhalation anaesthetics\", \"include\", \"halothane, enflurane, isoflurane\"], [\"study\", \"conducted on\", \"23 adult patients\"], [\"23 adult patients\", \"undergoing\", \"middle-ear surgery\"], [\"mean arterial pressure\", \"decreased from\", \"86 +/- 5 mmHg to 52 +/- 1 mmHg in halothane group\"], [\"mean arterial pressure\", \"decreased from\", \"79 +/- 5 mmHg to 53 +/- 1 mmHg in enflurane group\"], [\"mean arterial pressure\", \"decreased from\", \"80 +/- 4 mmHg to 49 +/- 1 mmHg in isoflurane group\"], [\"H concentration during hypotension\", \"was\", \"0.7 +/- 0.1 vol%\"], [\"E concentration during hypotension\", \"was\", \"1.6 +/- 0.2 vol%\"], [\"I concentration during hypotension\", \"was\", \"1.0 +/- 0.1 vol%\"], [\"patients\", \"received\", \"fentanyl and d-tubocurarine\"], [\"initial dose of labetalol\", \"was similar\", \"0.52 - 0.59 mg/kg in all groups\"], [\"heart rate during hypotension\", \"was stable without\", \"tachycardia or bradycardia\"], [\"operating conditions regarding bleeding\", \"estimated in\", \"double-blind manner\"], [\"operating conditions regarding bleeding\", \"did not differ significantly between\", \"groups\"], [\"serum creatinine concentration\", \"rose significantly from before hypotension to after\", \"in all groups\"], [\"serum creatinine concentration\", \"returned postoperatively to initial level\", \"in groups except isoflurane group\"], [\"after hypotension\", \"no rebound phenomenon in\", \"blood pressure or heart rate\"], [\"labetalol\", \"induces\", \"easily adjustable hypotension\"], [\"labetalol\", \"without compensatory\", \"tachycardia and rebound hypertension\"]]",
      "Dysfunctional overnight memory consolidation in ecstasy users .|Sleep plays an important role in the consolidation and integration of memory in a process called overnight memory consolidation .|Previous studies indicate that ecstasy users have marked and persistent neurocognitive and sleep - related impairments .|We extend past research by examining overnight memory consolidation among regular ecstasy users ( n = 12 ) and drug naive healthy controls ( n = 26 ) .|Memory recall of word pairs was evaluated before and after a period of sleep , with and without interference prior to testing .|In addition , we assessed neurocognitive performances across tasks of learning , memory and executive functioning .|Ecstasy users demonstrated impaired overnight memory consolidation , a finding that was more pronounced following associative interference .|Additionally , ecstasy users demonstrated impairments on tasks recruiting frontostriatal and hippocampal neural circuitry , in the domains of proactive interference memory , long - term memory , encoding , working memory and complex planning .|We suggest that ecstasy - associated dysfunction in fronto - temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users .": "[[\"Dysfunctional overnight memory consolidation\", \"in\", \"ecstasy users\"],\n [\"Sleep\", \"plays a role in\", \"overnight memory consolidation\"],\n [\"Ecstasy users\", \"have\", \"neurocognitive and sleep-related impairments\"],\n [\"Study\", \"examines\", \"overnight memory consolidation among regular ecstasy users and drug naive healthy controls\"],\n [\"Memory recall\", \"evaluated with\", \"word pairs\"],\n [\"Memory recall\", \"evaluated before and after\", \"a period of sleep\"],\n [\"Memory recall\", \"evaluated with and without\", \"interference prior to testing\"],\n [\"Study\", \"assessed\", \"neurocognitive performances\"],\n [\"Ecstasy users\", \"demonstrated\", \"impaired overnight memory consolidation\"],\n [\"Impaired overnight memory consolidation\", \"more pronounced following\", \"associative interference\"],\n [\"Ecstasy users\", \"demonstrated impairments on tasks recruiting\", \"frontostriatal and hippocampal neural circuitry\"],\n [\"Ecstasy users\", \"demonstrated impairments in\", \"proactive interference memory\"],\n [\"Ecstasy users\", \"demonstrated impairments in\", \"long-term memory\"],\n [\"Ecstasy users\", \"demonstrated impairments in\", \"encoding\"],\n [\"Ecstasy users\", \"demonstrated impairments in\", \"working memory\"],\n [\"Ecstasy users\", \"demonstrated impairments in\", \"complex planning\"],\n [\"Ecstasy-associated dysfunction\", \"may underlie\", \"overnight consolidation memory impairments in regular ecstasy users\"]]",
      "Convulsant effect of lindane and regional brain concentration of GABA and dopamine .|Lindane ( gamma - hexachlorocyclohexane ) is an organochlorine insecticide with known neurotoxic effects .|Its mechanism of action is not well understood although it has been proposed that lindane acts as a non - competitive antagonist at the gamma - aminobutyric acid ( GABA ) - A receptor .|We studied the effect of lindane ( 150 mg / kg ) on the GABAergic and dopaminergic systems by measuring the concentration of GABA , dopamine and its metabolites in 7 brain areas at the onset of seizures .|All animals suffered tonic convulsions at 18 . 3 + / - 1 . 4 min after lindane administration .|The concentration of GABA was only slightly but significantly decreased in the colliculi without modifications in the other areas .|The concentration of dopamine was increased in the mesencephalon and that of its metabolite DOPAC was also increased in the mesencephalon and the striatum .": "[[\"Lindane\", \"is a type of\", \"organochlorine insecticide\"], [\"Lindane\", \"has\", \"neurotoxic effects\"], [\"Lindane\", \"acts as\", \"non-competitive antagonist\"], [\"Lindane\", \"targets\", \"GABA-A receptor\"], [\"Study\", \"measured effect of\", \"lindane\"], [\"Lindane\", \"administered at\", \"150 mg/kg\"], [\"Lindane administration\", \"results in\", \"tonic convulsions\"], [\"GABA concentration\", \"decreased in\", \"colliculi\"], [\"Dopamine concentration\", \"increased in\", \"mesencephalon\"], [\"DOPAC concentration\", \"increased in\", \"mesencephalon\"], [\"DOPAC concentration\", \"increased in\", \"striatum\"]]",
      "Prophylactic lidocaine in the early phase of suspected myocardial infarction .|Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double - blind randomized trial of lidocaine vs placebo .|During the 1 hour after administration of the drug the incidence of ventricular fibrillation or sustained ventricular tachycardia among the 204 patients with acute myocardial infarction was low , 1 . 5 % .|Lidocaine , given in a 300 mg dose intramuscularly followed by 100 mg intravenously , did not prevent sustained ventricular tachycardia , although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine ( p less than 0 . 05 ) .|The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction .|The mean plasma lidocaine level of patients on beta - blocking agents was no different from that in patients not on beta blocking agents .|During the 1 - hour study period , the incidence of central nervous system side effects was significantly greater in the lidocaine group , hypotension occurred in 11 patients , nine of whom had received lidocaine , and four patients died from asystole , three of whom had had lidocaine .|We can not advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction .": "[[\"Prophylactic lidocaine\", \"used in\", \"early phase of suspected myocardial infarction\"],\n[\"Patients\", \"entered\", \"double-blind randomized trial\"],\n[\"Patients\", \"seen within\", \"6 hours of onset of symptoms\"],\n[\"Trial\", \"of\", \"lidocaine vs placebo\"],\n[\"Incidence of ventricular fibrillation or sustained ventricular tachycardia\", \"was low among\", \"patients with acute myocardial infarction\"],\n[\"Lidocaine\", \"administered as\", \"300 mg dose intramuscularly followed by 100 mg intravenously\"],\n[\"Lidocaine\", \"did not prevent\", \"sustained ventricular tachycardia\"],\n[\"Lidocaine\", \"caused significant reduction in\", \"warning arrhythmias\"],\n[\"Average plasma lidocaine level\", \"higher in\", \"patients without myocardial infarction\"],\n[\"Mean plasma lidocaine level\", \"no different in\", \"patients on beta-blocking agents vs not on beta-blocking agents\"],\n[\"Incidence of central nervous system side effects\", \"greater in\", \"lidocaine group\"],\n[\"Hypotension\", \"occurred in\", \"patients\"],\n[\"Patients\", \"received\", \"lidocaine\"],\n[\"Patients\", \"died from\", \"asystole\"],\n[\"Administration of lidocaine\", \"not advocated for\", \"prophylactically in early hours of suspected myocardial infarction\"]]",
      "Effects of exercise on the severity of isoproterenol - induced myocardial infarction .|The effect of exercise on the severity of isoproterenol - induced myocardial infarction was studied in male rats .|Ninety - three rats were randomly divided into three groups .|The exercise - isoproterenol ( E - 1 ) and exercise control ( EC ) groups exercised daily for thirty days on a treadmill at 1 mph , 2 % grade while animals of the sedentary - isoproterenol ( S - I ) group remained sedentary .|Eight animals were assigned to the sedentary control ( SC ) group which remained sedentary throughout the experimental period .|Forty - eight hours after the final exercise period , S - I and E - I animals received a single subcutaneous injection of isoproterenol ( 250 mg / kg body weight ) .|Animals of the S - I group exhibited significantly ( Pp less than 0 . 05 ) greater mortality from the effects of isoproterenol than animals of the E - I group .|Serum CPK activity for E - I animals was significantly ( p less than 0 . 05 ) greater than for animals in the S - I and EC groups twenty hours following isoproterenol injection .|No statistically significant differences were observed between the two isoproterenol treated groups for severity of the induced lesions , changes in heart weight , or heart weight to body weight ratios .|The results indicated that exercise reduced the mortality associated with the effects of large dosages of isoproterenol but had little on the severity of the infarction .": "[[\"Effects of exercise\", \"on\", \"severity of isoproterenol-induced myocardial infarction\"],\n[\"Effect of exercise\", \"studied in\", \"male rats\"],\n[\"Ninety-three rats\", \"divided into\", \"three groups\"],\n[\"Exercise-isoproterenol group (E-I)\", \"exercised daily for\", \"thirty days\"],\n[\"Exercise control group (EC)\", \"exercised daily for\", \"thirty days\"],\n[\"Sedentary-isoproterenol group (S-I)\", \"remained\", \"sedentary\"],\n[\"Sedentary control group (SC)\", \"remained\", \"sedentary\"],\n[\"E-I and S-I animals\", \"received\", \"isoproterenol injection\"],\n[\"Isoproterenol injection\", \"dosage\", \"250 mg/kg body weight\"],\n[\"S-I group\", \"exhibited greater\", \"mortality from isoproterenol\"],\n[\"E-I group\", \"had\", \"greater serum CPK activity\"],\n[\"Serum CPK activity\", \"measured\", \"twenty hours following isoproterenol injection\"],\n[\"No significant differences\", \"observed between\", \"isoproterenol treated groups for severity of induced lesions\"],\n[\"No significant differences\", \"observed between\", \"isoproterenol treated groups for changes in heart weight\"],\n[\"No significant differences\", \"observed between\", \"isoproterenol treated groups for heart weight to body weight ratios\"],\n[\"Exercise\", \"reduced\", \"mortality associated with large dosages of isoproterenol\"],\n[\"Exercise\", \"had little effect on\", \"severity of the infarction\"]]",
      "Medial changes in arterial spasm induced by L - norepinephrine .|In normal rats , the media of small arteries ( 0 . 4 - - 0 . 2 mm in diameter ) previously was shown to contain intracellular vacuoles , identified ultrastructurally as herniations of one smooth muscle cell into another .|The hypothesis that intense vasoconstriction would increase the number of such vacuoles has been tested .|In the media of the saphenous artery and its distal branch , vasoconstriction induced by L - norepinephrine produced many cell - to - cell hernias within 15 minutes .|At 1 day their number was reduced to about 1 / 10 of the original number .|By 7 days the vessel was almost restored to normal .|Triple stimulation over 1 day induced more severe changes in the media .|These findings suggest that smooth muscle cells are susceptible to damage in the course of their specific function .|The experimental data are discussed in relation to medial changes observed in other instances of arterial spasm .|Endothelial changes that developed in the same experimental model were described in a previous paper .": "[[\"Medial changes\", \"induced by\", \"L - norepinephrine\"],\n[\"Media of small arteries\", \"previously shown to contain\", \"intracellular vacuoles\"],\n[\"Intracellular vacuoles\", \"identified as\", \"herniations of one smooth muscle cell into another\"],\n[\"Hypothesis\", \"tested for\", \"increase in vacuoles due to intense vasoconstriction\"],\n[\"Vasoconstriction\", \"induced by\", \"L - norepinephrine\"],\n[\"Vasoconstriction\", \"produced\", \"cell-to-cell hernias within 15 minutes\"],\n[\"Number of cell-to-cell hernias\", \"reduced to\", \"about 1/10 of the original number after 1 day\"],\n[\"Vessel\", \"restored to\", \"almost normal by 7 days\"],\n[\"Triple stimulation over 1 day\", \"induced\", \"more severe changes in the media\"],\n[\"Smooth muscle cells\", \"susceptible to\", \"damage in the course of their specific function\"],\n[\"Experimental data\", \"discussed in relation to\", \"medial changes observed in other instances of arterial spasm\"],\n[\"Endothelial changes\", \"developed in\", \"the same experimental model\"],\n[\"Endothelial changes\", \"described in\", \"a previous paper\"]]",
      "Long - term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin .|Basic and clinical research has demonstrated that dementia of sporadic Alzheimer 's disease ( sAD ) type is associated with dysfunction of the insulin - receptor ( IR ) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells .|An alternative source of energy is d - galactose ( the C - 4 - epimer of d - glucose ) which is transported into the brain by insulin - independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway .|Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model , but the effects of oral galactose treatment on cognitive functions have never been tested .|We have investigated the effects of continuous daily oral galactose ( 200 mg / kg / day ) treatment on cognitive deficits in streptozotocin - induced ( STZ - icv ) rat model of sAD , tested by Morris Water Maze and Passive Avoidance test , respectively .|One month of oral galactose treatment initiated immediately after the STZ - icv administration , successfully prevented development of the STZ - icv - induced cognitive deficits .|Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg / kg / day .|Additionally , oral galactose administration led to the appearance of galactose in the blood .|The increase of galactose concentration in the cerebrospinal fluid was several times lower after oral than after parenteral administration of the same galactose dose .|Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD .": "[[\"Long-term oral galactose treatment\", \"prevents\", \"cognitive deficits in male Wistar rats treated with streptozotocin\"],\n[\"Dementia of sporadic Alzheimer's disease type\", \"is associated with\", \"dysfunction of the insulin-receptor system\"],\n[\"Dysfunction of the insulin-receptor system\", \"followed by\", \"decreased glucose transport via GLUT4\"],\n[\"Dysfunction of the insulin-receptor system\", \"followed by\", \"decreased glucose metabolism in brain cells\"],\n[\"D-galactose\", \"is transported into the brain by\", \"insulin-independent GLUT3 transporter\"],\n[\"D-galactose\", \"might be metabolized to\", \"glucose via the Leloir pathway\"],\n[\"Parenteral daily injections of galactose\", \"induce\", \"memory deterioration in rodents\"],\n[\"Parenteral daily injections of galactose\", \"are used to\", \"generate animal aging model\"],\n[\"Effects of oral galactose treatment on cognitive functions\", \"have never been tested\", \"\"],\n[\"Continuous daily oral galactose treatment\", \"investigated for effects on\", \"cognitive deficits in streptozotocin-induced rat model of sAD\"],\n[\"Oral galactose treatment\", \"initiated after\", \"STZ-icv administration\"],\n[\"Oral galactose treatment\", \"prevented\", \"development of STZ-icv-induced cognitive deficits\"],\n[\"Beneficial effect of oral galactose\", \"independent of\", \"rat age\"],\n[\"Beneficial effect of oral galactose\", \"independent of\", \"galactose dose ranging from 100 to 300 mg/kg/day\"],\n[\"Oral galactose administration\", \"led to\", \"appearance of galactose in the blood\"],\n[\"Increase of galactose concentration in cerebrospinal fluid\", \"lower after\", \"oral than after parenteral administration\"],\n[\"Oral galactose exposure\", \"might have beneficial effects on\", \"learning and memory ability\"],\n[\"Oral galactose exposure\", \"could be worth investigating for\", \"improvement of cognitive deficits associated with glucose hypometabolism in AD\"]]",
      "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release , cyclooxygenase gene expression and pain in a clinical pain model .|BACKGROUND : In addition to blocking nociceptive input from surgical sites , long - acting local anesthetics might directly modulate inflammation .|In the present study , we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 ( PGE2 ) production and cyclooxygenase ( COX ) gene expression that increases postoperative pain in human subjects .|METHODS : Subjects ( n = 114 ) undergoing extraction of impacted third molars received either 2 % lidocaine or 0 . 5 % bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h .|Oral mucosal biopsies were taken before surgery and 48 h after surgery .|After extraction , a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 ( TXB2 ) measurements .|RESULTS : The bupivacaine / rofecoxib group reported significantly less pain , as assessed by a visual analog scale , compared with the other three treatment groups over the first 4 h .|However , the bupivacaine / placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups .|Moreover , bupivacaine significantly increased COX - 2 gene expression at 48 h as compared with the lidocaine / placebo group .|Thromboxane levels were not significantly affected by any of the treatments , indicating that the effects seen were attributable to inhibition of COX - 2 , but not COX - 1 .|CONCLUSIONS : These results suggest that bupivacaine stimulates COX - 2 gene expression after tissue injury , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates .": "[[\"bupivacaine\", \"has effects on\", \"prostaglandin E2 release\"],\n [\"bupivacaine\", \"affects\", \"cyclooxygenase gene expression\"],\n [\"bupivacaine\", \"increases\", \"postoperative pain in human subjects\"],\n [\"lidocaine\", \"compared with\", \"bupivacaine\"],\n [\"Subjects\", \"underwent\", \"extraction of impacted third molars\"],\n [\"Subjects\", \"received\", \"2 % lidocaine or 0.5 % bupivacaine\"],\n [\"Subjects\", \"received\", \"rofecoxib 50 mg or placebo\"],\n [\"Oral mucosal biopsies\", \"were taken\", \"before and after surgery\"],\n [\"microdialysis probe\", \"placed at\", \"surgical site\"],\n [\"microdialysis probe\", \"used for measurements of\", \"PGE2 and thromboxane B2\"],\n [\"bupivacaine/rofecoxib group\", \"reported\", \"less pain\"],\n [\"bupivacaine/placebo group\", \"reported\", \"more pain at 24 h\"],\n [\"bupivacaine/placebo group\", \"had higher\", \"PGE2 levels during first 4 h\"],\n [\"bupivacaine\", \"increased\", \"COX-2 gene expression at 48 h\"],\n [\"lidocaine/placebo group\", \"compared with\", \"bupivacaine\"],\n [\"Thromboxane levels\", \"not affected by\", \"treatments\"],\n [\"effects seen\", \"attributable to\", \"inhibition of COX-2\"],\n [\"COX-2 gene expression\", \"associated with\", \"higher PGE2 production\"],\n [\"COX-2 gene expression\", \"associated with\", \"pain after local anesthetic effect dissipates\"]]",
      "Ocular - specific ER stress reduction rescues glaucoma in murine glucocorticoid - induced glaucoma .|Administration of glucocorticoids induces ocular hypertension in some patients .|If untreated , these patients can develop a secondary glaucoma that resembles primary open - angle glaucoma ( POAG ) .|The underlying pathology of glucocorticoid - induced glaucoma is not fully understood , due in part to lack of an appropriate animal model .|Here , we developed a murine model of glucocorticoid - induced glaucoma that exhibits glaucoma features that are observed in patients .|Treatment of WT mice with topical ocular 0 . 1 % dexamethasone led to elevation of intraocular pressure ( IOP ) , functional and structural loss of retinal ganglion cells , and axonal degeneration , resembling glucocorticoid - induced glaucoma in human patients .|Furthermore , dexamethasone - induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork ( TM ) .|Similar to patients , withdrawal of dexamethasone treatment reduced elevated IOP and ER stress in this animal model .|Dexamethasone induced the transcriptional factor CHOP , a marker for chronic ER stress , in the anterior segment tissues , and Chop deletion reduced ER stress in these tissues and prevented dexamethasone - induced ocular hypertension .|Furthermore , reduction of ER stress in the TM with sodium 4 - phenylbutyrate prevented dexamethasone - induced ocular hypertension in WT mice .|Our data indicate that ER stress contributes to glucocorticoid - induced ocular hypertension and suggest that reducing ER stress has potential as a therapeutic strategy for treating glucocorticoid - induced glaucoma .": "[[\"Ocular-specific ER stress reduction\", \"rescues\", \"murine glucocorticoid-induced glaucoma\"],\n[\"Administration of glucocorticoids\", \"induces\", \"ocular hypertension\"],\n[\"Patients\", \"can develop\", \"secondary glaucoma\"],\n[\"Secondary glaucoma\", \"resembles\", \"primary open-angle glaucoma (POAG)\"],\n[\"Pathology of glucocorticoid-induced glaucoma\", \"is not fully understood\", \"\"],\n[\"Researchers\", \"developed\", \"murine model of glucocorticoid-induced glaucoma\"],\n[\"Murine model of glucocorticoid-induced glaucoma\", \"exhibits\", \"glaucoma features observed in patients\"],\n[\"Treatment with topical ocular 0.1% dexamethasone\", \"led to\", \"elevation of intraocular pressure (IOP)\"],\n[\"Treatment with topical ocular 0.1% dexamethasone\", \"caused\", \"functional and structural loss of retinal ganglion cells\"],\n[\"Treatment with topical ocular 0.1% dexamethasone\", \"caused\", \"axonal degeneration\"],\n[\"Dexamethasone-induced ocular hypertension\", \"was associated with\", \"chronic ER stress of the trabecular meshwork (TM)\"],\n[\"Withdrawal of dexamethasone treatment\", \"reduced\", \"elevated IOP\"],\n[\"Withdrawal of dexamethasone treatment\", \"reduced\", \"ER stress\"],\n[\"Dexamethasone\", \"induced\", \"transcriptional factor CHOP\"],\n[\"CHOP\", \"is a marker for\", \"chronic ER stress\"],\n[\"Chop deletion\", \"reduced\", \"ER stress in anterior segment tissues\"],\n[\"Chop deletion\", \"prevented\", \"dexamethasone-induced ocular hypertension\"],\n[\"Reduction of ER stress in the TM\", \"prevented\", \"dexamethasone-induced ocular hypertension in WT mice\"],\n[\"ER stress\", \"contributes to\", \"glucocorticoid-induced ocular hypertension\"],\n[\"Reducing ER stress\", \"has potential as\", \"therapeutic strategy for treating glucocorticoid-induced glaucoma\"]]",
      "Safety and compliance with once - daily niacin extended - release / lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment ( IMPACT ) study .|Niacin extended - release / lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia .|This open - labeled , multicenter study evaluated the safety of bedtime niacin extended - release / lovastatin when dosed as initial therapy and patient compliance to treatment in various clinical practice settings .|A total of 4 , 499 patients with dyslipidemia requiring drug intervention was enrolled at 1 , 081 sites .|Patients were treated with 1 tablet ( 500 mg of niacin extended - release / 20 mg of lovastatin ) once nightly for 4 weeks and then 2 tablets for 8 weeks .|Patients also received dietary counseling , educational materials , and reminders to call a toll - free number that provided further education about dyslipidemia and niacin extended - release / lovastatin .|Primary end points were study compliance , increases in liver transaminases to > 3 times the upper limit of normal , and clinical myopathy .|Final study status was available for 4 , 217 patients ( 94 % ) .|Compliance to niacin extended - release / lovastatin was 77 % , with 3 , 245 patients completing the study .|Patients in the southeast and those enrolled by endocrinologists had the lowest compliance and highest adverse event rates .|Flushing was the most common adverse event , reported by 18 % of patients and leading to discontinuation by 6 % .|Incidence of increased aspartate aminotransferase and / or alanine aminotransferase > 3 times the upper limit of normal was < 0 . 3 % .|An increase of creatine phosphokinase to > 5 times the upper limit of normal occurred in 0 . 24 % of patients , and no cases of drug - induced myopathy were observed .|Niacin extended - release / lovastatin 1 , 000 / 40 mg , dosed as initial therapy , was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes .": "[[\"Niacin extended-release/lovastatin\", \"is approved for\", \"treatment of primary hypercholesterolemia and mixed dyslipidemia\"],\n[\"Study\", \"evaluated\", \"safety of niacin extended-release/lovastatin\"],\n[\"Study\", \"evaluated\", \"patient compliance to niacin extended-release/lovastatin\"],\n[\"Patients\", \"were enrolled with\", \"dyslipidemia requiring drug intervention\"],\n[\"Patients\", \"were treated with\", \"niacin extended-release/lovastatin\"],\n[\"Patients\", \"received\", \"dietary counseling\"],\n[\"Patients\", \"received\", \"educational materials\"],\n[\"Patients\", \"received\", \"reminders to call a toll-free number\"],\n[\"Toll-free number\", \"provided\", \"further education about dyslipidemia and niacin extended-release/lovastatin\"],\n[\"Primary end points\", \"were\", \"study compliance\"],\n[\"Primary end points\", \"were\", \"increases in liver transaminases\"],\n[\"Primary end points\", \"were\", \"clinical myopathy\"],\n[\"Compliance to niacin extended-release/lovastatin\", \"was\", \"77%\"],\n[\"Patients in the southeast and those enrolled by endocrinologists\", \"had\", \"the lowest compliance\"],\n[\"Patients in the southeast and those enrolled by endocrinologists\", \"had\", \"highest adverse event rates\"],\n[\"Flushing\", \"was the most common adverse event\", \"\"],\n[\"Flushing\", \"led to\", \"discontinuation by 6% of patients\"],\n[\"Incidence of increased aspartate aminotransferase and/or alanine aminotransferase\", \"was\", \"< 0.3%\"],\n[\"Increase of creatine phosphokinase\", \"occurred in\", \"0.24% of patients\"],\n[\"No cases\", \"were observed of\", \"drug-induced myopathy\"],\n[\"Niacin extended-release/lovastatin 1,000/40 mg\", \"was associated with\", \"good compliance\"],\n[\"Niacin extended-release/lovastatin 1,000/40 mg\", \"was associated with\", \"safety\"],\n[\"Niacin extended-release/lovastatin 1,000/40 mg\", \"had very low incidences of\", \"increased liver and muscle enzymes\"]]",
      "Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas .|Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters .|Radiolabelling , following the in vivo injection of 3H - 17 beta estradiol , was increased only over the nuclei of tumor cells ; stereologic analysis revealed a 4 . 5 - to 6 . 7 - times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells .|Despite rapid tubular excretion of estradiol which peaked in less than 1 h , the normal cells did not appear to bind the ligand .|This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas .": "[[\"Autoradiographic evidence\", \"is of\", \"estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas\"],\n[\"Estrogen binding sites\", \"were demonstrated by\", \"autoradiography\"],\n[\"Estrogen binding sites\", \"found in\", \"one transplantable and five primary diethylstilbesterol induced renal carcinomas\"],\n[\"Estrogen binding sites\", \"found in\", \"three hamsters\"],\n[\"Radiolabelling\", \"follows\", \"in vivo injection of 3H - 17 beta estradiol\"],\n[\"Radiolabelling\", \"was increased\", \"over the nuclei of tumor cells\"],\n[\"Stereologic analysis\", \"revealed\", \"higher concentration of reduced silver grains over nuclei than cytoplasm\"],\n[\"Concentration\", \"is\", \"4.5 to 6.7 times higher in nuclei than cytoplasm\"],\n[\"Rapid tubular excretion of estradiol\", \"peaked in\", \"less than 1 h\"],\n[\"Normal cells\", \"did not\", \"bind the ligand\"],\n[\"Report\", \"documents\", \"preferential in vivo binding of estrogen\"],\n[\"Estrogen\", \"binds preferentially to\", \"nuclei of cells in estrogen induced hamster renal carcinomas\"]]",
      "Positive skin tests in late reactions to radiographic contrast media .|In the last few years delayed reactions several hours after the injection of radiographic and contrast materials ( PRC ) have been described with increasing frequency .|The authors report two observations on patients with delayed reactions in whom intradermoreactions ( IDR ) and patch tests to a series of ionic and non ionic PRC were studied .|After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction ( dyspnea , loss of consciousness ) and delayed macro - papular rash appeared , whilst patient n degree 2 developed a generalised sensation of heat , persistent pain at the site of injection immediately and a generalised macro - papular reaction after 24 hours .|The skin tests revealed positive delayed reactions of 24 hours and 48 hours by IDR and patch tests to only some PRC with common chains in their structures .|The positive skin tests are in favour of immunological reactions and may help in diagnosis of allergy in the patients .": "[[\"Positive skin tests\", \"indicate\", \"late reactions to radiographic contrast media\"],\n [\"Delayed reactions\", \"occur several hours after\", \"injection of radiographic and contrast materials\"],\n [\"Authors\", \"report\", \"observations on patients with delayed reactions\"],\n [\"Patients with delayed reactions\", \"were studied with\", \"intradermoreactions (IDR) and patch tests\"],\n [\"Patient n degree 1\", \"had\", \"biphasic reaction after angiography by the venous route\"],\n [\"Patient n degree 1\", \"experienced\", \"immediate reaction (dyspnea, loss of consciousness)\"],\n [\"Patient n degree 1\", \"developed\", \"delayed macro-papular rash\"],\n [\"Patient n degree 2\", \"developed\", \"generalised sensation of heat immediately\"],\n [\"Patient n degree 2\", \"had\", \"persistent pain at the site of injection immediately\"],\n [\"Patient n degree 2\", \"developed\", \"generalised macro-papular reaction after 24 hours\"],\n [\"Skin tests\", \"revealed\", \"positive delayed reactions of 24 hours and 48 hours\"],\n [\"IDR and patch tests\", \"were positive to\", \"some PRC with common chains in their structures\"],\n [\"Positive skin tests\", \"are in favour of\", \"immunological reactions\"],\n [\"Positive skin tests\", \"may help in\", \"diagnosis of allergy in the patients\"]]",
      "Progressive bile duct injury after thiabendazole administration .|A 27 - yr - old man developed jaundice 2 wk after exposure to thiabendazole .|Cholestasis persisted for 3 yr , at which time a liver transplant was performed .|Two liver biopsy specimens and the hepatectomy specimen were remarkable for almost complete disappearance of interlobular bile ducts .|Prominent fibrosis and hepatocellular regeneration were also present ; however , the lobular architecture was preserved .|This case represents an example of \" idiosyncratic \" drug - induced liver damage in which the primary target of injury is the bile duct .|An autoimmune pathogenesis of the bile duct destruction is suggested .": "[[\"Progressive bile duct injury\", \"after\", \"thiabendazole administration\"],\n [\"27 - yr - old man\", \"developed\", \"jaundice\"],\n [\"jaundice\", \"occurred\", \"2 wk after exposure to thiabendazole\"],\n [\"Cholestasis\", \"persisted for\", \"3 yr\"],\n [\"27 - yr - old man\", \"had\", \"liver transplant\"],\n [\"liver transplant\", \"performed at\", \"3 yr after cholestasis persisted\"],\n [\"Two liver biopsy specimens and the hepatectomy specimen\", \"were remarkable for\", \"almost complete disappearance of interlobular bile ducts\"],\n [\"specimens\", \"showed\", \"prominent fibrosis\"],\n [\"specimens\", \"showed\", \"hepatocellular regeneration\"],\n [\"lobular architecture\", \"was\", \"preserved\"],\n [\"case\", \"represents\", \"example of idiosyncratic drug-induced liver damage\"],\n [\"primary target of injury\", \"is\", \"the bile duct\"],\n [\"autoimmune pathogenesis\", \"suggested for\", \"bile duct destruction\"]]",
      "Factors contributing to ribavirin - induced anemia .|BACKGROUND AND AIM : Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia .|This study was conducted to identify the factors contributing to ribavirin - induced anemia .|METHODS : Eighty - eight patients with chronic hepatitis C who received interferon - alpha - 2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study .|A hemoglobin concentration of < 10 g / dL was defined as ribavirin - induced anemia .|RESULTS : Ribavirin - induced anemia occurred in 18 ( 20 . 5 % ) patients during treatment .|A 2 g / dL decrease in hemoglobin concentrations in patients with anemia was observed at week 2 after the start of treatment .|The hemoglobin concentration in patients with > or = 2 g / dL decrease at week 2 was observed to be significantly lower even after week 2 than in patients with < 2 g / dL decrease ( P < 0 . 01 ) .|A significant relationship was observed between the rate of reduction of hemoglobin concentrations at week 2 and the severity of anemia ( P < 0 . 01 ) .|Such factors as sex ( female ) , age ( > or = 60 years old ) , and the ribavirin dose by body weight ( 12 mg / kg or more ) were significant by univariate analysis .|CONCLUSIONS : Careful administration is necessary in patients > or = 60 years old , in female patients , and in patients receiving a ribavirin dose of 12 mg / kg or more .|Patients who experience a fall in hemoglobin concentrations of 2 g / dL or more at week 2 after the start of treatment should be monitored with particular care .": "[[\"Interferon and ribavirin combination therapy\", \"produces\", \"hemolytic anemia\"],\n[\"Study\", \"conducted to identify\", \"factors contributing to ribavirin-induced anemia\"],\n[\"Patients\", \"received\", \"interferon-alpha-2b\"],\n[\"Patients\", \"received\", \"ribavirin\"],\n[\"Ribavirin-induced anemia\", \"defined as\", \"hemoglobin concentration of < 10 g/dL\"],\n[\"Ribavirin-induced anemia\", \"occurred in\", \"18 (20.5%) patients\"],\n[\"Anemia in patients\", \"observed at\", \"week 2 after start of treatment\"],\n[\"Hemoglobin concentration\", \"significantly lower in patients with > or = 2 g/dL decrease at week 2\", \"compared to patients with < 2 g/dL decrease\"],\n[\"Rate of reduction of hemoglobin concentrations at week 2\", \"related to\", \"severity of anemia\"],\n[\"Sex (female)\", \"significant factor by univariate analysis\", \"ribavirin-induced anemia\"],\n[\"Age (> or = 60 years old)\", \"significant factor by univariate analysis\", \"ribavirin-induced anemia\"],\n[\"Ribavirin dose by body weight (12 mg/kg or more)\", \"significant factor by univariate analysis\", \"ribavirin-induced anemia\"],\n[\"Careful administration\", \"necessary in patients\", \"> or = 60 years old\"],\n[\"Careful administration\", \"necessary in\", \"female patients\"],\n[\"Careful administration\", \"necessary in patients receiving\", \"ribavirin dose of 12 mg/kg or more\"],\n[\"Patients with hemoglobin concentrations fall of 2 g/dL or more at week 2\", \"should be monitored with particular care\", \"after start of treatment\"]]",
      "Five cases of encephalitis during treatment of loiasis with diethylcarbamazine .|Five cases of encephalitis following treatment with diethylcarbamazine ( DEC ) were observed in Congolese patients with Loa loa filariasis .|Two cases had a fatal outcome and one resulted in severe sequelae .|The notable fact was that this complication occurred in three patients hospitalized before treatment began , with whom particularly strict therapeutic precautions were taken , i . e . , initial dose less than 10 mg of DEC , very gradual dose increases , and associated anti - allergic treatment .|This type of drug - induced complication may not be that uncommon in highly endemic regions .|It occurs primarily , but not exclusively , in subjects presenting with a high microfilarial load .|The relationship between the occurrence of encephalitis and the decrease in microfilaremia is evident .|The pathophysiological mechanisms are discussed in the light of these observations and the few other comments on this subject published in the literature .": "[[\"Five cases\", \"of\", \"encephalitis\"], [\"encephalitis\", \"during treatment with\", \"diethylcarbamazine\"], [\"encephalitis\", \"following treatment with\", \"diethylcarbamazine\"], [\"Five cases\", \"observed in\", \"Congolese patients\"], [\"Congolese patients\", \"with\", \"Loa loa filariasis\"], [\"Two cases\", \"had\", \"fatal outcome\"], [\"One case\", \"resulted in\", \"severe sequelae\"], [\"This complication\", \"occurred in\", \"three patients\"], [\"Three patients\", \"hospitalized before\", \"treatment began\"], [\"Therapeutic precautions\", \"taken\", \"particularly strict\"], [\"Initial dose\", \"less than\", \"10 mg of DEC\"], [\"Dose increases\", \"very\", \"gradual\"], [\"Treatment\", \"associated with\", \"anti-allergic treatment\"], [\"Drug-induced complication\", \"may be\", \"not uncommon\"], [\"Drug-induced complication\", \"in\", \"highly endemic regions\"], [\"It occurs\", \"primarily in\", \"subjects with high microfilarial load\"], [\"Occurrence of encephalitis\", \"related to\", \"decrease in microfilaremia\"], [\"Pathophysiological mechanisms\", \"discussed in\", \"the light of these observations\"], [\"Comments\", \"published in\", \"the literature\"]]",
      "Nelarabine neurotoxicity with concurrent intrathecal chemotherapy : Case report and review of literature .|Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal ( IT ) chemotherapy is reported .|A 37 - year - old Caucasian woman with a history of T - cell lymphoblastic lymphoma was admitted for relapsed disease .|She was originally treated with induction chemotherapy followed by an autologous transplant .|She developed relapsed disease 10 months later with leukemic involvement .|She was re - induced with nelarabine 1500 mg / m ( 2 ) on days 1 , 3 , and 5 with 1 dose of IT cytarabine 100 mg on day 2 as central nervous system ( CNS ) prophylaxis .|At the time of treatment , she was on continuous renal replacement therapy due to sequelae of tumor lysis syndrome ( TLS ) .|She tolerated therapy well , entered a complete remission , and recovered her renal function .|She received a second cycle of nelarabine without additional IT prophylaxis one month later .|A week after this second cycle , she noted numbness in her lower extremities .|Predominantly sensory , though also motor and autonomic , peripheral neuropathy started in her feet , ascended proximally to the mid - thoracic region , and eventually included her distal upper extremities .|A magnetic resonance imaging ( MRI ) of her spine demonstrated changes from C2 to C6 consistent with subacute combined degeneration .|Nelarabine was felt to be the cause of her symptoms .|Her neuropathy stabilized and showed slight improvement and ultimately received an unrelated , reduced - intensity allogeneic transplant while in complete remission , but relapsed disease 10 weeks later .|She is currently being treated with best supportive care .|To our knowledge , this is the first published case report of severe neurotoxicity caused by nelarabine in a patient who received concurrent IT chemotherapy .": "[[\"Nelarabine neurotoxicity\", \"occurs with\", \"concurrent intrathecal chemotherapy\"],\n [\"Severe nelarabine neurotoxicity\", \"reported in\", \"a patient\"],\n [\"Patient\", \"received\", \"concurrent intrathecal (IT) chemotherapy\"],\n [\"Patient\", \"is a\", \"37-year-old Caucasian woman\"],\n [\"Patient\", \"has a history of\", \"T-cell lymphoblastic lymphoma\"],\n [\"Patient\", \"was admitted for\", \"relapsed disease\"],\n [\"Patient\", \"was treated with\", \"induction chemotherapy\"],\n [\"Patient\", \"underwent\", \"autologous transplant\"],\n [\"Patient\", \"developed\", \"relapsed disease 10 months later\"],\n [\"Relapsed disease\", \"involved\", \"leukemic involvement\"],\n [\"Patient\", \"was re-induced with\", \"nelarabine\"],\n [\"Nelarabine dosage\", \"was\", \"1500 mg/m(2) on days 1, 3, and 5\"],\n [\"Patient\", \"received\", \"1 dose of IT cytarabine 100 mg on day 2\"],\n [\"IT cytarabine\", \"used for\", \"CNS prophylaxis\"],\n [\"At the time of treatment\", \"patient was on\", \"continuous renal replacement therapy\"],\n [\"Continuous renal replacement therapy\", \"due to\", \"sequelae of tumor lysis syndrome (TLS)\"],\n [\"Patient\", \"tolerated\", \"therapy\"],\n [\"Patient\", \"entered\", \"complete remission\"],\n [\"Patient\", \"recovered\", \"renal function\"],\n [\"Patient\", \"received\", \"second cycle of nelarabine\"],\n [\"Second cycle of nelarabine\", \"was without\", \"additional IT prophylaxis\"],\n [\"Patient\", \"noted numbness in\", \"lower extremities\"],\n [\"Patient developed\", \"peripheral neuropathy\", \"sensory, motor and autonomic\"],\n [\"Peripheral neuropathy\", \"started in\", \"feet\"],\n [\"Peripheral neuropathy\", \"ascended to\", \"mid-thoracic region\"],\n [\"Peripheral neuropathy\", \"included\", \"distal upper extremities\"],\n [\"MRI of spine\", \"demonstrated changes\", \"from C2 to C6\"],\n [\"Changes in spine\", \"consistent with\", \"subacute combined degeneration\"],\n [\"Nelarabine\", \"felt to be\", \"cause of symptoms\"],\n [\"Patient's neuropathy\", \"stabilized and showed\", \"slight improvement\"],\n [\"Patient\", \"received\", \"unrelated, reduced-intensity allogeneic transplant\"],\n [\"Patient\", \"was in\", \"complete remission\"],\n [\"Patient\", \"relapsed\", \"10 weeks later\"],\n [\"Patient\", \"is being treated with\", \"best supportive care\"],\n [\"Case report\", \"is the first published\", \"of severe neurotoxicity caused by nelarabine\"],\n [\"Severe neurotoxicity\", \"caused by\", \"nelarabine\"],\n [\"Patient\", \"received\", \"concurrent IT chemotherapy\"]]",
      "Studies on the bradycardia induced by bepridil .|Bepridil , a novel active compound for prophylactic treatment of anginal attacks , induced persistent bradycardia and a non - specific anti - tachycardial effect , the mechanisms of which were investigated in vitro and in vivo .|In vitro perfusion of bepridil in the life - support medium for isolated sino - atrial tissue from rabbit heart , caused a reduction in action potential ( AP ) spike frequency ( recorded by KCl microelectrodes ) starting at doses of 5 X 10 ( - 6 ) M .|This effect was dose - dependent up to concentrations of 5 X 10 ( - 5 ) M , whereupon blockade of sinus activity set in .|Bepridil at a dose of 5 X 10 ( - 6 ) M , induced a concomitant reduction in AP amplitude ( falling from 71 + / - 8 mV to 47 + / - 6 mV ) , maximum systolic depolarization velocity ( phase 0 ) which fell from 1 . 85 + / - 0 . 35 V / s to 0 . 84 + / - 0 . 28 V / s , together with maximum diastolic depolarization velocity ( phase 4 ) which fell from 38 + / - 3 mV / s to 24 + / - 5 mV / s .|In vivo injection of bepridil at a dose of 5 mg / kg ( i . v . ) into 6 anaesthetized dogs which had undergone ablation of all the extrinsic cardiac afferent nerve supply , together with a bilateral medullo - adrenalectomy , caused a marked reduction in heart rate which fell from 98 . 7 + / - 4 . 2 beats / min to 76 + / - 5 . 3 beats / min sustained for more than 45 min .|It is concluded that bepridil reduces heart rate by acting directly on the sinus node .|This effect , which results in a flattening of the phase 0 and phase 4 slope , together with a longer AP duration , may be due to an increase in the time constants of slow inward ionic currents ( already demonstrated elsewhere ) , but also to an increased time constant for deactivation of the outward potassium current ( Ip ) .": "[[\"Bepridil\", \"induces\", \"bradycardia\"],\n[\"Bepridil\", \"is for\", \"prophylactic treatment of anginal attacks\"],\n[\"Bepridil\", \"has\", \"anti-tachycardial effect\"],\n[\"Mechanisms\", \"were investigated by\", \"in vitro and in vivo studies\"],\n[\"Bepridil\", \"caused reduction in\", \"action potential spike frequency\"],\n[\"Bepridil\", \"has effect starting at doses of\", \"5 X 10(-6) M\"],\n[\"Effect of Bepridil\", \"is dose-dependent up to\", \"5 X 10(-5) M\"],\n[\"Bepridil\", \"causes\", \"blockade of sinus activity\"],\n[\"Bepridil at 5 X 10(-6) M\", \"induces reduction in\", \"AP amplitude\"],\n[\"Bepridil at 5 X 10(-6) M\", \"reduces\", \"maximum systolic depolarization velocity\"],\n[\"Bepridil at 5 X 10(-6) M\", \"reduces\", \"maximum diastolic depolarization velocity\"],\n[\"In vivo injection of Bepridil\", \"causes\", \"reduction in heart rate\"],\n[\"Bepridil\", \"acts directly on\", \"sinus node\"],\n[\"Bepridil\", \"results in\", \"flattening of phase 0 and phase 4 slope\"],\n[\"Bepridil\", \"prolongs\", \"AP duration\"],\n[\"Bepridil\", \"may increase time constants of\", \"slow inward ionic currents\"],\n[\"Bepridil\", \"may increase time constant for deactivation of\", \"outward potassium current (Ip)\"]]",
      "Phenytoin encephalopathy as probable idiosyncratic reaction : case report .|A case of phenytoin ( DPH ) encephalopathy with increasing seizures and EEG and mental changes is described .|Despite adequate oral dosage of DPH ( 5 mg / kg / daily ) the plasma level was very low ( 2 . 8 microgramg / ml ) .|The encephalopathy was probably an idiosyncratic and not toxic or allergic reaction .|In fact the concentration of free DPH was normal , the patient presented a retarded morbilliform rash during DPH treatment , the protidogram was normal , and an intradermic DPH injection had no local effect .|The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures , with EEG and mental changes occurring simultaneously , should alert the physician to the possible need for eliminating DPH from the therapeutic regimen , even if plasma concentrations are low .": "[[\"Phenytoin encephalopathy\", \"characterized as\", \"probable idiosyncratic reaction\"],\n [\"Case report\", \"describes\", \"phenytoin encephalopathy\"],\n [\"Phenytoin encephalopathy\", \"associated with\", \"increasing seizures\"],\n [\"Phenytoin encephalopathy\", \"associated with\", \"EEG changes\"],\n [\"Phenytoin encephalopathy\", \"associated with\", \"mental changes\"],\n [\"DPH\", \"administered at\", \"adequate oral dosage\"],\n [\"Adequate oral dosage of DPH\", \"specified as\", \"5 mg/kg/daily\"],\n [\"Plasma level of DPH\", \"was\", \"very low\"],\n [\"Very low plasma level of DPH\", \"quantified as\", \"2.8 microgram/ml\"],\n [\"Encephalopathy\", \"considered\", \"idiosyncratic\"],\n [\"Encephalopathy\", \"not considered\", \"toxic\"],\n [\"Encephalopathy\", \"not considered\", \"allergic reaction\"],\n [\"Concentration of free DPH\", \"was\", \"normal\"],\n [\"Patient\", \"presented\", \"retarded morbilliform rash\"],\n [\"Retarded morbilliform rash\", \"occurred during\", \"DPH treatment\"],\n [\"Protidogram\", \"was\", \"normal\"],\n [\"Intradermic DPH injection\", \"had\", \"no local effect\"],\n [\"Authors\", \"conclude\", \"possibility of eliminating DPH\"],\n [\"Unexpected increase in seizures\", \"should alert\", \"physician\"],\n [\"EEG and mental changes\", \"occurring simultaneously\", \"should alert physician\"],\n [\"Possible need for eliminating DPH\", \"due to\", \"unexpected increase in seizures with EEG and mental changes\"],\n [\"Plasma concentrations\", \"being\", \"low\"]]",
      "Contrast medium nephrotoxicity after renal artery and coronary angioplasty .|BACKGROUND : Renal dysfunction induced by iodinated contrast medium ( CM ) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty ( PTRA ) .|PURPOSE : To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention ( PCI ) .|MATERIAL AND METHODS : A total of 33 patients successfully treated with PTRA ( PTRA group , mean age 70 + / - 12 years , 23 female , basal creatinine 1 . 46 + / - 0 . 79 , range 0 . 7 - 4 . 9 mg / dl ) were compared with 33 patients undergoing successful PCI ( PCI group ) , matched for basal creatinine ( 1 . 44 + / - 0 . 6 , range 0 . 7 - 3 . 4 mg / dl ) , gender , and age .|In both groups postprocedural ( 48 h ) serum creatinine was measured .|RESULTS : Postprocedural creatinine level decreased nonsignificantly in the PTRA group ( 1 . 46 + / - 0 . 8 vs . 1 . 34 + / - 0 . 5 mg / dl , P = NS ) and increased significantly in the PCI group ( 1 . 44 + / - 0 . 6 vs . 1 . 57 + / - 0 . 7 mg / dl , P < 0 . 02 ) .|Changes in serum creatinine after intervention ( after - before ) were significantly different between the PTRA and PCI groups ( - 0 . 12 + / - 0 . 5 vs . 0 . 13 + / - 0 . 3 , P = 0 . 014 ) .|This difference was not related to either a different clinical risk profile or to the volume of CM administered .|CONCLUSION : In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients .|The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity .": "[[\"Contrast medium nephrotoxicity\", \"occurs after\", \"renal artery and coronary angioplasty\"],\n[\"Renal dysfunction\", \"induced by\", \"iodinated contrast medium administration\"],\n[\"Renal dysfunction\", \"can minimize\", \"benefit of interventional procedure\"],\n[\"Patients undergoing renal angioplasty\", \"referred to as\", \"PTRA\"],\n[\"Patients submitted to percutaneous coronary intervention\", \"referred to as\", \"PCI\"],\n[\"Study\", \"compares\", \"susceptibility to nephrotoxic effect of CM in PTRA and PCI patients\"],\n[\"PTRA group\", \"had\", \"33 patients\"],\n[\"PTRA group\", \"mean age\", \"70 +/- 12 years\"],\n[\"PTRA group\", \"gender composition\", \"23 female\"],\n[\"PTRA group\", \"basal creatinine level\", \"1.46 +/- 0.79 mg/dl\"],\n[\"PCI group\", \"compared with\", \"PTRA group\"],\n[\"PCI group\", \"had\", \"33 patients\"],\n[\"PCI group\", \"matched for basal creatinine\", \"1.44 +/- 0.6 mg/dl\"],\n[\"Postprocedural serum creatinine\", \"measured in\", \"both groups\"],\n[\"Postprocedural creatinine level\", \"decreased nonsignificantly in\", \"PTRA group\"],\n[\"Postprocedural creatinine level\", \"increased significantly in\", \"PCI group\"],\n[\"Changes in serum creatinine after intervention\", \"were significantly different between\", \"PTRA and PCI groups\"],\n[\"Difference in changes of serum creatinine\", \"not related to\", \"different clinical risk profile\"],\n[\"Difference in changes of serum creatinine\", \"not related to\", \"volume of CM administered\"],\n[\"Patients submitted to PTRA\", \"showed lower susceptibility to\", \"renal damage induced by CM\"],\n[\"Effectiveness of PTRA on renal function\", \"barely influenced by\", \"CM toxicity\"]]",
      "Meloxicam - induced liver toxicity .|We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam .|Recently introduced in Belgium , meloxicam is the first nonsteroidal antiinflammatory drug with selective action on the inducible form of cyclooxygenase 2 .|The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism .|This first case of meloxicam related liver toxicity demonstrates the potential of this drug to induce hepatic damage .": "[[\"Meloxicam\", \"induces\", \"liver toxicity\"],\n[\"Female patient\", \"developed\", \"acute cytolytic hepatitis due to meloxicam\"],\n[\"Female patient\", \"has\", \"rheumatoid arthritis\"],\n[\"Meloxicam\", \"introduced in\", \"Belgium\"],\n[\"Meloxicam\", \"is a\", \"nonsteroidal antiinflammatory drug\"],\n[\"Meloxicam\", \"has selective action on\", \"inducible form of cyclooxygenase 2\"],\n[\"Acute cytolytic hepatitis\", \"occurred after\", \"meloxicam administration\"],\n[\"Acute cytolytic hepatitis\", \"was associated with\", \"development of antinuclear antibodies\"],\n[\"Development of antinuclear antibodies\", \"suggests\", \"hypersensitivity mechanism\"],\n[\"First case of meloxicam related liver toxicity\", \"demonstrates\", \"potential of meloxicam to induce hepatic damage\"]]",
      "Prevention of etomidate - induced myoclonus : which is superior : Fentanyl , midazolam , or a combination ? A Retrospective comparative study .|BACKGROUND : In this retrospective comparative study , we aimed to compare the effectiveness of fentanyl , midazolam , and a combination of fentanyl and midazolam to prevent etomidate - induced myoclonus .|MATERIAL AND METHODS : This study was performed based on anesthesia records .|Depending on the drugs that would be given before the induction of anesthesia with etomidate , the patients were separated into 4 groups : no pretreatment ( Group NP ) , fentanyl 1 ug . kg - 1 ( Group F ) , midazolam 0 . 03 mg . kg - 1 ( Group M ) , and midazolam 0 . 015 mg . kg - 1 + fentanyl 0 . 5 ug . kg - 1 ( Group FM ) .|Patients who received the same anesthetic procedure were selected : 2 minutes after intravenous injections of the pretreatment drugs , anesthesia is induced with 0 . 3 mg . kg - 1 etomidate injected intravenously over a period of 20 - 30 seconds .|Myoclonic movements are evaluated , which were observed and graded according to clinical severity during the 2 minutes after etomidate injection .|The severity of pain due to etomidate injection , mean arterial pressure , heart rate , and adverse effects were also evaluated .|RESULTS : Study results showed that myoclonus incidence was 85 % , 40 % , 70 % , and 25 % in Group NP , Group F , Group M , and Group FM , respectively , and were significantly lower in Group F and Group FM .|CONCLUSIONS : We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate - induced myoclonus .": "[[\"Prevention of etomidate-induced myoclonus\", \"compared effectiveness of\", \"fentanyl\"],\n[\"Prevention of etomidate-induced myoclonus\", \"compared effectiveness of\", \"midazolam\"],\n[\"Prevention of etomidate-induced myoclonus\", \"compared effectiveness of\", \"combination of fentanyl and midazolam\"],\n[\"Study\", \"performed based on\", \"anesthesia records\"],\n[\"Patients\", \"separated into groups based on\", \"pretreatment drugs\"],\n[\"Group NP\", \"received\", \"no pretreatment\"],\n[\"Group F\", \"received\", \"fentanyl 1 ug/kg\"],\n[\"Group M\", \"received\", \"midazolam 0.03 mg/kg\"],\n[\"Group FM\", \"received\", \"midazolam 0.015 mg/kg + fentanyl 0.5 ug/kg\"],\n[\"Anesthesia\", \"induced with\", \"etomidate\"],\n[\"Myoclonic movements\", \"evaluated and graded after\", \"etomidate injection\"],\n[\"Study results\", \"showed myoclonus incidence\", \"85% in Group NP\"],\n[\"Study results\", \"showed myoclonus incidence\", \"40% in Group F\"],\n[\"Study results\", \"showed myoclonus incidence\", \"70% in Group M\"],\n[\"Study results\", \"showed myoclonus incidence\", \"25% in Group FM\"],\n[\"Group F and Group FM\", \"had significantly lower\", \"myoclonus incidence\"],\n[\"Pretreatment with fentanyl\", \"effective in preventing\", \"etomidate-induced myoclonus\"],\n[\"Pretreatment with combination of fentanyl and midazolam\", \"effective in preventing\", \"etomidate-induced myoclonus\"]]",
      "Metallothionein induction reduces caspase - 3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine - treated rats .|Hippocampal integrity is essential for cognitive functions .|On the other hand , induction of metallothionein ( MT ) by ZnSO ( 4 ) and its role in neuroprotection has been documented .|The present study aimed to explore the effect of MT induction on carmustine ( BCNU ) - induced hippocampal cognitive dysfunction in rats .|A total of 60 male Wistar albino rats were randomly divided into four groups ( 15 / group ) : The control group injected with single doses of normal saline ( i . c . v ) followed 24 h later by BCNU solvent ( i . v ) .|The second group administered ZnSO ( 4 ) ( 0 . 1 micromol / 10 microl normal saline , i . c . v , once ) then BCNU solvent ( i . v ) after 24 h .|Third group received BCNU ( 20 mg / kg , i . v , once ) 24 h after injection with normal saline ( i . c . v ) .|Fourth group received a single dose of ZnSO ( 4 ) ( 0 . 1 micromol / 10 microl normal saline , i . c . v ) then BCNU ( 20 mg / kg , i . v , once ) after 24 h .|The obtained data revealed that BCNU administration resulted in deterioration of learning and short - term memory ( STM ) , as measured by using radial arm water maze , accompanied with decreased hippocampal glutathione reductase ( GR ) activity and reduced glutathione ( GSH ) content .|Also , BCNU administration increased serum tumor necrosis factor - alpha ( TNFalpha ) , hippocampal MT and malondialdehyde ( MDA ) contents as well as caspase - 3 activity in addition to histological alterations .|ZnSO ( 4 ) pretreatment counteracted BCNU - induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase - 3 .|The histological features were improved in hippocampus of rats treated with ZnSO ( 4 ) + BCNU compared to only BCNU - treated animals .|In conclusion , MT induction halts BCNU - induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha , MDA and caspase - 3 activity with subsequent preservation of cognition .": "[[\"Metallothionein induction\", \"reduces\", \"caspase-3 activity\"],\n [\"Metallothionein induction\", \"reduces\", \"TNFalpha levels\"],\n [\"Metallothionein induction\", \"preserves\", \"cognitive function\"],\n [\"Metallothionein induction\", \"preserves\", \"intact hippocampal neurons\"],\n [\"Hippocampal integrity\", \"is essential for\", \"cognitive functions\"],\n [\"Induction of metallothionein\", \"has role in\", \"neuroprotection\"],\n [\"MT induction\", \"explored for effect on\", \"carmustine-induced hippocampal cognitive dysfunction\"],\n [\"Control group\", \"injected with\", \"normal saline\"],\n [\"Control group\", \"followed by\", \"BCNU solvent\"],\n [\"Second group\", \"administered\", \"ZnSO(4)\"],\n [\"Second group\", \"then administered\", \"BCNU solvent\"],\n [\"Third group\", \"received\", \"BCNU\"],\n [\"Third group\", \"after injection with\", \"normal saline\"],\n [\"Fourth group\", \"received\", \"ZnSO(4)\"],\n [\"Fourth group\", \"then received\", \"BCNU\"],\n [\"BCNU administration\", \"resulted in\", \"deterioration of learning\"],\n [\"BCNU administration\", \"resulted in\", \"deterioration of short-term memory\"],\n [\"BCNU administration\", \"accompanied with decreased\", \"hippocampal glutathione reductase activity\"],\n [\"BCNU administration\", \"accompanied with reduced\", \"glutathione content\"],\n [\"BCNU administration\", \"increased\", \"serum TNFalpha\"],\n [\"BCNU administration\", \"increased\", \"hippocampal MT content\"],\n [\"BCNU administration\", \"increased\", \"hippocampal MDA content\"],\n [\"BCNU administration\", \"increased\", \"caspase-3 activity\"],\n [\"BCNU administration\", \"caused\", \"histological alterations\"],\n [\"ZnSO(4) pretreatment\", \"counteracted\", \"BCNU-induced inhibition of GR\"],\n [\"ZnSO(4) pretreatment\", \"counteracted\", \"BCNU-induced depletion of GSH\"],\n [\"ZnSO(4) pretreatment\", \"resulted in reduction of\", \"MDA levels\"],\n [\"ZnSO(4) pretreatment\", \"resulted in reduction of\", \"TNFalpha levels\"],\n [\"ZnSO(4) pretreatment\", \"resulted in reduction of\", \"caspase-3 activity\"],\n [\"ZnSO(4) + BCNU treatment\", \"improved\", \"histological features in hippocampus\"],\n [\"MT induction\", \"halts\", \"BCNU-induced hippocampal toxicity\"],\n [\"MT induction\", \"prevented\", \"GR inhibition\"],\n [\"MT induction\", \"prevented\", \"GSH depletion\"],\n [\"MT induction\", \"counteracted increased levels of\", \"TNFalpha\"],\n [\"MT induction\", \"counteracted increased levels of\", \"MDA\"],\n [\"MT induction\", \"counteracted increased levels of\", \"caspase-3 activity\"],\n [\"MT induction\", \"preserved\", \"cognition\"]]",
      "The effect of recombinant human insulin - like growth factor - I on chronic puromycin aminonucleoside nephropathy in rats .|We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside ( PAN ) nephropathy , an experimental model of glomerular disease .|Therefore , we examined whether recombinant human ( rh ) IGF - I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy .|The glomerulopathy was induced by seven serial injections of PAN over 12 wk .|Experimental animals ( n = 6 ) received rhIGF - I , 400 micrograms / d , whereas control rats ( n = 6 ) received the vehicle .|rhIGF - I improved weight gain by 14 % ( p < 0 . 05 ) , without altering hematocrit or blood pressure in rats with renal disease .|Urinary protein excretion was unaltered by rhIGF - I treatment in rats with chronic PAN nephropathy .|After 12 wk , the inulin clearance was higher in rhIGF - I - treated rats , 0 . 48 + / - 0 . 08 versus 0 . 24 + / - 0 . 06 mL / min / 100 g of body weight in untreated PAN nephropathy animals , p < 0 . 05 .|The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis , tubulointerstitial injury , or renal cortical malondialdehyde content .|In rats with PAN nephropathy , administration of rhIGF - I increased IGF - I and GH receptor gene expression , without altering the steady state level of IGF - I receptor mRNA .|In normal rats with intact kidneys , rhIGF - I administration ( n = 4 ) did not alter weight gain , blood pressure , proteinuria , GFR , glomerular planar area , renal cortical malondialdehyde content , or glomerular or tubulointerstitial damage , compared with untreated animals ( n = 4 ) .|rhIGF - I treatment reduced the steady state renal IGF - I mRNA level but did not modify gene expression of the IGF - I or GH receptors .|We conclude that : 1 ) administration of rhIGF - I improves growth and GFR in rats with chronic PAN nephropathy and 2 ) unlike rhGH , long - term use of rhIGF - I does not worsen renal functional and structural injury in this disease model .": "[[\"recombinant human insulin-like growth factor-I (rhIGF-I)\", \"examined for\", \"treatment of growth failure in rats with chronic PAN nephropathy\"],\n [\"glomerulopathy\", \"induced by\", \"serial injections of PAN\"],\n [\"experimental animals\", \"received\", \"rhIGF-I\"],\n [\"control rats\", \"received\", \"vehicle\"],\n [\"rhIGF-I\", \"improved\", \"weight gain in rats with renal disease\"],\n [\"rhIGF-I treatment\", \"did not alter\", \"urinary protein excretion in rats with chronic PAN nephropathy\"],\n [\"rhIGF-I-treated rats\", \"had higher\", \"inulin clearance\"],\n [\"improvement in GFR\", \"not associated with\", \"enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content\"],\n [\"rhIGF-I administration\", \"increased\", \"IGF-I and GH receptor gene expression in rats with PAN nephropathy\"],\n [\"rhIGF-I administration\", \"did not alter\", \"steady state level of IGF-I receptor mRNA in rats with PAN nephropathy\"],\n [\"rhIGF-I administration in normal rats\", \"did not alter\", \"weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage\"],\n [\"rhIGF-I treatment in normal rats\", \"reduced\", \"steady state renal IGF-I mRNA level\"],\n [\"rhIGF-I treatment in normal rats\", \"did not modify\", \"gene expression of the IGF-I or GH receptors\"],\n [\"administration of rhIGF-I\", \"improves\", \"growth and GFR in rats with chronic PAN nephropathy\"],\n [\"long-term use of rhIGF-I\", \"does not worsen\", \"renal functional and structural injury in chronic PAN nephropathy disease model\"]]",
      "Increased vulnerability to 6 - hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors .|Motor impairment , dopamine ( DA ) neuronal activity and proenkephalin ( PENK ) gene expression in the caudate - putamen ( CPu ) were measured in 6 - OHDA - lesioned and treated ( L - DOPA + benserazide ) CB1 KO and WT mice .|A lesion induced by 6 - OHDA produced more severe motor deterioration in CB1 KO mice accompanied by more loss of DA neurons and increased PENK gene expression in the CPu .|Oxidative / nitrosative and neuroinflammatory parameters were estimated in the CPu and cingulate cortex ( Cg ) .|CB1 KO mice exhibited higher MDA levels and iNOS protein expression in the CPu and Cg compared to WT mice .|Treatment with L - DOPA + benserazide ( 12 weeks ) resulted in less severe dyskinesias in CB1 KO than in WT mice .|The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion , and reduced L - DOPA - induced dyskinesias .|These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L - DOPA - induced dyskinesias .": "[[\"Increased vulnerability\", \"to\", \"6-hydroxydopamine lesion\"], [\"mice lacking CB1 cannabinoid receptors\", \"have\", \"reduced development of dyskinesias\"], [\"Motor impairment\", \"measured in\", \"CB1 KO and WT mice\"], [\"DA neuronal activity\", \"measured in\", \"CB1 KO and WT mice\"], [\"PENK gene expression\", \"measured in\", \"CB1 KO and WT mice\"], [\"6-OHDA\", \"induced\", \"more severe motor deterioration in CB1 KO mice\"], [\"6-OHDA\", \"caused\", \"more loss of DA neurons in CB1 KO mice\"], [\"6-OHDA\", \"increased\", \"PENK gene expression in the CPu\"], [\"Oxidative/nitrosative parameters\", \"estimated in\", \"CPu and Cg\"], [\"Neuroinflammatory parameters\", \"estimated in\", \"CPu and Cg\"], [\"CB1 KO mice\", \"exhibited higher\", \"MDA levels in the CPu and Cg\"], [\"CB1 KO mice\", \"exhibited higher\", \"iNOS protein expression in the CPu and Cg\"], [\"CB1 KO mice\", \"compared to\", \"WT mice\"], [\"L-DOPA + benserazide treatment\", \"resulted in\", \"less severe dyskinesias in CB1 KO mice\"], [\"Lack of CB1 receptors\", \"increased\", \"severity of motor impairment\"], [\"Lack of CB1 receptors\", \"increased\", \"DA lesion\"], [\"Lack of CB1 receptors\", \"reduced\", \"L-DOPA-induced dyskinesias\"], [\"Activation of CB1 receptors\", \"offers\", \"neuroprotection against dopaminergic lesion\"], [\"Activation of CB1 receptors\", \"prevents\", \"development of L-DOPA-induced dyskinesias\"]]",
      "Safety and efficacy of fluocinolone acetonide intravitreal implant ( 0 . 59 mg ) in birdshot retinochoroidopathy .|PURPOSE : To report the treatment outcomes of the fluocinolone acetonide intravitreal implant ( 0 . 59 mg ) in patients with birdshot retinochoroidopathy whose disease is refractory or intolerant to conventional immunomodulatory therapy .|METHODS : A retrospective case series involving 11 birdshot retinochoroidopathy patients ( 11 eyes ) .|Eleven patients ( 11 eyes ) underwent surgery for fluocinolone acetonide implant ( 0 . 59 mg ) .|Treatment outcomes of interest were noted at baseline , before fluocinolone acetonide implant , and then at 6 months , 1 year , 2 years , 3 years , and beyond 3 years .|Disease activity markers , including signs of ocular inflammation , evidence of retinal vasculitis , Swedish interactive threshold algorithm - short wavelength automated perimetry Humphrey visual field analysis , electroretinographic parameters , and optical coherence tomography were recorded .|Data on occurrence of cataract and raised intraocular pressure were collected in all eyes .|RESULTS : Intraocular inflammation was present in 54 . 5 , 9 . 9 , 11 . 1 , and 0 % of patients at baseline , 6 months , 1 year , 2 years , 3 years , and beyond 3 years after receiving the implant , respectively .|Active vasculitis was noted in 36 . 3 % patients at baseline and 0 % at 3 years of follow - up .|More than 20 % ( 47 . 61 - 67 . 2 % ) reduction in central retinal thickness was noted in all patients with cystoid macular edema at 6 months , 1 year , 2 years , and 3 years postimplant .|At baseline , 54 . 5 % patients were on immunomodulatory agents .|This percentage decreased to 45 . 45 , 44 . 4 , and 14 . 28 % at 1 year , 2 years , and 3 years postimplant , respectively .|Adverse events included increased intraocular pressure ( 54 . 5 % ) and cataract formation ( 100 % ) .|CONCLUSION : The data suggest that fluocinolone acetonide implant ( 0 . 59 mg ) helps to control inflammation in otherwise treatment - refractory cases of birdshot retinochoroidopathy .|It is associated with significant side effects of cataract and ocular hypertension requiring treatment .": "[[\"fluocinolone acetonide intravitreal implant (0.59 mg)\", \"used for\", \"birdshot retinochoroidopathy\"],\n[\"fluocinolone acetonide intravitreal implant (0.59 mg)\", \"used in patients with\", \"disease refractory or intolerant to conventional immunomodulatory therapy\"],\n[\"retrospective case series\", \"involved\", \"11 birdshot retinochoroidopathy patients (11 eyes)\"],\n[\"11 patients (11 eyes)\", \"underwent\", \"surgery for fluocinolone acetonide implant (0.59 mg)\"],\n[\"treatment outcomes\", \"noted at\", \"baseline, before fluocinolone acetonide implant\"],\n[\"treatment outcomes\", \"noted at\", \"various time points postimplant\"],\n[\"disease activity markers\", \"included\", \"ocular inflammation signs\"],\n[\"disease activity markers\", \"included\", \"retinal vasculitis evidence\"],\n[\"disease activity markers\", \"included\", \"visual field analysis\"],\n[\"disease activity markers\", \"included\", \"electroretinographic parameters\"],\n[\"disease activity markers\", \"included\", \"optical coherence tomography\"],\n[\"data\", \"collected on\", \"occurrence of cataract\"],\n[\"data\", \"collected on\", \"raised intraocular pressure\"],\n[\"intraocular inflammation\", \"present in\", \"percentage of patients at various time points\"],\n[\"active vasculitis\", \"noted in\", \"percentage of patients at baseline and at 3 years\"],\n[\"reduction in central retinal thickness\", \"noted in\", \"all patients with cystoid macular edema at various time points\"],\n[\"patients\", \"on immunomodulatory agents\", \"percentage at baseline\"],\n[\"patients\", \"on immunomodulatory agents\", \"percentage decreased postimplant at various time points\"],\n[\"adverse events\", \"included\", \"increased intraocular pressure\"],\n[\"adverse events\", \"included\", \"cataract formation\"],\n[\"fluocinolone acetonide implant (0.59 mg)\", \"helps to control\", \"inflammation in treatment-refractory cases of birdshot retinochoroidopathy\"],\n[\"fluocinolone acetonide implant (0.59 mg)\", \"associated with\", \"significant side effects\"],\n[\"significant side effects\", \"include\", \"cataract\"],\n[\"significant side effects\", \"include\", \"ocular hypertension\"]]",
      "Reduced cardiotoxicity of doxorubicin given in the form of N - ( 2 - hydroxypropyl ) methacrylamide conjugates : and experimental study in the rat .|A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg / kg doxorubicin ( DOX ) given either as free drug or in the form of three N - ( 2 - hydroxypropyl ) methacrylamide ( HPMA ) copolymer conjugates .|In these HPMA copolymers , DOX was covalently bound via peptide linkages that were either non - biodegradable ( Gly - Gly ) or degradable by lysosomal proteinases ( Gly - Phe - Leu - Gly ) .|In addition , one biodegradable conjugate containing galactosamine was used ; this residue was targeted to the liver .|Over the first 3 weeks after the i . v .|administration of free and polymer - bound DOX , all animals showed a transient reduction in body weight .|However , the maximal reduction in body weight seen in animals that received polymer - bound DOX ( 4 mg / kg ) was significantly lower than that observed in those that received free DOX ( 4 mg / kg ) or a mixture of the unmodified parent HPMA copolymer and free DOX ( 4 mg / kg ; P less than 0 . 01 ) .|Throughout the study ( 20 weeks ) , deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX ; in these cases , histological investigations revealed marked changes in the heart that were consistent with DOX - induced cardiotoxicity .|Sequential measurements of cardiac output in surviving animals that received either free DOX or the mixture of HPMA copolymer and free DOX showed a reduction of approximately 30 % in function beginning at the 4th week after drug administration .|The heart rate in these animals was approximately 12 % lower than that measured in age - matched control rats ( P less than 0 . 05 ) .|Animals that were given the HPMA copolymer conjugates containing DOX exhibited no significant change in cardiac output throughout the study ( P less than 0 . 05 ) .|In addition , no significant histological change was observed in the heart of animals that received DOX in the form of HPMA copolymer conjugates and were killed at the end of the study .|However , these animals had shown a significant increase in heart rate beginning at 8 weeks after drug administration ( P less than 0 . 01 ) . ( ABSTRACT TRUNCATED AT 400 WORDS )": "[[\"Doxorubicin\", \"form of\", \"N-(2-hydroxypropyl)methacrylamide conjugates\"], [\"Doxorubicin\", \"used to evaluate\", \"general acute toxicity\"], [\"Doxorubicin\", \"used to evaluate\", \"late cardiotoxicity\"], [\"Doxorubicin\", \"administered as\", \"free drug\"], [\"Doxorubicin\", \"administered as\", \"HPMA copolymer conjugates\"], [\"HPMA copolymers\", \"bound DOX via\", \"peptide linkages\"], [\"Peptide linkages\", \"could be\", \"non-biodegradable\"], [\"Peptide linkages\", \"could be\", \"degradable by lysosomal proteinases\"], [\"Biodegradable conjugate\", \"contained\", \"galactosamine\"], [\"Galactosamine\", \"targeted to\", \"the liver\"], [\"Animals\", \"showed\", \"transient reduction in body weight\"], [\"Polymer-bound DOX\", \"caused\", \"lower maximal reduction in body weight\"], [\"Free DOX\", \"caused\", \"higher maximal reduction in body weight\"], [\"Deaths related to cardiotoxicity\", \"observed in\", \"animals that received free DOX\"], [\"Deaths related to cardiotoxicity\", \"observed in\", \"animals that received mixture of HPMA copolymer and free DOX\"], [\"Cardiac output\", \"reduced by\", \"30%\"], [\"Heart rate\", \"lower than\", \"age-matched control rats\"], [\"HPMA copolymer conjugates containing DOX\", \"exhibited no significant change in\", \"cardiac output\"], [\"HPMA copolymer conjugates containing DOX\", \"showed no significant histological change in\", \"the heart\"], [\"Animals given HPMA copolymer conjugates containing DOX\", \"had shown\", \"significant increase in heart rate\"]]",
      "Diffuse skeletal pain after administration of alendronate .|BACKGROUND : Osteoporosis is caused by bone resorption in excess of bone formation , and bisphosphonates , are used to inhibit bone resorption .|Alendronate , a biphosphonate , is effective for both the treatment and prevention of osteoporosis in postmenopausal women .|Side effects are relatively few and prominently gastrointestinal .|Musculoskeletal pain may be an important side effect in these patients .|We presented a patient admitted to our out - patient clinic with diffuse skeletal pain after three consecutive administration of alendronate .|CONCLUSION : We conclude that patients with osteoporosis can report pain , and bisphosphonate - related pain should also be considered before ascribing this complaint to osteoporosis .": "[[\"Diffuse skeletal pain\", \"occurs after\", \"administration of alendronate\"],\n[\"Osteoporosis\", \"is caused by\", \"bone resorption in excess of bone formation\"],\n[\"Bisphosphonates\", \"are used to\", \"inhibit bone resorption\"],\n[\"Alendronate\", \"is a type of\", \"bisphosphonate\"],\n[\"Alendronate\", \"is effective for\", \"treatment and prevention of osteoporosis in postmenopausal women\"],\n[\"Side effects of alendronate\", \"are\", \"relatively few\"],\n[\"Side effects of alendronate\", \"are prominently\", \"gastrointestinal\"],\n[\"Musculoskeletal pain\", \"may be\", \"an important side effect\"],\n[\"Patient\", \"admitted with\", \"diffuse skeletal pain after alendronate administration\"],\n[\"Patients with osteoporosis\", \"can report\", \"pain\"],\n[\"Bisphosphonate-related pain\", \"should be considered\", \"before ascribing to osteoporosis\"]]",
      "Metformin protects against seizures , learning and memory impairments and oxidative damage induced by pentylenetetrazole - induced kindling in mice .|Cognitive impairment , the most common and severe comorbidity of epilepsy , greatly diminishes the quality of life .|However , current therapeutic interventions for epilepsy can also cause untoward cognitive effects .|Thus , there is an urgent need for new kinds of agents targeting both seizures and cognition deficits .|Oxidative stress is considered to play an important role in epileptogenesis and cognitive deficits , and antioxidants have a putative antiepileptic potential .|Metformin , the most commonly prescribed antidiabetic oral drug , has antioxidant properties .|This study was designed to evaluate the ameliorative effects of metformin on seizures , cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole - induced kindling animals .|Male C57BL / 6 mice were administered with subconvulsive dose of pentylenetetrazole ( 37 mg / kg , i . p . ) every other day for 14 injections .|Metformin was injected intraperitoneally in dose of 200mg / kg along with alternate - day PTZ .|We found that metformin suppressed the progression of kindling , ameliorated the cognitive impairment and decreased brain oxidative stress .|Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures .": "[[\"Metformin\", \"protects against\", \"seizures\"],\n [\"Metformin\", \"protects against\", \"learning impairments\"],\n [\"Metformin\", \"protects against\", \"memory impairments\"],\n [\"Metformin\", \"protects against\", \"oxidative damage\"],\n [\"Oxidative damage\", \"induced by\", \"pentylenetetrazole-induced kindling\"],\n [\"Cognitive impairment\", \"is comorbidity of\", \"epilepsy\"],\n [\"Cognitive impairment\", \"diminishes\", \"quality of life\"],\n [\"Therapeutic interventions for epilepsy\", \"cause\", \"untoward cognitive effects\"],\n [\"Agents\", \"targeting\", \"seizures\"],\n [\"Agents\", \"targeting\", \"cognition deficits\"],\n [\"Oxidative stress\", \"plays role in\", \"epileptogenesis\"],\n [\"Oxidative stress\", \"plays role in\", \"cognitive deficits\"],\n [\"Antioxidants\", \"have\", \"antiepileptic potential\"],\n [\"Metformin\", \"is prescribed antidiabetic oral drug\", \"\"],\n [\"Metformin\", \"has\", \"antioxidant properties\"],\n [\"Study\", \"designed to evaluate\", \"ameliorative effects of metformin\"],\n [\"Metformin\", \"on\", \"seizures\"],\n [\"Metformin\", \"on\", \"cognitive impairment\"],\n [\"Metformin\", \"on\", \"brain oxidative stress markers\"],\n [\"Pentylenetetrazole-induced kindling\", \"observed in\", \"animals\"],\n [\"Male C57BL/6 mice\", \"administered with\", \"pentylenetetrazole\"],\n [\"Metformin\", \"injected intraperitoneally in dose of\", \"200mg/kg\"],\n [\"Metformin\", \"administered with\", \"alternate-day PTZ\"],\n [\"Metformin\", \"suppressed\", \"progression of kindling\"],\n [\"Metformin\", \"ameliorated\", \"cognitive impairment\"],\n [\"Metformin\", \"decreased\", \"brain oxidative stress\"],\n [\"Metformin\", \"may be potential agent for treatment of\", \"epilepsy\"],\n [\"Metformin\", \"protective medicine against\", \"cognitive impairment induced by seizures\"]]",
      "Famotidine - associated delirium .|A series of six cases .|Famotidine is a histamine H2 - receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost .|Although all of the currently available H2 - receptor antagonists have shown the propensity to cause delirium , only two previously reported cases have been associated with famotidine .|The authors report on six cases of famotidine - associated delirium in hospitalized patients who cleared completely upon removal of famotidine .|The pharmacokinetics of famotidine are reviewed , with no change in its metabolism in the elderly population seen .|The implications of using famotidine in elderly persons are discussed .": "[[\"Famotidine\", \"associated with\", \"delirium\"], [\"Famotidine\", \"is a type of\", \"histamine H2-receptor antagonist\"], [\"Famotidine\", \"used for\", \"prevention of stress ulcers\"], [\"Famotidine\", \"used in\", \"inpatient settings\"], [\"Famotidine\", \"popularity due to\", \"low cost\"], [\"H2-receptor antagonists\", \"propensity to cause\", \"delirium\"], [\"Famotidine\", \"cases previously reported\", \"two\"], [\"Authors\", \"report on\", \"six cases of famotidine-associated delirium\"], [\"Hospitalized patients\", \"cleared upon removal of\", \"famotidine\"], [\"Pharmacokinetics of famotidine\", \"reviewed with no change in\", \"metabolism in the elderly population\"], [\"Implications\", \"discussed for\", \"using famotidine in elderly persons\"]]",
      "Hemodynamics and myocardial metabolism under deliberate hypotension .|An experimental study in dogs .|Coronary blood flow , cardiac work and metabolism were studied in dogs under sodium nitroprusside ( SNP ) and trimetaphan ( TMP ) deliberate hypotension ( 20 % and 40 % mean pressure decrease from baseline ) .|Regarding the effects of drug - induced hypotension on coronary blood flow , aortic and coronary sinus metabolic data ( pH , pO2 , pCO2 ) we could confirm that nitroprusside hypotension could be safely used to 30 % mean blood pressure decrease from control , trimetaphan hypotension to 20 % mean blood pressure decrease .|Cardiac work was significantly reduced during SNP hypotension .|Myocardial O2 consumption and O2 availability were directly dependent on the coronary perfusion .|Careful invasive monitoring of the blood pressure , blood gases and of the ECG ST - T segment is mandatory .": "[[\"Hemodynamics and myocardial metabolism\", \"studied under\", \"deliberate hypotension\"],\n[\"Deliberate hypotension\", \"studied in\", \"dogs\"],\n[\"Coronary blood flow, cardiac work and metabolism\", \"were studied in\", \"dogs\"],\n[\"Dogs\", \"underwent\", \"sodium nitroprusside (SNP) deliberate hypotension\"],\n[\"Dogs\", \"underwent\", \"trimetaphan (TMP) deliberate hypotension\"],\n[\"Sodium nitroprusside (SNP) deliberate hypotension\", \"causes\", \"20% and 40% mean pressure decrease from baseline\"],\n[\"Trimetaphan (TMP) deliberate hypotension\", \"causes\", \"20% and 40% mean pressure decrease from baseline\"],\n[\"Nitroprusside hypotension\", \"can be used safely to\", \"30% mean blood pressure decrease from control\"],\n[\"Trimetaphan hypotension\", \"can be used safely to\", \"20% mean blood pressure decrease\"],\n[\"Cardiac work\", \"was reduced during\", \"SNP hypotension\"],\n[\"Myocardial O2 consumption and O2 availability\", \"dependent on\", \"coronary perfusion\"],\n[\"Invasive monitoring\", \"is mandatory for\", \"blood pressure\"],\n[\"Invasive monitoring\", \"is mandatory for\", \"blood gases\"],\n[\"Invasive monitoring\", \"is mandatory for\", \"ECG ST-T segment\"]]",
      "Rhabdomyolysis and brain ischemic stroke in a heroin - dependent male under methadone maintenance therapy .|OBJECTIVE : There are several complications associated with heroin abuse , some of which are life - threatening .|Methadone may aggravate this problem .|METHOD : A clinical case description .|RESULTS : A 33 - year - old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin .|He had used heroin since age 20 , and had used 150 mg methadone daily for 6 months .|He was found unconsciousness at home and was sent to our hospital .|In the ER , his opiate level was 4497 ng / ml .|In the ICU , we found rhabdomyolysis , acute renal failure and acute respiratory failure .|After transfer to an internal ward , we noted aphasia and weakness of his left limbs .|After MRI , we found cerebral ischemic infarction .|CONCLUSION : Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke .|Patients under methadone maintenance therapy should be warned regarding these serious adverse events .|Hypotheses of heroin - related rhabdomyolysis and stroke in heroin abusers are discussed .": "[[\"Rhabdomyolysis\", \"associated with\", \"heroin abuse\"],\n [\"Brain ischemic stroke\", \"associated with\", \"heroin abuse\"],\n [\"Methadone\", \"may aggravate\", \"heroin abuse complications\"],\n [\"33-year-old man\", \"presented with\", \"rhabdomyolysis\"],\n [\"33-year-old man\", \"presented with\", \"cerebral ischemic stroke\"],\n [\"33-year-old man\", \"used\", \"heroin\"],\n [\"33-year-old man\", \"age of first use\", \"20\"],\n [\"33-year-old man\", \"used\", \"150 mg methadone daily\"],\n [\"33-year-old man\", \"duration of methadone use\", \"6 months\"],\n [\"33-year-old man\", \"found\", \"unconsciousness at home\"],\n [\"33-year-old man\", \"sent to\", \"hospital\"],\n [\"In the ER\", \"opiate level was\", \"4497 ng/ml\"],\n [\"In the ICU\", \"found\", \"rhabdomyolysis\"],\n [\"In the ICU\", \"found\", \"acute renal failure\"],\n [\"In the ICU\", \"found\", \"acute respiratory failure\"],\n [\"After transfer to an internal ward\", \"noted\", \"aphasia\"],\n [\"After transfer to an internal ward\", \"noted\", \"weakness of left limbs\"],\n [\"After MRI\", \"found\", \"cerebral ischemic infarction\"],\n [\"Simultaneous use of methadone and heroin\", \"may increase risk of\", \"rhabdomyolysis\"],\n [\"Simultaneous use of methadone and heroin\", \"may increase risk of\", \"ischemic stroke\"],\n [\"Patients under methadone maintenance therapy\", \"should be warned\", \"serious adverse events\"],\n [\"Hypotheses\", \"discussed\", \"heroin-related rhabdomyolysis\"],\n [\"Hypotheses\", \"discussed\", \"stroke in heroin abusers\"]]",
      "Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy .|The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy .|Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen .|Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia .|4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy .|Cyclical low - dose oestrogen therapy with 7 - - 13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma .": "[[\"Prevention and treatment\", \"of\", \"endometrial disease\"], [\"endometrial disease\", \"in\", \"climacteric women\"], [\"climacteric women\", \"receiving\", \"oestrogen therapy\"], [\"treatment regimens\", \"described in\", \"74 patients\"], [\"74 patients\", \"with\", \"endometrial disease\"], [\"74 patients\", \"among\", \"850 climacteric women\"], [\"850 climacteric women\", \"receiving\", \"oestrogen therapy\"], [\"Cystic hyperplasia\", \"associated with\", \"unopposed oestrogen therapy without progestagen\"], [\"Two courses\", \"caused\", \"reversion to normal\"], [\"reversion to normal\", \"in\", \"57 cases of cystic hyperplasia\"], [\"reversion to normal\", \"in\", \"6 of the 8 cases of atypical hyperplasia\"], [\"5 mg norethisterone daily\", \"caused\", \"reversion to normal\"], [\"endometrial carcinoma\", \"demonstrated\", \"problems of inappropriate and unsupervised unopposed oestrogen therapy\"], [\"endometrial carcinoma\", \"difficulty in\", \"distinguishing severe hyperplasia from malignancy\"], [\"Cyclical low-dose oestrogen therapy\", \"does not seem to increase\", \"risk of endometrial hyperplasia\"], [\"Cyclical low-dose oestrogen therapy\", \"does not seem to increase\", \"risk of endometrial carcinoma\"], [\"Cyclical low-dose oestrogen therapy\", \"with\", \"7-13 days of progestagen\"]]",
      "Studies of risk factors for aminoglycoside nephrotoxicity .|The epidemiology of aminoglycoside - induced nephrotoxicity is not fully understood .|Experimental studies in healthy human volunteers indicate aminoglycosides cause proximal tubular damage in most patients , but rarely , if ever , cause glomerular or tubular dysfunction .|Clinical trials of aminoglycosides in seriously ill patients indicate that the relative risk for developing acute renal failure during therapy ranges from 8 to 10 and that the attributable risk is 70 % to 80 % .|Further analysis of these data suggests that the duration of therapy , plasma aminoglycoside levels , liver disease , advanced age , high initial estimated creatinine clearance and , possibly , female gender all increase the risk for nephrotoxicity .|Other causes of acute renal failure , such as shock , appear to have an additive effect .|Predictive models have been developed from these analyses that should be useful for identifying patients at high risk .|These models may also be useful in developing insights into the pathophysiology of aminoglycoside - induced nephrotoxicity .": "[[\"Studies\", \"are of\", \"risk factors for aminoglycoside nephrotoxicity\"],\n[\"Epidemiology\", \"is of\", \"aminoglycoside-induced nephrotoxicity\"],\n[\"Epidemiology\", \"is not\", \"fully understood\"],\n[\"Experimental studies\", \"indicate\", \"aminoglycosides cause proximal tubular damage\"],\n[\"Aminoglycosides\", \"cause\", \"proximal tubular damage\"],\n[\"Aminoglycosides\", \"rarely cause\", \"glomerular or tubular dysfunction\"],\n[\"Clinical trials\", \"indicate\", \"relative risk for developing acute renal failure\"],\n[\"Relative risk\", \"is during therapy\", \"8 to 10\"],\n[\"Attributable risk\", \"is for developing acute renal failure\", \"70 % to 80 %\"],\n[\"Further analysis\", \"suggests\", \"factors increasing risk for nephrotoxicity\"],\n[\"Duration of therapy\", \"increases\", \"risk for nephrotoxicity\"],\n[\"Plasma aminoglycoside levels\", \"increase\", \"risk for nephrotoxicity\"],\n[\"Liver disease\", \"increases\", \"risk for nephrotoxicity\"],\n[\"Advanced age\", \"increases\", \"risk for nephrotoxicity\"],\n[\"High initial estimated creatinine clearance\", \"increases\", \"risk for nephrotoxicity\"],\n[\"Female gender\", \"possibly increases\", \"risk for nephrotoxicity\"],\n[\"Other causes\", \"have\", \"additive effect on acute renal failure\"],\n[\"Predictive models\", \"have been developed\", \"from analyses\"],\n[\"Predictive models\", \"should be useful for\", \"identifying patients at high risk\"],\n[\"Predictive models\", \"may be useful in\", \"developing insights into pathophysiology\"],\n[\"Pathophysiology\", \"is of\", \"aminoglycoside-induced nephrotoxicity\"]]",
      "Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes : a matched case - control study .|AIMS : This study sought to assess the risk of developing coronary artery disease ( CAD ) associated with initial treatment of type 2 diabetes with different sulphonylureas .|METHODS : In type 2 diabetic patients , cases who developed CAD were compared retrospectively with controls that did not .|The 20 - year risk of CAD at diagnosis of diabetes , using the UKPDS risk engine , was used to match cases with controls .|RESULTS : The 76 cases of CAD were compared with 152 controls .|The hazard of developing CAD ( 95 % CI ) associated with initial treatment increased by 2 . 4 - fold ( 1 . 3 - 4 . 3 , P = 0 . 004 ) with glibenclamide ; 2 - fold ( 0 . 9 - 4 . 6 , P = 0 . 099 ) with glipizide ; 2 . 9 - fold ( 1 . 6 - 5 . 1 , P = 0 . 000 ) with either , and was unchanged with metformin .|The hazard decreased 0 . 3 - fold ( 0 . 7 - 1 . 7 , P = 0 . 385 ) with glimepiride , 0 . 4 - fold ( 0 . 7 - 1 . 3 , P = 0 . 192 ) with gliclazide , and 0 . 4 - fold ( 0 . 7 - 1 . 1 , P = 0 . 09 ) with either .|CONCLUSIONS : Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride .|If confirmed , this may be important because most Indian patients receive the cheaper older sulphonylureas , and present guidelines do not distinguish between individual agents .": "[[\"Risk of coronary artery disease\", \"associated with\", \"initial sulphonylurea treatment of patients with type 2 diabetes\"], [\"This study\", \"sought to assess\", \"the risk of developing coronary artery disease (CAD) associated with initial treatment of type 2 diabetes with different sulphonylureas\"], [\"Cases\", \"compared with\", \"controls\"], [\"Cases\", \"developed\", \"CAD\"], [\"Controls\", \"did not develop\", \"CAD\"], [\"20-year risk of CAD\", \"used to match\", \"cases with controls\"], [\"76 cases of CAD\", \"compared with\", \"152 controls\"], [\"Hazard of developing CAD\", \"increased by\", \"2.4-fold with glibenclamide\"], [\"Hazard of developing CAD\", \"increased by\", \"2-fold with glipizide\"], [\"Hazard of developing CAD\", \"increased by\", \"2.9-fold with either glibenclamide or glipizide\"], [\"Hazard of developing CAD\", \"unchanged with\", \"metformin\"], [\"Hazard of developing CAD\", \"decreased by\", \"0.3-fold with glimepiride\"], [\"Hazard of developing CAD\", \"decreased by\", \"0.4-fold with gliclazide\"], [\"Hazard of developing CAD\", \"decreased by\", \"0.4-fold with either glimepiride or gliclazide\"], [\"Treatment of type 2 diabetes with glibenclamide or glipizide\", \"is associated with\", \"increased risk of CAD\"], [\"Treatment of type 2 diabetes with gliclazide or glimepiride\", \"is associated with\", \"decreased risk of CAD\"], [\"Indian patients\", \"receive\", \"cheaper older sulphonylureas\"], [\"Present guidelines\", \"do not distinguish between\", \"individual agents\"]]",
      "Gemfibrozil - lovastatin therapy for primary hyperlipoproteinemias .|The specific aim of this retrospective , observational study was to assess safety and efficacy of long - term ( 21 months / patient ) , open - label , gemfibrozil - lovastatin treatment in 80 patients with primary mixed hyperlipidemia ( 68 % of whom had atherosclerotic vascular disease ) .|Because ideal lipid targets were not reached ( low - density lipoprotein ( LDL ) cholesterol less than 130 mg / dl , high - density lipoprotein ( HDL ) cholesterol greater than 35 mg / dl , or total cholesterol / HDL cholesterol less than 4 . 5 mg / dl ) with diet plus a single drug , gemfibrozil ( 1 . 2 g / day ) - lovastatin ( primarily 20 or 40 mg ) treatment was given .|Follow - up visits were scheduled with 2 - drug therapy every 6 to 8 weeks , an average of 10 . 3 visits per patient , with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured .|Only 1 of the 4 , 446 liver function tests ( 0 . 02 % ) , a gamma glutamyl transferase , was greater than or equal to 3 times the upper normal limit .|Of the 714 creatine phosphokinase levels , 9 % were high ; only 1 ( 0 . 1 % ) was greater than or equal to 3 times the upper normal limit .|With 2 - drug therapy , mean total cholesterol decreased 22 % from 255 to 200 mg / dl , triglyceride levels decreased 35 % from 236 to 154 mg / dl , LDL cholesterol decreased 26 % from 176 to 131 mg / dl , and the total cholesterol / HDL cholesterol ratio decreased 24 % from 7 . 1 to 5 . 4 , all p less than or equal to 0 . 0001 .|Myositis , attributable to the drug combination and symptomatic enough to discontinue it , occurred in 3 % of patients , and in 1 % with concurrent high creatine phosphokinase ( 769 U / liter ) ; no patients had rhabdomyolysis or myoglobinuria . ( ABSTRACT TRUNCATED AT 250 WORDS )": "Based on the provided prompt, here are the extracted relationships:\n\n1. [[\"Gemfibrozil - lovastatin therapy\", \"is for\", \"primary hyperlipoproteinemias\"]]\n2. [[\"Study\", \"aims to assess\", \"safety and efficacy of gemfibrozil - lovastatin treatment\"]]\n3. [[\"Gemfibrozil - lovastatin treatment\", \"duration\", \"21 months/patient\"]]\n4. [[\"Patients\", \"had\", \"primary mixed hyperlipidemia\"]]\n5. [[\"68% of patients\", \"had\", \"atherosclerotic vascular disease\"]]\n6. [[\"Gemfibrozil - lovastatin treatment\", \"was given because\", \"ideal lipid targets were not reached\"]]\n7. [[\"Gemfibrozil\", \"dosage\", \"1.2 g/day\"]]\n8. [[\"Lovastatin\", \"dosage\", \"primarily 20 or 40 mg\"]]\n9. [[\"Follow-up visits\", \"scheduled every\", \"6 to 8 weeks\"]]\n10. [[\"Patients\", \"had an average of\", \"10.3 visits\"]]\n11. [[\"Liver function tests\", \"number measured\", \"741 batteries of 6\"]]\n12. [[\"Creatine phosphokinase levels\", \"number measured\", \"714\"]]\n13. [[\"Gamma glutamyl transferase\", \"was greater than or equal to\", \"3 times the upper normal limit\"]]\n14. [[\"Creatine phosphokinase levels\", \"9% were\", \"high\"]]\n15. [[\"With 2-drug therapy\", \"mean total cholesterol decreased\", \"22%\"]]\n16. [[\"With 2-drug therapy\", \"triglyceride levels decreased\", \"35%\"]]\n17. [[\"With 2-drug therapy\", \"LDL cholesterol decreased\", \"26%\"]]\n18. [[\"With 2-drug therapy\", \"total cholesterol/HDL cholesterol ratio decreased\", \"24%\"]]\n19. [[\"Myositis\", \"attributable to\", \"the drug combination\"]]\n20. [[\"Myositis\", \"led to discontinuation in\", \"3% of patients\"]]\n21. [[\"High creatine phosphokinase\", \"occurred in\", \"1% of patients\"]]\n22. [[\"Patients\", \"had no\", \"rhabdomyolysis or myoglobinuria\"]]",
      "Growth - associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide .|PURPOSE : GAP43 has been thought to be linked with mossy fiber sprouting ( MFS ) in various experimental models of epilepsy .|To investigate how GAP43 expression ( GAP43 - ir ) correlates with MFS , we assessed the intensity ( densitometry ) and extension ( width ) of GAP43 - ir in the inner molecular layer of the dentate gyrus ( IML ) of rats subject to status epilepticus induced by pilocarpine ( Pilo ) , previously injected or not with cycloheximide ( CHX ) , which has been shown to inhibit MFS .|METHODS : CHX was injected before the Pilo injection in adult Wistar rats .|The Pilo group was injected with the same drugs , except for CHX .|Animals were killed between 30 and 60 days later , and brain sections were processed for GAP43 immunohistochemistry .|RESULTS : Densitometry showed no significant difference regarding GAP43 - ir in the IML between Pilo , CHX + Pilo , and control groups .|However , the results of the width of the GAP43 - ir band in the IML showed that CHX + Pilo and control animals had a significantly larger band ( p = 0 . 03 ) as compared with that in the Pilo group .|CONCLUSIONS : Our current finding that animals in the CHX + Pilo group have a GAP43 - ir band in the IML , similar to that of controls , reinforces prior data on the blockade of MFS in these animals .|The change in GAP43 - ir present in Pilo - treated animals was a thinning of the band to a very narrow layer just above the granule cell layer that is likely to be associated with the loss of hilar cell projections that express GAP - 43 .": "Based on the provided prompt, here are the relationships extracted:\n\n1. [[\"Growth-associated protein 43 expression\", \"is in\", \"hippocampal molecular layer of chronic epileptic rats\"], [\"Growth-associated protein 43 expression\", \"treated with\", \"cycloheximide\"]]\n2. [[\"GAP43\", \"linked with\", \"mossy fiber sprouting\"]]\n3. [[\"GAP43 expression\", \"correlates with\", \"mossy fiber sprouting\"]]\n4. [[\"Researchers\", \"assessed\", \"intensity of GAP43 expression\"], [\"Researchers\", \"assessed\", \"extension of GAP43 expression\"]]\n5. [[\"Intensity\", \"measured by\", \"densitometry\"], [\"Extension\", \"measured by\", \"width\"]]\n6. [[\"GAP43 expression\", \"in\", \"inner molecular layer of the dentate gyrus\"]]\n7. [[\"Rats\", \"subject to\", \"status epilepticus\"], [\"Status epilepticus\", \"induced by\", \"pilocarpine\"]]\n8. [[\"Rats\", \"injected with\", \"cycloheximide\"], [\"Cycloheximide\", \"shown to\", \"inhibit mossy fiber sprouting\"]]\n9. [[\"CHX\", \"injected before\", \"Pilo injection\"]]\n10. [[\"Pilo group\", \"injected with\", \"same drugs except for CHX\"]]\n11. [[\"Animals\", \"killed between\", \"30 and 60 days later\"]]\n12. [[\"Brain sections\", \"processed for\", \"GAP43 immunohistochemistry\"]]\n13. [[\"Densitometry\", \"showed no significant difference\", \"GAP43 expression in the IML between Pilo, CHX + Pilo, and control groups\"]]\n14. [[\"Width of the GAP43-ir band in the IML\", \"significantly larger in\", \"CHX + Pilo and control animals compared with Pilo group\"]]\n15. [[\"Animals in the CHX + Pilo group\", \"have\", \"GAP43-ir band in the IML similar to that of controls\"]]\n16. [[\"Blockade of MFS\", \"in\", \"CHX + Pilo group animals\"]]\n17. [[\"Change in GAP43-ir\", \"present in\", \"Pilo-treated animals\"]]\n18. [[\"Pilo-treated animals\", \"had thinning of\", \"GAP43-ir band\"]]\n19. [[\"GAP43-ir band\", \"just above\", \"granule cell layer\"]]\n20. [[\"Loss of hilar cell projections\", \"likely associated with\", \"GAP-43\"]]\n\nPlease note that some relationships are inferred from the context, such as the researchers conducting the assessment, and the use of \"we\" in the text to refer to the actions taken by the researchers.",
      "Indomethacin - induced morphologic changes in the rat urinary bladder epithelium .|OBJECTIVES : To evaluate the morphologic changes in rat urothelium induced by indomethacin .|Nonsteroidal anti - inflammatory drug - induced cystitis is a poorly recognized and under - reported condition .|In addition to tiaprofenic acid , indomethacin has been reported to be associated with this condition .|METHODS : Three groups were established : a control group ( n = 10 ) , a high - dose group ( n = 10 ) , treated with one intraperitoneal injection of indomethacin 20 mg / kg , and a therapeutic dose group ( n = 10 ) in which oral indomethacin was administered 3 . 25 mg / kg body weight daily for 3 weeks .|The animals were then killed and the bladders removed for light and electron microscopic studies .|RESULTS : The light microscopic findings showed some focal epithelial degeneration that was more prominent in the high - dose group .|When compared with the control group , both indomethacin groups revealed statistically increased numbers of mast cells in the mucosa ( P < 0 . 0001 ) and penetration of lanthanum nitrate through intercellular areas of the epithelium .|Furthermore , the difference in mast cell counts between the high and therapeutic dose groups was also statistically significant ( P < 0 . 0001 ) .|CONCLUSIONS : Indomethacin resulted in histopathologic findings typical of interstitial cystitis , such as leaky bladder epithelium and mucosal mastocytosis .|The true incidence of nonsteroidal anti - inflammatory drug - induced cystitis in humans must be clarified by prospective clinical trials .": "[[\"Indomethacin\", \"induces\", \"morphologic changes in the rat urinary bladder epithelium\"],\n[\"Indomethacin\", \"associated with\", \"nonsteroidal anti-inflammatory drug-induced cystitis\"],\n[\"Control group\", \"consists of\", \"10 rats\"],\n[\"High-dose group\", \"consists of\", \"10 rats\"],\n[\"High-dose group\", \"treated with\", \"intraperitoneal injection of indomethacin 20 mg/kg\"],\n[\"Therapeutic dose group\", \"consists of\", \"10 rats\"],\n[\"Therapeutic dose group\", \"treated with\", \"oral indomethacin 3.25 mg/kg body weight daily for 3 weeks\"],\n[\"Animals\", \"were killed and\", \"bladders removed for studies\"],\n[\"Light microscopic findings\", \"showed\", \"focal epithelial degeneration\"],\n[\"Focal epithelial degeneration\", \"more prominent in\", \"high-dose group\"],\n[\"Indomethacin groups\", \"revealed\", \"increased numbers of mast cells in the mucosa\"],\n[\"Indomethacin groups\", \"showed\", \"penetration of lanthanum nitrate through intercellular areas of the epithelium\"],\n[\"Difference in mast cell counts\", \"statistically significant between\", \"high and therapeutic dose groups\"],\n[\"Indomethacin\", \"resulted in\", \"histopathologic findings typical of interstitial cystitis\"],\n[\"Nonsteroidal anti-inflammatory drug-induced cystitis\", \"incidence must be clarified by\", \"prospective clinical trials\"]]",
      "A dramatic drop in blood pressure following prehospital GTN administration .|A male in his sixties with no history of cardiac chest pain awoke with chest pain following an afternoon sleep .|The patient did not self medicate .|The patient 's observations were within normal limits , he was administered oxygen via a face mask and glyceryl trinitrate ( GTN ) .|Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate , this was rectified by atropine sulphate and a fluid challenge .|There was no further deterioration in the patient 's condition during transport to hospital .|There are very few documented case like this in the prehospital scientific literature .|The cause appears to be the Bezold - Jarish reflex , stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre .|Prehospital care providers who are managing any patient with a syncopal episode that fails to recover within a reasonable time frame should consider the Bezold - Jarisch reflex as the cause and manage the patient accordingly .": "[[\"blood pressure\", \"drop following\", \"prehospital GTN administration\"],\n [\"A male in his sixties\", \"awoke with\", \"chest pain\"],\n [\"A male in his sixties\", \"has no history of\", \"cardiac chest pain\"],\n [\"The patient\", \"did not\", \"self medicate\"],\n [\"The patient's observations\", \"were within\", \"normal limits\"],\n [\"The patient\", \"was administered\", \"oxygen via a face mask\"],\n [\"The patient\", \"was administered\", \"glyceryl trinitrate (GTN)\"],\n [\"The patient\", \"experienced\", \"sudden drop in blood pressure\"],\n [\"The patient\", \"experienced\", \"drop in heart rate\"],\n [\"drop in blood pressure and heart rate\", \"rectified by\", \"atropine sulphate\"],\n [\"drop in blood pressure and heart rate\", \"rectified by\", \"fluid challenge\"],\n [\"The patient's condition\", \"no further deterioration during\", \"transport to hospital\"],\n [\"case\", \"documented in\", \"prehospital scientific literature\"],\n [\"cause\", \"appears to be\", \"Bezold-Jarish reflex\"],\n [\"Bezold-Jarish reflex\", \"stimulation of\", \"ventricular walls\"],\n [\"ventricular walls\", \"decreases\", \"sympathetic outflow from the vasomotor centre\"],\n [\"Prehospital care providers\", \"managing\", \"patient with a syncopal episode\"],\n [\"patient with a syncopal episode\", \"fails to recover within\", \"reasonable time frame\"],\n [\"Prehospital care providers\", \"should consider\", \"Bezold-Jarish reflex\"],\n [\"Prehospital care providers\", \"manage the patient accordingly\", \"Bezold-Jarish reflex\"]]",
      "Does domperidone potentiate mirtazapine - associated restless legs syndrome ?|There is now evidence to suggest a central role for the dopaminergic system in restless legs syndrome ( RLS ) .|For example , the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists , whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms .|To our knowledge , there is no previous report regarding whether domperidone , a peripheral dopamine D2 receptor antagonist , can also induce or aggravate symptoms of RLS .|Mirtazapine , the first noradrenergic and specific serotonergic antidepressant ( NaSSA ) , has been associated with RLS in several recent publications .|The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy .|Our patient started to have symptoms of RLS only after he had been treated with mirtazapine , and his RLS symptoms resolved completely upon discontinuation of his mirtazapine .|Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine - associated RLS .|However , physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals , especially those receiving concomitant dopamine D2 receptor antagonists .": "[[\"domperidone\", \"potentiate\", \"mirtazapine-associated restless legs syndrome\"], [\"dopaminergic system\", \"central role in\", \"restless legs syndrome\"], [\"symptoms of RLS\", \"improved by\", \"levodopa\"], [\"symptoms of RLS\", \"improved by\", \"dopamine agonists\"], [\"dopamine D2 receptor antagonists\", \"can induce or aggravate\", \"RLS symptoms\"], [\"domperidone\", \"is a\", \"peripheral dopamine D2 receptor antagonist\"], [\"domperidone\", \"induce or aggravate\", \"symptoms of RLS\"], [\"mirtazapine\", \"is a\", \"noradrenergic and specific serotonergic antidepressant\"], [\"mirtazapine\", \"has been associated with\", \"RLS\"], [\"depressed patient\", \"developed\", \"RLS\"], [\"mirtazapine\", \"added to\", \"domperidone therapy\"], [\"patient\", \"had symptoms of\", \"RLS\"], [\"patient\", \"treated with\", \"mirtazapine\"], [\"RLS symptoms\", \"resolved upon discontinuation of\", \"mirtazapine\"], [\"use of mirtazapine\", \"temporal relationship with\", \"symptoms of RLS\"], [\"mirtazapine\", \"can be associated with\", \"RLS\"], [\"physicians\", \"should be aware of\", \"mirtazapine association with RLS\"]]",
      "Physical training decreases susceptibility to subsequent pilocarpine - induced seizures in the rat .|Regular motor activity has many benefits for mental and physical condition but its implications for epilepsy are still controversial .|In order to elucidate this problem , we have studied the effect of long - term physical activity on susceptibility to subsequent seizures .|Male Wistar rats were subjected to repeated training sessions in a treadmill and swimming pool .|Thereafter , seizures were induced by pilocarpine injections in trained and non - trained control groups .|During the acute period of status epilepticus , we measured : ( 1 ) the latency of the first motor sign , ( 2 ) the intensity of seizures , ( 3 ) the time when it occurred within the 6 - h observation period , and ( 4 ) the time when the acute period ended .|All these behavioral parameters showed statistically significant changes suggesting that regular physical exercises decrease susceptibility to subsequently induced seizures and ameliorate the course of experimentally induced status epilepticus .": "[[\"Physical training\", \"decreases\", \"susceptibility to subsequent pilocarpine-induced seizures\"], \n[\"Regular motor activity\", \"has benefits for\", \"mental and physical condition\"], \n[\"Implications for epilepsy\", \"are\", \"still controversial\"], \n[\"Study\", \"aimed to elucidate\", \"effect of long-term physical activity on susceptibility to seizures\"], \n[\"Male Wistar rats\", \"subjected to\", \"repeated training sessions\"], \n[\"Training sessions\", \"included\", \"treadmill and swimming pool activities\"], \n[\"Seizures\", \"induced by\", \"pilocarpine injections\"], \n[\"Seizures\", \"induced in\", \"trained and non-trained control groups\"], \n[\"During status epilepticus\", \"measured\", \"latency of the first motor sign\"], \n[\"During status epilepticus\", \"measured\", \"intensity of seizures\"], \n[\"During status epilepticus\", \"measured\", \"time when seizures occurred within the 6-h observation period\"], \n[\"During status epilepticus\", \"measured\", \"time when the acute period ended\"], \n[\"Behavioral parameters\", \"showed\", \"statistically significant changes\"], \n[\"Regular physical exercises\", \"decrease\", \"susceptibility to induced seizures\"], \n[\"Regular physical exercises\", \"ameliorate\", \"course of experimentally induced status epilepticus\"]]",
      "Hepatocellular oxidant stress following intestinal ischemia - reperfusion injury .|Reperfusion of ischemic intestine results in acute liver dysfunction characterized by hepatocellular enzyme release into plasma , reduction in bile flow rate , and neutrophil sequestration within the liver .|The pathophysiology underlying this acute hepatic injury is unknown .|This study was undertaken to determine whether oxidants are associated with the hepatic injury and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo .|Rats were subjected to a standardized intestinal ischemia - reperfusion injury .|Hepatic tissue was assayed for lipid peroxidation products and oxidized and reduced glutathione .|There was no change in hepatic tissue total glutathione following intestinal ischemia - reperfusion injury .|Oxidized glutathione ( GSSG ) increased significantly following 30 and 60 min of reperfusion .|There was no increase in any of the products of lipid peroxidation associated with this injury .|An increase in GSSG within hepatic tissue during intestinal reperfusion suggests exposure of hepatocytes to an oxidant stress .|The lack of a significant increase in products of lipid peroxidation suggests that the oxidant stress is of insufficient magnitude to result in irreversible injury to hepatocyte cell membranes .|These data also suggest that the measurement of tissue GSSG may be a more sensitive indicator of oxidant stress than measurement of products of lipid peroxidation .": "[[\"Hepatocellular oxidant stress\", \"follows\", \"intestinal ischemia - reperfusion injury\"],\n[\"Reperfusion of ischemic intestine\", \"results in\", \"acute liver dysfunction\"],\n[\"Acute liver dysfunction\", \"characterized by\", \"hepatocellular enzyme release into plasma\"],\n[\"Acute liver dysfunction\", \"characterized by\", \"reduction in bile flow rate\"],\n[\"Acute liver dysfunction\", \"characterized by\", \"neutrophil sequestration within the liver\"],\n[\"Pathophysiology\", \"underlying\", \"acute hepatic injury\"],\n[\"Pathophysiology\", \"is\", \"unknown\"],\n[\"Study\", \"undertaken to determine\", \"association of oxidants with hepatic injury\"],\n[\"Study\", \"undertaken to determine\", \"value of methods of assessing oxidant exposure\"],\n[\"Rats\", \"subjected to\", \"intestinal ischemia - reperfusion injury\"],\n[\"Hepatic tissue\", \"assayed for\", \"lipid peroxidation products\"],\n[\"Hepatic tissue\", \"assayed for\", \"oxidized and reduced glutathione\"],\n[\"Change in hepatic tissue total glutathione\", \"following\", \"intestinal ischemia - reperfusion injury\"],\n[\"Oxidized glutathione (GSSG)\", \"increased significantly following\", \"30 and 60 min of reperfusion\"],\n[\"Increase in products of lipid peroxidation\", \"associated with\", \"this injury\"],\n[\"Increase in GSSG within hepatic tissue\", \"suggests\", \"exposure of hepatocytes to an oxidant stress\"],\n[\"Lack of significant increase in products of lipid peroxidation\", \"suggests\", \"oxidant stress of insufficient magnitude to result in irreversible injury to hepatocyte cell membranes\"],\n[\"Data\", \"suggest\", \"measurement of tissue GSSG may be more sensitive indicator of oxidant stress\"],\n[\"Measurement of tissue GSSG\", \"compared to\", \"measurement of products of lipid peroxidation\"]]",
      "GEM - P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma .|Hodgkin lymphoma ( HL ) is a relatively chemosensitive malignancy .|However , for those who relapse , high - dose chemotherapy with autologous stem cell transplant is the treatment of choice which relies on adequate disease control with salvage chemotherapy .|Regimens commonly used often require inpatient administration and can be difficult to deliver due to toxicity .|Gemcitabine and cisplatin have activity in HL , non - overlapping toxicity with first - line chemotherapeutics , and may be delivered in an outpatient setting .|In this retrospective single - centre analysis , patients with relapsed or refractory HL treated with gemcitabine 1 , 000 mg / m ( 2 ) day ( D ) 1 , D8 and D15 ; methylprednisolone 1 , 000 mg D1 - 5 ; and cisplatin 100 mg / m ( 2 ) D15 , every 28 days ( GEM - P ) were included .|Demographic , survival , response and toxicity data were recorded .|Forty - one eligible patients were identified : median age 27 .|One hundred and twenty - two cycles of GEM - P were administered in total ( median 3 cycles ; range 1 - 6 ) .|Twenty of 41 ( 48 % ) patients received GEM - P as second - line treatment and 11 / 41 ( 27 % ) as third - line therapy .|Overall response rate ( ORR ) to GEM - P in the entire cohort was 80 % ( complete response ( CR ) 37 % , partial response 44 % ) with 14 / 15 CR confirmed as a metabolic CR on PET and ORR of 85 % in the 20 second - line patients .|The most common grade 3 / 4 toxicities were haematological : neutropenia 54 % and thrombocytopenia 51 % .|Median follow - up from the start of GEM - P was 4 . 5 years .|Following GEM - P , 5 - year progression - free survival was 46 % ( 95 % confidence interval ( CI ) , 30 - 62 % ) and 5 - year overall survival was 59 % ( 95 % CI , 43 - 74 % ) .|Fourteen of 41 patients proceeded directly to autologous transplant .|GEM - P is a salvage chemotherapy with relatively high response rates , leading to successful transplantation in appropriate patients , in the treatment of relapsed or refractory HL .": "Based on the provided prompt, here are the extracted relationships:\n\n- [[\"GEM - P chemotherapy\", \"is active in\", \"treatment of relapsed Hodgkin lymphoma\"]]\n- [[\"Hodgkin lymphoma\", \"is a\", \"relatively chemosensitive malignancy\"]]\n- [[\"High - dose chemotherapy with autologous stem cell transplant\", \"is the treatment of choice for\", \"those who relapse\"]]\n- [[\"Salvage chemotherapy\", \"relies on\", \"adequate disease control\"]]\n- [[\"Gemcitabine and cisplatin\", \"have activity in\", \"HL\"]]\n- [[\"Gemcitabine and cisplatin\", \"have\", \"non - overlapping toxicity with first - line chemotherapeutics\"]]\n- [[\"Gemcitabine and cisplatin\", \"may be delivered in\", \"an outpatient setting\"]]\n- [[\"Patients with relapsed or refractory HL\", \"treated with\", \"GEM - P\"]]\n- [[\"GEM - P\", \"administered every\", \"28 days\"]]\n- [[\"Forty - one patients\", \"were\", \"eligible\"]]\n- [[\"Forty - one patients\", \"median age\", \"27\"]]\n- [[\"GEM - P\", \"administered in total\", \"122 cycles\"]]\n- [[\"Twenty of 41 patients\", \"received\", \"GEM - P as second - line treatment\"]]\n- [[\"11 of 41 patients\", \"received\", \"GEM - P as third - line therapy\"]]\n- [[\"Overall response rate to GEM - P\", \"was\", \"80%\"]]\n- [[\"Complete response rate to GEM - P\", \"was\", \"37%\"]]\n- [[\"Partial response rate to GEM - P\", \"was\", \"44%\"]]\n- [[\"14 of 15 complete responses\", \"confirmed as\", \"metabolic CR on PET\"]]\n- [[\"Overall response rate of second - line patients to GEM - P\", \"was\", \"85%\"]]\n- [[\"Most common grade 3 / 4 toxicities\", \"were\", \"haematological\"]]\n- [[\"Neutropenia\", \"occurred in\", \"54% of patients\"]]\n- [[\"Thrombocytopenia\", \"occurred in\", \"51% of patients\"]]\n- [[\"Median follow - up from start of GEM - P\", \"was\", \"4.5 years\"]]\n- [[\"5 - year progression - free survival following GEM - P\", \"was\", \"46%\"]]\n- [[\"5 - year overall survival following GEM - P\", \"was\", \"59%\"]]\n- [[\"Fourteen of 41 patients\", \"proceeded to\", \"autologous transplant\"]]\n- [[\"GEM - P\", \"is a\", \"salvage chemotherapy\"]]\n- [[\"GEM - P\", \"leads to\", \"successful transplantation in appropriate patients\"]]\n- [[\"GEM - P\", \"used in treatment of\", \"relapsed or refractory HL\"]]",
      "Blockade of endothelial - mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin - induced diabetic nephropathy .|OBJECTIVE : A multicenter , controlled trial showed that early blockade of the renin - angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy , suggesting that other mechanism ( s ) are involved in the pathogenesis of early diabetic nephropathy ( diabetic nephropathy ) .|We have previously demonstrated that endothelial - mesenchymal - transition ( EndoMT ) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin ( STZ ) - induced diabetes .|In the present study , we hypothesized that blocking EndoMT reduces the early development of diabetic nephropathy .|RESEARCH DESIGN AND METHODS : EndoMT was induced in a mouse pancreatic microvascular endothelial cell line ( MMEC ) in the presence of advanced glycation end products ( AGEs ) and in the endothelial lineage - traceble mouse line Tie2 - Cre ; Loxp - EGFP by administration of AGEs , with nonglycated mouse albumin serving as a control .|Phosphorylated Smad3 was detected by immunoprecipitation / Western blotting and confocal microscopy .|Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 ( SIS3 ) were performed in MMECs and in STZ - induced diabetic nephropathy in Tie2 - Cre ; Loxp - EGFP mice .|RESULTS : Confocal microscopy and real - time PCR demonstrated that AGEs induced EndoMT in MMECs and in Tie2 - Cre ; Loxp - EGFP mice .|Immunoprecipitation / Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ - induced diabetic nephropathy .|Confocal microscopy and real - time PCR further demonstrated that SIS3 abrogated EndoMT , reduced renal fibrosis , and retarded progression of nephropathy .|CONCLUSIONS : EndoMT is a novel pathway leading to early development of diabetic nephropathy .|Blockade of EndoMT by SIS3 may provide a new strategy to retard the progression of diabetic nephropathy and other diabetes complications .": "[[\"Blockade of endothelial-mesenchymal transition\", \"delays\", \"early development of streptozotocin-induced diabetic nephropathy\"],\n[\"Smad3 inhibitor\", \"used for\", \"blockade of endothelial-mesenchymal transition\"],\n[\"Early blockade of the renin-angiotensin system\", \"did not retard\", \"progression of nephropathy\"],\n[\"Patients with type 1 diabetes and normoalbuminuria\", \"subject of\", \"early blockade of the renin-angiotensin system\"],\n[\"Other mechanisms\", \"are involved in\", \"pathogenesis of early diabetic nephropathy\"],\n[\"Endothelial-mesenchymal-transition (EndoMT)\", \"contributes to\", \"early development of renal interstitial fibrosis\"],\n[\"EndoMT\", \"occurs independently of\", \"microalbuminuria\"],\n[\"Blocking EndoMT\", \"hypothesized to reduce\", \"early development of diabetic nephropathy\"],\n[\"EndoMT\", \"was induced in\", \"mouse pancreatic microvascular endothelial cell line (MMEC)\"],\n[\"EndoMT\", \"induced by\", \"advanced glycation end products (AGEs)\"],\n[\"Phosphorylated Smad3\", \"detected by\", \"immunoprecipitation/Western blotting\"],\n[\"Phosphorylated Smad3\", \"detected by\", \"confocal microscopy\"],\n[\"Blocking studies\", \"used\", \"receptor for AGE siRNA\"],\n[\"Blocking studies\", \"used\", \"specific inhibitor of Smad3 (SIS3)\"],\n[\"Blocking studies\", \"performed in\", \"MMECs\"],\n[\"Blocking studies\", \"performed in\", \"STZ-induced diabetic nephropathy in Tie2-Cre; Loxp-EGFP mice\"],\n[\"AGEs\", \"induced\", \"EndoMT in MMECs\"],\n[\"AGEs\", \"induced\", \"EndoMT in Tie2-Cre; Loxp-EGFP mice\"],\n[\"Smad3\", \"activated by\", \"AGEs\"],\n[\"Smad3\", \"inhibited by\", \"SIS3 in MMECs\"],\n[\"Smad3\", \"inhibited by\", \"SIS3 in STZ-induced diabetic nephropathy\"],\n[\"SIS3\", \"abrogated\", \"EndoMT\"],\n[\"SIS3\", \"reduced\", \"renal fibrosis\"],\n[\"SIS3\", \"retarded\", \"progression of nephropathy\"],\n[\"EndoMT\", \"novel pathway leading to\", \"early development of diabetic nephropathy\"],\n[\"Blockade of EndoMT by SIS3\", \"may provide\", \"new strategy to retard progression of diabetic nephropathy\"],\n[\"Blockade of EndoMT by SIS3\", \"may provide\", \"new strategy for other diabetes complications\"]]",
      "Reducing harm associated with anticoagulation : practical considerations of argatroban therapy in heparin - induced thrombocytopenia .|Argatroban is a hepatically metabolized , direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin - induced thrombocytopenia ( HIT ) and for patients with or at risk of HIT undergoing percutaneous coronary intervention ( PCI ) .|The objective of this review is to summarize practical considerations of argatroban therapy in HIT .|The US FDA - recommended argatroban dose in HIT is 2 microg / kg / min ( reduced in patients with hepatic impairment and in paediatric patients ) , adjusted to achieve activated partial thromboplastin times ( aPTTs ) 1 . 5 - 3 times baseline ( not > 100 seconds ) .|Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion , e . g .|heart failure , yet are unnecessary for renal dysfunction , adult age , sex , race / ethnicity or obesity .|Argatroban 0 . 5 - 1 . 2 microg / kg / min typically supports therapeutic aPTTs .|The FDA - recommended dose during PCI is 25 microg / kg / min ( 350 microg / kg initial bolus ) , adjusted to achieve activated clotting times ( ACTs ) of 300 - 450 sec .|For PCI , argatroban has not been investigated in hepatically impaired patients ; dose adjustment is unnecessary for adult age , sex , race / ethnicity or obesity , and lesser doses may be adequate with concurrent glycoprotein IIb / IIIa inhibition .|Argatroban prolongs the International Normalized Ratio , and published approaches for monitoring the argatroban - to - warfarin transition should be followed .|Major bleeding with argatroban is 0 - 10 % in the non - interventional setting and 0 - 5 . 8 % periprocedurally .|Argatroban has no specific antidote , and if excessive anticoagulation occurs , argatroban infusion should be stopped or reduced .|Improved familiarity of healthcare professionals with argatroban therapy in HIT , including in special populations and during PCI , may facilitate reduction of harm associated with HIT ( e . g . fewer thromboses ) or its treatment ( e . g . fewer argatroban medication errors ) .": "[[\"Argatroban\", \"is used for\", \"prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT)\"],\n [\"Argatroban\", \"is used for\", \"patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)\"],\n [\"Argatroban therapy\", \"objective of review\", \"summarize practical considerations in HIT\"],\n [\"Argatroban dose\", \"recommended by\", \"US FDA\"],\n [\"Argatroban dose\", \"is\", \"2 microg/kg/min in HIT\"],\n [\"Argatroban dose\", \"adjusted for\", \"hepatic impairment\"],\n [\"Argatroban dose\", \"adjusted for\", \"paediatric patients\"],\n [\"Argatroban dose\", \"adjusted to achieve\", \"activated partial thromboplastin times (aPTTs) 1.5 - 3 times baseline\"],\n [\"Dose adjustment\", \"not needed for\", \"renal dysfunction\"],\n [\"Dose adjustment\", \"not needed for\", \"adult age\"],\n [\"Dose adjustment\", \"not needed for\", \"sex\"],\n [\"Dose adjustment\", \"not needed for\", \"race/ethnicity\"],\n [\"Dose adjustment\", \"not needed for\", \"obesity\"],\n [\"Argatroban dose\", \"typically supports\", \"therapeutic aPTTs\"],\n [\"FDA-recommended dose during PCI\", \"is\", \"25 microg/kg/min\"],\n [\"FDA-recommended dose during PCI\", \"includes\", \"350 microg/kg initial bolus\"],\n [\"PCI dose adjustment\", \"not investigated in\", \"hepatically impaired patients\"],\n [\"PCI dose adjustment\", \"unnecessary for\", \"adult age\"],\n [\"PCI dose adjustment\", \"unnecessary for\", \"sex\"],\n [\"PCI dose adjustment\", \"unnecessary for\", \"race/ethnicity\"],\n [\"PCI dose adjustment\", \"unnecessary for\", \"obesity\"],\n [\"Argatroban\", \"prolongs\", \"International Normalized Ratio\"],\n [\"Monitoring\", \"required for\", \"argatroban-to-warfarin transition\"],\n [\"Major bleeding with argatroban\", \"rate in non-interventional setting\", \"0 - 10%\"],\n [\"Major bleeding with argatroban\", \"rate periprocedurally\", \"0 - 5.8%\"],\n [\"Argatroban\", \"has no\", \"specific antidote\"],\n [\"Excessive anticoagulation with argatroban\", \"should be managed by\", \"stopping or reducing infusion\"],\n [\"Healthcare professionals\", \"improved familiarity with\", \"argatroban therapy in HIT\"],\n [\"Reduction of harm associated with HIT\", \"may result from\", \"fewer thromboses\"],\n [\"Reduction of harm associated with HIT treatment\", \"may result from\", \"fewer argatroban medication errors\"]]",
      "Coronary computerized tomography angiography for rapid discharge of low - risk patients with cocaine - associated chest pain .|BACKGROUND : Most patients presenting to emergency departments ( EDs ) with cocaine - associated chest pain are admitted for at least 12 hours and receive a \" rule out acute coronary syndrome \" protocol , often with noninvasive testing prior to discharge .|In patients without cocaine use , coronary computerized tomography angiography ( CTA ) has been shown to be useful for identifying a group of patients at low risk for cardiac events who can be safely discharged .|It is unclear whether a coronary CTA strategy would be efficacious in cocaine - associated chest pain , as coronary vasospasm may account for some of the ischemia .|We studied whether a negative coronary CTA in patients with cocaine - associated chest pain could identify a subset safe for discharge .|METHODS : We prospectively evaluated the safety of coronary CTA for low - risk patients who presented to the ED with cocaineassociated chest pain ( self - reported or positive urine test ) .|Consecutive patients received either immediate coronary CTA in the ED ( without serial markers ) or underwent coronary CTA after a brief observation period with serial cardiac marker measurements .|Patients with negative coronary CTA ( maximal stenosis less than 50 % ) were discharged .|The main outcome was 30 - day cardiovascular death or myocardial infarction .|RESULTS : A total of 59 patients with cocaine - associated chest pain were evaluated .|Patients had a mean age of 45 . 6 + / - 6 . 6 yrs and were 86 % black , 66 % male .|Seventy - nine percent had a normal or nonspecific ECG and 85 % had a TIMI score < 2 .|Twenty patients received coronary CTA immediately in the ED , 18 of whom were discharged following CTA ( 90 % ) .|Thirty - nine received coronary CTA after a brief observation period , with 37 discharged home following CTA ( 95 % ) .|Six patients had coronary stenosis > or = 50 % .|During the 30 - day follow - up period , no patients died of a cardiovascular event ( 0 % ; 95 % CI , 0 - 6 . 1 % ) and no patient sustained a nonfatal myocardial infarction ( 0 % ; 95 % CI , 0 - 6 . 1 % ) .|CONCLUSIONS : Although cocaine - associated myocardial ischemia can result from coronary vasoconstriction , patients with cocaine associated chest pain , a non - ischemic ECG , and a TIMI risk score < 2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30 - day adverse events .": "[[\"Coronary computerized tomography angiography (CTA)\", \"used for\", \"rapid discharge of low-risk patients with cocaine-associated chest pain\"],\n [\"Patients\", \"presenting to\", \"emergency departments (EDs)\"],\n [\"Patients\", \"admitted for\", \"at least 12 hours\"],\n [\"Patients\", \"receive\", \"rule out acute coronary syndrome protocol\"],\n [\"Patients\", \"often receive\", \"noninvasive testing prior to discharge\"],\n [\"Coronary CTA\", \"shown to be useful for\", \"identifying low risk for cardiac events\"],\n [\"Coronary CTA\", \"unclear efficacy for\", \"cocaine-associated chest pain\"],\n [\"Negative coronary CTA\", \"could identify\", \"subset safe for discharge\"],\n [\"Study\", \"evaluated\", \"safety of coronary CTA for low-risk patients\"],\n [\"Patients\", \"presented to\", \"ED with cocaine-associated chest pain\"],\n [\"Patients\", \"received\", \"immediate coronary CTA in the ED\"],\n [\"Patients\", \"underwent\", \"coronary CTA after observation period with serial cardiac marker measurements\"],\n [\"Patients with negative coronary CTA\", \"discharged\", \"\"],\n [\"Main outcome\", \"was\", \"30-day cardiovascular death or myocardial infarction\"],\n [\"Total of 59 patients\", \"evaluated for\", \"cocaine-associated chest pain\"],\n [\"Patients\", \"had mean age of\", \"45.6 years\"],\n [\"Patients\", \"were\", \"86% black\"],\n [\"Patients\", \"were\", \"66% male\"],\n [\"Seventy-nine percent of patients\", \"had\", \"normal or nonspecific ECG\"],\n [\"Eighty-five percent of patients\", \"had\", \"TIMI score < 2\"],\n [\"Twenty patients\", \"received\", \"coronary CTA immediately in the ED\"],\n [\"Eighteen of twenty patients\", \"discharged following\", \"CTA\"],\n [\"Thirty-nine patients\", \"received\", \"coronary CTA after observation period\"],\n [\"Thirty-seven of thirty-nine patients\", \"discharged home following\", \"CTA\"],\n [\"Six patients\", \"had\", \"coronary stenosis > or = 50%\"],\n [\"During 30-day follow-up\", \"no patients died of\", \"cardiovascular event\"],\n [\"During 30-day follow-up\", \"no patient sustained\", \"nonfatal myocardial infarction\"],\n [\"Conclusions\", \"indicate\", \"patients with non-ischemic ECG and TIMI risk score < 2 may be safely discharged after negative coronary CTA\"],\n [\"Conclusions\", \"indicate\", \"low risk of 30-day adverse events after negative coronary CTA\"]]",
      "Ethambutol and optic neuropathy .|PURPOSE : To demonstrate the association between ethambutol and optic neuropathy .|METHOD : Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed .|The clinical characteristics and initial and final visual acuity were analyzed to determine visual outcome .|RESULTS : All patients had optic neuropathy between 1 to 6 months ( mean = 2 . 9 months ) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg / kg / day ( mean = 17 mg / kg / day ) .|Seven ( 54 % ) of the 13 patients experienced visual recovery after stopping the drug .|Of 6 patients with irreversible visual impairment , 4 patients had diabetes mellitus , glaucoma and a history of heavy smoking .|CONCLUSION : Early recognition of optic neuropathy should be considered in patients with ethambutol therapy .|A low dose and prompt discontinuation of the drug is recommended particularly in individuals with diabetes mellitus , glaucoma or who are heavy smokers .": "[[\"Ethambutol\", \"associated with\", \"optic neuropathy\"],\n[\"Purpose\", \"to demonstrate association between\", \"Ethambutol and optic neuropathy\"],\n[\"Thirteen patients\", \"developed\", \"optic neuropathy\"],\n[\"Thirteen patients\", \"treated with\", \"Ethambutol\"],\n[\"Ethambutol treatment\", \"for\", \"tuberculosis of the lung or lymph node\"],\n[\"Ethambutol treatment\", \"occurred at\", \"Siriraj Hospital\"],\n[\"Ethambutol treatment\", \"timeframe\", \"between 1997 and 2001\"],\n[\"Clinical characteristics and initial and final visual acuity\", \"analyzed to determine\", \"visual outcome\"],\n[\"Patients\", \"had optic neuropathy\", \"after starting Ethambutol therapy\"],\n[\"Optic neuropathy onset\", \"timeframe\", \"between 1 to 6 months\"],\n[\"Ethambutol therapy\", \"dosage range\", \"from 13 to 20 mg/kg/day\"],\n[\"Seven patients\", \"experienced\", \"visual recovery\"],\n[\"Visual recovery\", \"occurred after\", \"stopping the drug\"],\n[\"Six patients\", \"with\", \"irreversible visual impairment\"],\n[\"Four patients\", \"had\", \"diabetes mellitus, glaucoma, and a history of heavy smoking\"],\n[\"Conclusion\", \"Early recognition of\", \"optic neuropathy should be considered\"],\n[\"Conclusion\", \"recommendation for\", \"low dose and prompt discontinuation of Ethambutol\"],\n[\"Recommendation\", \"particularly for\", \"individuals with diabetes mellitus, glaucoma or who are heavy smokers\"]]",
      "Cardioprotective effects of Picrorrhiza kurroa against isoproterenol - induced myocardial stress in rats .|The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots ( PK ) on isoproterenol - induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated .|Oral pre - treatment with PK ( 80 mg kg ( - 1 ) day ( - 1 ) for 15 days ) significantly prevented the isoproterenol - induced myocardial infarction and maintained the rats at near normal status .": "[[\"Picrorrhiza kurroa\", \"has\", \"cardioprotective effects\"], [\"Picrorrhiza kurroa\", \"used against\", \"isoproterenol-induced myocardial stress\"], [\"ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK)\", \"has effect on\", \"isoproterenol-induced myocardial infarction in rats\"], [\"ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK)\", \"investigated for\", \"lipid metabolism in serum and heart tissue\"], [\"Oral pre-treatment with PK\", \"prevented\", \"isoproterenol-induced myocardial infarction\"], [\"Oral pre-treatment with PK\", \"maintained\", \"rats at near normal status\"]]",
      "Acute interstitial nephritis due to nicergoline ( Sermion ) .|We report a case of acute interstitial nephritis ( AIN ) due to nicergoline ( Sermion ) .|A 50 - year - old patient admitted to our hospital for fever and acute renal failure .|Before admission , he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department .|Thereafter , he experienced intermittent fever and skin rash .|On admission , clinical symptoms ( i . e . arthralgia and fever ) and laboratory findings ( i . e . eosinophilia and renal failure ) suggested AIN , and which was confirmed by pathologic findings on renal biopsy .|A lymphocyte transformation test demonstrated a positive result against nicergoline .|Treatment was consisted of withdrawal of nicergoline and intravenous methylprednisolone , and his renal function was completely recovered .|To our knowledge , this is the first report of nicergoline - associated AIN .": "[[\"Acute interstitial nephritis\", \"due to\", \"nicergoline (Sermion)\"],\n [\"Case\", \"of\", \"acute interstitial nephritis\"],\n [\"Acute interstitial nephritis\", \"due to\", \"nicergoline (Sermion)\"],\n [\"50-year-old patient\", \"admitted for\", \"fever and acute renal failure\"],\n [\"50-year-old patient\", \"had been taking\", \"nicergoline\"],\n [\"50-year-old patient\", \"had been taking\", \"bendazac lysine\"],\n [\"Nicergoline\", \"due to\", \"retinal vein occlusion\"],\n [\"Patient\", \"experienced\", \"intermittent fever\"],\n [\"Patient\", \"experienced\", \"skin rash\"],\n [\"Clinical symptoms\", \"suggested\", \"AIN\"],\n [\"Laboratory findings\", \"suggested\", \"AIN\"],\n [\"AIN\", \"confirmed by\", \"pathologic findings on renal biopsy\"],\n [\"Lymphocyte transformation test\", \"demonstrated\", \"positive result against nicergoline\"],\n [\"Treatment\", \"consisted of\", \"withdrawal of nicergoline\"],\n [\"Treatment\", \"consisted of\", \"intravenous methylprednisolone\"],\n [\"Patient\", \"renal function\", \"completely recovered\"],\n [\"Report\", \"is the first\", \"of nicergoline-associated AIN\"]]",
      "Convulsion following intravenous fluorescein angiography .|Tonic - clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47 - year - old male .|Despite precautions this adverse reaction recurred on re - exposure to intravenous fluorescein .": "[[\"Convulsion\", \"following\", \"intravenous fluorescein angiography\"],\n[\"Tonic-clonic seizures\", \"followed\", \"intravenous fluorescein injection\"],\n[\"Intravenous fluorescein injection\", \"used for\", \"fundus angiography\"],\n[\"47-year-old male\", \"experienced\", \"Tonic-clonic seizures\"],\n[\"Adverse reaction\", \"recurred on\", \"re-exposure to intravenous fluorescein\"]]"
}